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Supervisor:  Karen L. Rascati 
 
Objectives: To assess prevalence and correlates of cancer-related sleep disturbance (SD) 
and hypnotic use, and evaluate changes in cancer symptom burden and health-related 
quality of life (HRQoL) associated with sleep disturbance change and hypnotic use. 
Methods: Secondary analysis of the Symptom Outcomes and Practice Patterns (SOAPP) 
survey of 3,106 adult (aged ≥ 18 years) outpatients receiving treatment for breast, lung, 
prostate, or colorectal cancer between March 3, 2006 and May 19, 2008. At baseline and 
approximately four weeks later, patients scored severity of nineteen cancer symptoms from 
0=‘Not present’ to 10=‘As bad as you can imagine’. Both patients and clinicians scored 
symptom-burden interference for six HRQoL items (from 0=’Did not interfere’ to 
10=’interfered completely’). Correlates of SD and hypnotic use were identified using linear 
and logistic regression, respectively. Multivariate analyses tested whether hypnotic use 
(Hotelling’s T2) or change in SD severity (multivariate linear regression) were associated 
with changes in symptom burden and HRQoL. Cancer-specific subgroups were evaluated 
when sample size permitted. 
Results: SD scores were available for 2,748 participants: 71% female, 86% white, mean 
age 61 years (range, 23-93 years). Primary cancer sites: breast (51%), colorectal (24%), 
lung (15%), and prostate (10%). The majority (62.8%) reported SD and 23.5% used 
 vi 
hypnotics. The most important SD correlates were other cancer symptoms, regardless of 
their severity. Distress was the strongest and only universal correlate; cognitive difficulty, 
drowsiness, and fatigue were also common across cancer-specific subgroups. Hypnotic use 
was two to three times higher among whites, versus blacks. Several sedating medications 
correlated positively with hypnotic use, including opioid analgesics and promethazine. 
Hypnotic use correlated positively with clinician-identified distress, but not with clinician-
identified sleep disturbance. Reduced sleep disturbance severity (SDS) correlated with 
improvement in nearly all symptoms (most notably: distress, dry mouth, and fatigue), and 
with improved HRQoL (possibly mediated by other symptoms). Hypnotic use correlated 
modestly with lower overall symptom burden, but not HRQoL change.  
Conclusions: Relationships observed between SD and many other cancer symptoms argue 
in favor of therapies that target multiple symptoms. Patterns of hypnotic use raise questions 
about whether cancer-related SD is being treated adequately, equitably, and effectively.  
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Chapter 1:  Background and Literature Review 
This chapter provides a discussion of background literature relevant to the present study, 
beginning with an overview of sleep disturbance in general, including definitions, risk factors, and 
clinical implications. This is followed by a brief summary of literature characterizing sleep 
disturbance in the oncology setting, including prevalence and oncology-specific risk factors, 
available treatments, evidence relating to use of those treatments in people with cancer. (For a 
detailed treatment of these topics, please refer to the previously published works listed below.) 
The chapter closes with a statement of rationale for the proposed study. 
 
For more detail on pharmacotherapies for insomnia and insomnia in the setting of cancer, 
please refer to these previously published works. 
 
Scalo JF, Rascati KL. Pharmacotherapy for Insomnia. In: McCall WV, ed. Advances in the 
Management of Primary and Secondary Insomnia. London, UK: Future Medicine; 
2014:72-90. [The first author was the primary author.] 
 
and  
 
Scalo JF, Rascati KL. Insomnia in the Setting of Cancer. In: McCall WV, ed. Advances in 
the Management of Primary and Secondary Insomnia. London, UK: Future Medicine; 
2014:32-54. [The first author was the primary author.] 
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1.1 SECTION I:  OVERVIEW OF SLEEP DISTURBANCE  
Sleep is essential for health and well-being, and it is well established that sleep disturbance 
is associated with numerous physiological and psychological impairments. Sleep disturbance is 
also costly; poor sleep increases patients’ medical expenditures and decreases productivity at work 
and school. This section provides a brief overview of the characterization and measurement of 
sleep disturbance, risk factors and epidemiology, and associated clinical and socioeconomic 
outcomes. 
 
1.1.1 Defining sleep disturbance 
The terms sleep disturbance and insomnia are often used interchangeably to describe 
difficulty falling asleep, staying asleep, and / or dissatisfaction with the quality of one’s sleep. 
Diagnostic criteria for insomnia, however, are more specific and require the presence of daytime 
symptoms that reflect the pathologic effects of disturbed sleep.  
 The International Classification of Sleep Disorders, Third Edition (ICSD-3)1 and the 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)2 define insomnia 
as sleep difficulties that occur at least three nights per week for at least three months, and that are 
accompanied by daytime sequelae such as fatigue, memory impairment, irritability, sleepiness, or 
impaired performance at work or school. These diagnostic criteria have been in flux over recent 
years, and in research literature the operational definitions of sleep disturbance vary considerably.  
For the purposes of this work, the term sleep disturbance is used as a generic term for difficulty 
sleeping and does not reflect a particular definition or set of diagnostic criteria. The term insomnia 
will be used to identify cases in which disturbed sleep is known to be accompanied by related 
daytime dysfunction. 
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1.1.2 Measuring sleep disturbance 
A variety of instruments are available to assess patients’ subjective experience of sleep 
disturbance, including the Pittsburgh Sleep Quality Index, the Insomnia Severity Index, and the 
Epworth Sleepiness Scale.3 Objective measurements are also possible using sleep actigraphs and 
polysomnography. Sleep actigraphs are small accelerometer-containing devices that record 
motion. Generally worn on the wrist, an actigraph collects information that indicates a patient’s 
sleep/wake cycles as well as the level of arousal or activity during sleep.4 Polysomnography 
provides comprehensive reporting of internal physiological activity during sleep with electrical 
field recordings of the brain (electroencephalogram), eyes (electro-occulogram), skeletal muscles 
(electromyogram), and heart (electrocardiogram).4   
Actigraphy is commonly used in the diagnosis of insomnia,3 as it is relatively easy and 
economical, and can provide measurements for several sleep parameters of clinical interest, 
including: 
• Sleep onset latency (SOL): time elapsed between bedtime and sleep onset 
• Wake time after sleep onset (WASO) 
• Number of awakenings 
• Total sleep period: time from initial sleep onset to final awakening 
• Total sleep time (TST): actual time spent asleep, not including waking episodes 
• Sleep efficiency: the ratio of total sleep time to total sleep period 
 
Polysomnography is not routinely used for diagnosis of insomnia, unless there is reason to 
suspect an additional sleep disorder (e.g., sleep apnea or movement disorders), but is used 
extensively in sleep research. From polysomnography recordings, investigators have discovered 
that sleep occurs in phases, or stages. The two main phases of sleep are the rapid eye movement 
(REM) phase and the non-rapid eye movement (NREM) phase.5 NREM sleep can be further 
divided into stages S1 through S4. Humans typically cycle through all four stages of NREM plus 
the REM stage five or six times nightly, with each cycle lasting about 90 minutes.6 Sleepers in 
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stages S1 and S2 exhibit high frequency brain-wave activity and are relatively easy to awaken 
(lighter sleep), while sleepers in stages S3 and S4, referred to collectively as delta phase or slow 
wave sleep (SWS), exhibit low frequency cortical waves and are more resistant to being awoken 
(deeper sleep).7  
 
1.1.3 Risk factors for sleep disturbance 
Sleep disturbance may be attributable to a number of factors. Often, sleep disturbance is 
secondary to mental disorders (e.g., depression, anxiety, Alzheimer’s disease, or schizophrenia), 
or may result from physical conditions, such as chronic pain, cancer, sleep apnea, or restless legs 
syndrome.8 Some patients suffer from circadian disorders, in which hormonal timing of sleep 
cycles are disrupted,9,10 and shift-workers commonly experience difficulty achieving restorative 
sleep during daylight hours.11 There are many medications that can interfere with sleep,12 as can 
environmental conditions, including noises and uncomfortable temperatures.13 Stressors that 
commonly contribute to insomnia include work-, family-, and school-related problems.14 In 1987, 
Spielman, Caruso, and Glovinsky proposed what is now called the 3P model, which classifies risk 
factors as having predisposing, precipitating, and/or perpetuating effects on the development of 
insomnia. For example, individuals who tend to experience high levels of anxiety and worry may 
be predisposed to experience disrupted sleep in response to a stressful life event.15,16 Acute 
disruptions to sleep may be precipitated by events such as job loss, new onset of a medical 
condition, birth of a child, or death of loved one.14 As the precipitating event resolves, or as the 
individual adjusts, normal sleep should return. Chronic insomnia may develop, however, in the 
presence of perpetuating factors. Sustained or repeated exposure to life stress can result in 
conditioned somatic (bodily) and cognitive hyperarousal,17 characterized by increased metabolic 
rates, elevated temperature and heart rate, and increased cortisol secretion due to activation of the 
hypothalamic-pituitary-adrenal axis.18 Maladaptive behaviors, such as remaining in bed despite 
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failure to fall asleep, and worrying excessively about not sleeping, may also engender cognitive 
and/or psychological hyperarousal at bedtime.17  
 
1.1.4 Genetics of sleep disturbance 
Particular genetic risk factors for sleep disturbance have yet to be identified, but studies 
have discovered a high degree of familial aggregation among first-degree relatives with insomnia, 
which provides strong evidence of a genetic contribution to etiology.14,19,20 Further investigation is 
needed, however, including genome-wide association studies (GWASs) to search for genetic 
regions linked with particular sleep disturbance symptoms. Two such studies have found that 
subjects with insomnia share genotypic differences in regions thought to be involved in the 
regulation of circadian rhythms.21,22 Another GWAS has identified three genes that may associated 
with sleep duration (statistical significance cutoff was not met).  For one of these, KLF6, 
expression was observed to be higher in subjects whose sleep was restricted during the study, 
suggesting that sleep may alter gene expression and vice versa.23 More recently, a meta-analysis 
of GWASs identified an association between sleep latency and three variants of the gene RBFOX3; 
the authors predict, based on analysis of co-expression with other genes, that RBFOX3 plays a role 
in the release of neurotransmitters that trigger sleep onset.24 
Better understanding of the genetics of sleep can help to identify novel targets for 
pharmacotherapy. In addition, insight into the complex interplay of sleep with other homeostatic 
systems could inform development of behavioral and environmental interventions to improve 
sleep. There is still much to learn, however, about the precise genes involved as well as their 
functions. Furthermore, genetic risk factors for insomnia are likely to be manifold, so genome-
wide searches for other insomnia-related characteristics should be continued. 
 
 
 
6 
1.1.5 Epidemiology of sleep disturbance 
Between one-third and one-half of US adults experience sleep disturbance, and about one 
in five (22%) also suffer from daytime sequelae such as fatigue, motor incoordination, and 
impaired cognition.25-27 Sleep disturbances are more common among women, and prevalence 
increases with age. Before the age of 46 years, women are 1.4 times more likely than men to 
experience insomnia; the risk ratio increases to 1.7 after age 46.28 Reports of difficulty maintaining 
sleep are more frequent in adults aged 65 years and older, but it remains unclear to what extent 
this increase is due to changes in sleep itself, increased prevalence of comorbid conditions that 
may interrupt sleep, or lifestyle factors that contribute to perceived satisfaction with sleep.27-31 
Lower socioeconomic status is also associated with higher prevalence of insomnia, but conflicting 
results from multivariate analyses indicate that this relationship may reflect some other common 
cause (or causes).28 Finally, prevalence of insomnia appears to vary with race/ethnicity, but the 
literature is limited and somewhat mixed. 
Studies evaluating the prevalence of insomnia among different racial/ethnic groups have 
primarily focused on comparisons between whites and blacks. Several studies found that blacks 
take longer to fall asleep, sleep for shorter periods of time, and report less satisfaction with sleep 
than whites.32-38 Interestingly, there appears to be an age by race interaction, with reports of 
insomnia increasing among older whites, but decreasing among older blacks.39 Further 
investigation into this effect is needed, however, as it may reflect social coping mechanisms (e.g., 
withholding complaints to be socially acceptable, or acceptance of hardships over a lifetime), 
rather than a true difference in prevalence.39,40 Regarding other racial/ethnic groups, the literature 
is scant and more research is needed, but there is some evidence that Native Americans and 
Hispanics have more difficulty sleeping than whites, while Asian Americans appear to experience 
sleep disturbance at rates similar to whites in the US.34,36,37,41  
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1.1.6 Clinical implications of sleep disturbance 
Although there is still much to learn about the various functions of sleep, there is evidence 
that important physical and mental processes take place during this time.  It is thought that physical 
restoration occurs during SWS, which is accompanied by the release of growth hormone and an 
increase in anabolic (tissue-building) activity.42 Sleep deficits, on the other hand, are accompanied 
by detrimental metabolic changes, including impaired glucose tolerance, up-regulated appetite, 
and decreased energy expenditure.43 Lack of sleep can disrupt regulation of the immune system, 
with effects such as increased production of inflammatory cytokines, increased C-reactive protein 
(a marker of inflammation), and decreased immune cell response.44-47  
Sleep is also considered essential for cognitive function. Memory consolidation 
(reinforcement) is thought to occur during REM and NREM stages of sleep,48 and clearance of 
neurotoxins from the cerebrospinal fluid increases dramatically during sleep. Lymphatic vessels, 
which transport toxic metabolic waste products from peripheral tissue, are not present in the central 
nervous system. Instead, neuronal metabolites are flushed from cerebrospinal fluid into interstitial 
fluid via hydrodynamic changes meditated by glial cells.49 That this process, termed the glymphatic 
system, is suppressed during the awake state helps to explain the restorative effects of sleep.50 
Polysomnography studies confirm that insomnia sufferers spend less time in SWS, which likely 
explains their complaints of next day fatigue and cognitive difficulties.51 
Patients who chronically experience disturbed sleep are at increased risk for developing a 
wide range of illnesses, including anxiety and/or depression,52-55 alcohol abuse,56 hypertension,57 
stroke,58 diabetes,59 obesity,59,60 and cancer.61 In light of these far-reaching effects, it is not 
surprising that several investigations have confirmed an association between sleep disturbances 
and reduced quality of life.62-69 In a recent study of the association between insomnia and health-
related quality of life (HRQoL) in a large, nationally representative sample, reduced HRQoL 
scores were observed in both the physical and mental domains for persons with diagnosed 
insomnia.70 
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1.1.7 Socioeconomic burden of sleep disturbance 
The socioeconomic cost of sleep disturbance is mediated by effects in many domains, 
including exacerbation of other disease states, increased risk of motor-vehicle accidents, and 
decreased workplace productivity.71,72 Sleep disturbance may itself be a risk factor for poor 
economic status, as workers with disturbed sleep experience increased odds of negative work 
outcomes, including decreased concentration and productivity, and increased absenteeism and 
accidents.73 A few studies have attempted to quantify the economic impact of insomnia, but 
updated research is needed. These studies, by different researchers using various methods and data 
sources, all confirmed that costs related to sleep disorders in the US are substantial.  Specifically, 
estimates were: $11.96 billion [US$1995] for outpatient visits, $1.97 billion [US$1995] for 
medications, $41.1 billion [US$1994] for lost productivity, and between $43.15 and $56.02 billion 
[US$1988] for accidents, but these studies are all prior to 2000.74-76 The most recent studies are 
from Ozminkowski and Wang, who found that sleep disturbances increased patients’ costs by 
about $1200 [US$2003] yearly,77 and Pollack et. al., who estimated yearly increased healthcare 
and productivity costs of $858 [US$2002-2003] per patient.78 
 
1.1.8 Treatment of sleep disturbance 
Guidelines form the American Academy of Sleep Medicine list cognitive and behavioral 
therapies, such as biofeedback or relaxation therapy, as first-line choices for treatment of 
insomnia.3 Short-term pharmacotherapy may also be used, preferably supplemented with cognitive 
or behavioral therapy.3 These therapies are discussed in detail in the following publication: Scalo 
JF, Rascati KL. Pharmacotherapy for Insomnia. In: McCall WV, ed. Advances in the Management 
of Primary and Secondary Insomnia. London, UK: Future Medicine; 2014:72-90. 
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1.1.9 Sleep disturbance and cancer 
In the context of cancer, sleep is especially important.  Patients who have difficulty 
sleeping experience increased frequency and severity of cancer pain and fatigue,79-83 and are at 
increased risk for anxiety and depression.  The effects of disturbed sleep on immune, metabolic, 
and other homeostatic systems not only hinder patients’ recovery, but may also promote cancer 
progression.61,84,85 Patients experiencing disturbed sleep report poorer quality of life79,86,87 and often 
have worse prognoses.88,89   Unfortunately, disturbed sleep is among the most common and severe 
symptoms reported by patients with cancer.90  
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1.2 SECTION II: SLEEP DISTURBANCE IN THE CONTEXT OF CANCER 
For additional detail on this topic, please see: Scalo JF, Rascati KL. Insomnia in the Setting 
of Cancer. In: McCall WV, ed. Advances in the Management of Primary and Secondary Insomnia. 
London, UK: Future Medicine; 2014:32-54. 
 
1.2.1 Prevalence of sleep disturbance in cancer 
Numerous studies have assessed the prevalence of insomnia and/or sleep disturbance in the 
setting of cancer, but results vary widely, with estimates ranging from fewer than 20% (in a sample 
of 300 women treated with radiotherapy for non metastatic breast cancer)84 to more than 90% (in 
a sample of 102 adults receiving palliative treatment for advanced cancer)91 of patients. 
Inconsistency in published estimates is partially due to variations in study designs, including 
differences in the way sleep disturbance is defined and measured, the type and stage of cancer 
studied, and study design and methodology.  
A few large studies have estimated sleep disturbance prevalence in samples representing 
multiple cancer types. In a mixed sample (in terms of cancer sites, as well as progression, and 
treatment; N=982) surveyed by Davidson et. al. (2002), 31% of participants reported insomnia 
symptoms.89 Stepanski et. al. (2009) found that 55% of participants undergoing cancer treatment 
(N=11,445) had trouble sleeping, and 26% classified their sleep troubles as moderate to severe.81 
In a sample of participants receiving chemotherapy for cancer (N=823), Palesh et. al. (2010) found 
that 81% reported disturbed sleep and 43% met the diagnostic criteria for insomnia.80 Savard et. 
al. (2011) surveyed patients with a first diagnosis of non metastatic cancer (N=991) scheduled for 
curative surgery; 31% reported sleep disturbance, and 28.5% met the diagnostic criteria for 
insomnia.92 Most recently, Romito et. al. (2014) classified 66% of chemotherapy recipients 
(N=403) as bad sleepers.93  
Correlates of sleep disturbance were evaluated in most of these prevalence studies, but the 
set of variables in each was fairly limited and there was little overlap between studies. Furthermore, 
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only Davidson et. al. (2002) and Stepanski et. al. (2009) captured multiple stages of cancer and 
modes of cancer treatment. The variation across these studies complicates the interpretation and 
synthesis of their findings. Nonetheless, from these and other studies, a number of potential risk 
factors for sleep disturbance have been identified.  
 
1.2.2 Risk factors for sleep disturbance in cancer 
Simply receiving a cancer diagnosis may precipitate nearly half of all cases of insomnia,88,89 
and existing insomnia can increase in severity after diagnosis.61,84,85 Inflammation, a hallmark of 
cancer,94-96 causes pain, cognitive impairment, and general malaise that can interrupt sleep,97 and 
is also observed to disrupt normal sleep architecture.98-100 Drugs and procedures used to treat cancer 
(or its symptoms) can also contribute to disturbed sleep.92,101,102 Severe and persistent circadian 
rhythm disruptions have been observed in patients receiving chemotherapy,103 and evidence is 
emerging that certain chemotherapeutic agents may increase the production of pro-inflammatory 
cytokines by immune cells.104 Corticosteroids are used extensively in the setting of cancer to 
control nausea, prevent or treat hypersensitivity reactions to infusions, decrease pain, increase 
appetite, reduce inflammation, and even as a component of chemotherapy, but their excitatory 
effects on the central nervous system can substantially interfere with sleep.105 When hospitalized, 
patients must endure noises, lights, discomfort, and interruptions by medical personnel,106 and for 
patients with advanced cancer, the onset of delirium late in the day can substantially disrupt 
sleep.107 Sleep is also made more difficult as a result of the many symptoms experienced by persons 
with cancer, including fatigue, pain, nausea, and vomiting.92,108-110 
 
1.2.3 Consequences of sleep disturbance in cancer 
Disturbed sleep can reduce health-related quality of life for persons with cancer,87,91,111 and 
may even worsen prognosis.88,89 Disruptions to sleep can decrease pain thresholds in healthy 
patients,112 and, for patients already in pain, a poor night’s sleep can increase next-day pain 
 
 
12 
intensity.113 Similarly, sleep disturbance also often occurs together with, and may have reciprocal 
relationships with fatigue114-117 and depression.118,119 Certain symptoms have been observed to occur 
together with such frequency that they are identified as symptom clusters. Identification of 
symptom clusters has clinical relevance, because there is evidence that symptom clusters 
synergistically affect outcomes in persons with cancer. For example, the independent effects of 
sleep disturbance, depression, and fatigue on functional performance may be augmented through 
multiple interactions.120 Better understanding of the relationships between these symptoms could 
help clinicians target therapies for more efficient and effective overall symptom control. Although 
no single model of these relationships has been consistently supported, the largest study to date, 
by Stepanski et. al. (2009) modeled the relationship between five commonly clustered symptoms 
(depression, pain, disturbed sleep, fatigue, and drowsiness), and found sleep to influence both pain 
and fatigue.81  
In the general population, sleep disturbance is associated with widespread detrimental 
effects. Sleep loss can disrupt the immune system, leading to increased inflammatory activity and 
decreased immune cell response,44-47 and has also been linked to metabolic changes, including 
impaired glucose tolerance, up-regulated appetite, and decreased energy expenditure.43 Chronic 
sleep disruption is a risk factor for a wide range of illnesses, including anxiety and depression,52-55 
alcohol abuse,56 hypertension,57 stroke,58 diabetes,59 obesity,59,60 In light of this, it is likely that sleep 
disturbance may interact with more cancer symptoms than those with which it is most commonly 
associated. 
 
1.2.4 Treatments for sleep disturbance 
Treatments for sleep disturbance include pharmacologic and non-pharmacologic 
interventions. Among non-pharmacological approaches, cognitive behavioral therapy for insomnia 
(CBT-I) is the most studied in the setting of cancer; it is free of adverse effects and it appears to 
be efficacious.121-124 CBT-I works by correcting beliefs and behaviors that interfere with sleep, and, 
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while the therapeutic effects are long-lasting, they are slow to manifest.3 Therefore, CBT-I may be 
ineffectual for patients needing acute relief or whose insomnia is not primarily due to beliefs and 
behaviors. Immediate effects, on the other hand, can be achieved with sleep-promoting 
medications (hypnotics) such as benzodiazepines (BZDs; flurazepam, temazepam, triazolam), 
benzodiazepine receptor agonists (BzRAs; zolpidem, eszopiclone, zaleplon) and melatonin 
agonists (ramelteon).125-130 125,128-131 Certain antidepressants (doxepin, trazodone, mirtazapine),125-127 
anticonvulsants (gabapentin, pregabalin),132-134 and antipsychotic (olanzapine, quetiapine) 125-127 
medications also have sleep promoting effects, as do many antihistamines (diphenhydramine, 
doxylamine, chlorpheniramine, promethazine, hydroxyzine).125-127 
 
1.2.5 Evidence relating to treatment of sleep disturbance in cancer 
1.2.5.1 Prevalence of hypnotic use 
Hypnotic use appears to be common in oncology [Table 1.1]. In a 2004 survey of 1,984 
Canadian patients, 41% received prescriptions for hypnotics, 37% had used hypnotics at some time 
since their diagnosis, and 23% were currently using hypnotics.135 Predictors of hypnotic use 
included anxiety or psychological difficulties, chemotherapy (current or past), opioid use, and 
older age.135 The vast majority (79%) used BZDs, followed by antidepressants (10%), and 
zopiclone (9%).135 These results are consistent with an earlier (1996) study of 1,012 Canadian 
patients with cancer, in which 22% reported hypnotic use (hypnotic type was not specified).89 
Hypnotic use was especially high in patients with lung cancer (40%), and lowest for those with 
genitourinary cancers (15%).89 Similarly, in a study of 909 oncology patients in Israel in the late 
1990s, 25.7% reported using sleeping pills or tranquilizers in the previous week.136 Higher rates of 
hypnotic use were observed in a study of 100 outpatients with terminal cancer in Western Canada; 
more than half (53%) reported using some intervention for sleep disturbance, with sleep 
medication (unspecified) being the most common (37%).82 
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Studies on the use of hypnotics in US oncology patients date back to the 1970s, but recent 
data are lacking. In 1977, Derogatis et. al.137 surveyed 1,579 inpatients at five large cancer centers 
in the northeast and California over a six-month period. The mean age was 54 years, 52% had 
recurrence of a primary lesion, and 58% had metastatic disease. The majority of subjects were 
female (60%), white (80%), and married (66%). In this sample, 38% were prescribed hypnotics 
(barbiturates, chloral derivatives, and benzodiazepines) and hypnotics accounted for 48% of all 
prescribed psychotropics.137 The authors noted, however, that the estimate may have been inflated 
by routine use of hypnotics for surgical patients. Sleep was indicated as the prescribing reason for 
85% of hypnotics and 44% of all psychotropics (including anxiolytics, antidepressants, and 
anticonvulsants).137 The most frequently prescribed hypnotic was the benzodiazepine flurazepam 
(71%), followed by the barbiturate pentobarbital (19%), and chloral derivatives (9%).137 
In the 1980s, hypnotic use remained high, but the choice of hypnotic class changed 
markedly. As evidenced in the following studies, barbiturates and chloral derivatives were 
replaced with the relatively safer benzodiazepine and antihistamine hypnotics. 
Between January 1981 and February 1982, Jaeger et. al.138 surveyed 1,000 patients with 
advanced cancer at Cavalry Hospital, New York. Mean age was 68.2 years, and 93% of subjects 
had metastatic disease.138 Females made up 55% of the sample, the racial distribution was 73% 
white, 23% black, and 4% other, and marital status was: 34% married, 37% widowed, 17% single, 
13% divorced.138 More than half (56%) of participants were prescribed a hypnotic 
(diphenhydramine, flurazepam, or pentobarbital) and hypnotics comprised 33% of psychotropic 
(anxiolytics, antidepressants, hypnotic) prescriptions.138 Sleep was the prescribing reason for 94% 
of hypnotic prescriptions and 34% of all psychotropic prescriptions.138 The most frequently 
prescribed hypnotic was the antihistamine diphenhydramine (66%), followed by the 
benzodiazepine flurazepam (32%), and the barbiturate pentobarbital (2%).138  
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Table 1.1  Estimates of hypnotic us in persons with cancer. 
Study  
Authors 
Study 
Period 
Sample 
Size 
Hypnotic 
Users 
Hypnotic  
Types 
Sample  
Population 
Outside the United States 
Paltiel et. al. 136 Apr 1997– 
Nov 1998  
  909 26% Not specified Oncology patients in 
three Israeli hospitals 
Casault et. al.135 
 
2004 1,984 22% 
 
Not specified Patients visiting the 
outpatient oncology 
clinic at the L’Hôtel-
Dieu de Québec in 
Canada 
Sela, Watanabe, & 
Nekolaichuk82 
Published 
in 2004 
  100 37% Not specified Outpatients with 
terminal cancer in 
Western Canada 
Inside the United States, prior to the introduction of benzodiazepine receptor agonists (current standard of care) 
Derogatis et. al.137 
 
Apr 1977 
– Sep 1977 
1,579 38% 71% Flurazepama 
19% Barbiturate 
pentobarbital  
  9% Chloral derivatives  
Inpatients at five large 
cancer centers in the 
northeast United States 
and California 
Jaeger et. al.138 
 
Jan  1981 
– Feb 1982 
1,000 56% 
 
66% Diphenhydramineb 
32% Flurazepama 
  9% Barbiturate 
pentobarbital  
Patients with advanced 
cancer at Cavalry 
Hospital, New York 
Stiefel et. al.139 Dec 1987   200 43% 42% Diphenhydramineb 
33% Triazolama   
  8% Midazolama  
  6% Chloral derivatives  
  5% Pentobarbital  
  3% Phenobarbital  
  3% Temazepamb  
Charts of 200 
consecutive adult 
patients admitted to 
Memorial Sloan-
Kettering Cancer 
Center, New York 
Inside the United States, after to the introduction of benzodiazepine receptor agonists (current standard of care) 
Guo et. al.140 Sep 2002 – 
Oct 2003 
   96 24% Not specified Acute rehabilitation 
inpatients at M.D. 
Anderson Cancer 
Center, Houston, Texas 
Koopman et. al.141 Published 
in 2002 
   97 37% Not specified Women with metastatic 
or locally recurrent 
breast cancer  
Costantini, Ale-Ali, 
and Helsten142 
April 1, 
2008 to 
March 31, 
2010 
 124 32% 39% Benzodiazepines 
37% Benzodiazepine 
receptor agonists 
  9% Trazodonec 
  6% Gabapentind 
  6% Melatonin 
  2% Diphenhydramineb 
+ acetaminophen 
Women receiving 
chemotherapy for breast 
cancer 
a Benzodiazepine,  b Antihistamine, c Antidepressant, d Anticonvulsant 
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In 1987, Stiefel et. al. reviewed medical charts of 200 patients admitted to the Memorial 
Sloan-Kettering Cancer Center, New York.139 Just over half (55%) were male, and mean age was 
52 years. Mean time since diagnosis was 23 months, and the majority (86%) had a history of (or 
current) metastatic disease.139 Almost half (43%) of psychotropic prescriptions were for hypnotics 
(benzodiazepines, barbiturates, chloral derivatives, and diphenhydramine), and hypnotics 
comprised 95% of all prescriptions for sleep.139 The most frequently prescribed hypnotics were 
benzodiazepines (44%), followed by the antihistamine diphenhydramine (41%), barbiturates (9%), 
and chloral derivatives (6%).139 
In 1992, zolpidem (Ambien®, Sanofi) became the first benzodiazepine receptor agonist 
(BzRA) to enter the US market, followed by zaleplon (Sonata®, Pfizer) in 1999 and eszopiclone 
(Lunesta®, Sunovion Pharmaceuticals) in 2004.143 With the hypnotic efficacy similar to 
benzodiazepines, but fewer side effects, BzRAs (also called Z-meds) quickly became the drug of 
choice for sleep disturbance. In 2003, benzodiazepines represented only about 11% of 
prescriptions for insomnia in the US, while antidepressants and BzRAs accounted for about 22% 
and 18%, respectively.144 Since 2000, hypnotic use in the general population has increased overall, 
but BzRA use has grown most dramatically, increasing nearly four-fold from 2000 to 2010.145 
BzRAs are now the most commonly prescribed medication for insomnia in the US (about 38% of 
prescriptions), followed closely by the antidepressants trazodone and doxepin (36%, combined).145    
Despite the dramatic shift in prescribing patterns for hypnotics in the US population, there 
is little recent information on their use in oncology. To characterize symptom burden and 
pharmacologic management of patients with cancer, Guo et. al. reviewed medical records of 96 
inpatients with mixed cancer types undergoing acute inpatient rehabilitation between September 
1, 2002 and October 31, 2003 at M.D. Anderson Cancer Center, Houston, Texas.140 Median age 
was 64 years, and males comprised 53% of the sample.140 Upon discharge, 24% were given 
hypnotics (particular drugs or drug classes were not identified).140  
Two studies have estimated hypnotic use in women with breast cancer. The first, published 
in 2002 by Koopman et. al., surveyed 97 women with metastatic or locally recurrent breast cancer 
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who were participating in a randomized clinical trial of psychotherapy for psychosocial 
adjustment.141 Mean age was 53.0 years, and the racial distribution was 90% white, 6% Asian, 1% 
black, 1% Native American, and 2% other.141 Just over half (53%) were married, 35% were 
separated, divorced, or widowed, and 1% had never been married.141 About one-third (37%) of this 
sample reported use of sleeping pills (unspecified) within the last 30 days, with higher frequency 
of use among those also reporting pain or depressive symptoms.141 
From April 1, 2008 to March 31, 2010, Costantini, Ale-Ali, and Helsten evaluated sleep 
aid prescribing practices for 124 women receiving chemotherapy for breast cancer. Mean age was 
51 years, 57.3% were premenopausal, and 62.1% were married. Sleep aid use prior to 
chemotherapy was reported by 13.7% of patients, and 32.3% received prescriptions for sleep aids 
during chemotherapy. The most commonly prescribed sleep aids were benzodiazepines (39.2%), 
followed by BzRAs (37.2%), the antidepressant trazodone (9.8%), the anticonvulsant gabapentin 
(5.9%), melatonin (5.9%), and the antihistamine diphenhydramine (with acetaminophen, 2%).142  
Beyond these studies, little is known about current patterns of hypnotic use in the US in 
persons with cancer. Given the prevalence of sleep disturbance and historical patterns of hypnotic 
use in these patients, it is reasonable to expect that hypnotic use remains high. It is, therefore, 
important to characterize patterns of use, as such information is essential for evaluation of 
healthcare distribution, utilization, and outcomes. 
 
1.2.5.2 Outcomes associated with hypnotic use in persons with cancer 
Despite a history of frequent hypnotic use in oncology, there is scant evidence, to date, 
regarding their use in this population.  
Benzodiazepines for treatment of sleep disturbance have been evaluated in two studies of 
patients with terminal cancer, and one study of women undergoing surgery for breast cancer. 
Ehsanullah et. al. (1982) randomly assigned 24 patients with terminal cancer to one of two 
treatment groups: 5 mg diazepam or 10 mg diazepam.146 After five nights, and a two-day drug free 
 
 
18 
washout period, subjects were switched to the other dose for an additional 5 nights.146 Seven 
patients died before completing the study.146 Each morning, nurses rated subjects as sleeping 
“well”, “the same”, or “badly” the previous night.146 Most patients were rated as having slept well 
at both the 5 mg dose (15/19) and 10 mg dose (17/21), but side effects were common, especially 
daytime drowsiness (58%), dry mouth (29%), and amnesia (21%).146 
Matsuo and Morita retrospectively reviewed use of midazolam (n=104, mean dose=10 mg) 
and flunitrazepam (n=59, mean dose=2 mg) in patients with terminal cancer who were treated in 
Japan between April 2002 through July 2005.147 Efficacy was rated as “poor”, “fair”, or “good” 
based on subjective reports by patients and/or clinicians, as recorded in medical records.147 
Presence of adverse events (hangover, delirium, and/or respiratory depression) was evaluated in a 
similar fashion.147 Efficacy was 91% for midazolam (63% good, 28% fair) and 81% for 
flutrazepam (44% good, 37% fair), and as with the previous study, adverse events were common 
for both midazolam and flutrazepam: hangover (34% and 19%, respectively), next morning 
delirium (11% and 15%), and respiratory depression (3.8% and 17%).147 
In a double-blinded, placebo-controlled trial published in 1994 by Jacobsen et. al., 100 
women who had received 0.125 mg of triazolam the night before surgery for breast cancer were 
randomized to triazolam 0.125 mg (n = 49, with the option to increase to 0.25 mg on subsequent 
nights) or placebo (n = 51) for three nights.148 Seventy-nine participants completed all three nights 
of the study, 84% of the triazolam group (n = 41) and 75% of the placebo group (n = 38).148 For 
patients who withdrew after night two (N = 15, triazolam n = 6, placebo n = 9), data for night two 
were substituted for night three.148 No participant was removed from the study due to poor response 
or adverse reactions, but eleven participants chose to discontinue (triazolam n = 4, placebo n = 
7).148 Each morning, subjects were asked to estimate the time to sleep onset (minutes) and number 
of wakings after sleep onset, and to evaluate general quality of sleep (1 = very bad, to 7 = very 
good).148 In addition, two visual analog scales (VAS, 100mm) were used to estimate difficulty 
falling asleep (0 = easiest ever, to 100 = hardest ever) and feeling rested the following morning (0 
= not al all rested, to 100 = as rested as I have ever been).148 Compared to the placebo group, 
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patients on triazolam had less difficulty falling asleep (p = 0.002), reported fewer awakenings (p 
= 0.004), felt more rested in the morning (p = 0.008), and rated their sleep quality higher (p < 
0.001).148 There was no difference in estimated time to fall asleep.148 
Two BzRAs, zolpidem and eszopiclone, have been studied in patients with cancer. Joffe 
et. al. investigated whether adding zolpidem to venlafaxine could improve sleep for women 
experiencing menopausal symptoms from breast cancer treatment.149 This double-blinded study 
randomized 53 women to zolpidem 10 mg (n = 25) or placebo (n = 28) for five weeks between 
February 2004 and July 2007.149 Thirty-eight women completed the study, 88% on zolpidem and 
57% on placebo.149 Improved sleep was defined as a decrease in wake time after sleep onset 
(WASO) of at least 15 minutes (measured objectively by actigraphy) or a decrease (improvement) 
of at least 3 points on the Pittsburgh Sleep Quality Index (a subjective measure).149 More women 
in the zolpidem group had improved sleep (40% vs 14%; p = 0.035), and endpoint scores in the 
zolpidem group improved (WASO improved 9%, PSQI score improved 15%), whereas scores 
worsened in the placebo group (WASO worsened 2%, PSQI worsened 26%).149 
Between September 2006 and December 2009, eszopiclone was evaluated in patients with 
hematologic malignancies who experienced mucositis pain severe enough to require patient-
controlled analgesia (PCA).150 PCA provides a continuous infusion of intravenous opioid 
analgesia, and also allows patients to self-administer, within limits, additional boluses of 
medication as needed. Dimsdale et. al. randomized 45 patients to eszopiclone (n = 22, 2-3 mg, 
depending on age and potential drug interactions) or placebo (n = 23) for two nights.150 Sleep 
measures (time to fall asleep, time asleep, number of wakings, depth of sleep, level of sleepiness) 
were based on patients’ subjective reports, surveyed each morning.150 Likert-type scales were used 
for both depth of sleep (0 = poor, to 10 = excellent) and level of sleepiness (0 = very sleepy, to 10 
= not sleepy at all).150 The eszopiclone group reported greater total sleep time (mean difference = 
84.07 min, p = 0.05), fewer number of wakings (mean difference = -2.82, p < 0.001), better sleep 
quality (mean difference = 2.09, p = 0.05), and better sleep depth (mean difference = 1.57, p = 
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0.05).150 Time to fall asleep and current level of sleepiness were not significantly different, and 
there were no significant differences in use of opioid analgesia.150 
Some medications used “off-label” for sleep disturbance (see Section 2.4.2) have also been 
evaluated in persons with cancer.  Kim et. al. (published in 2008) conducted a four-week open-
label trial of mirtazapine for treatment of nausea, vomiting, and insomnia in Korean patients with 
cancer and depression.151 Of the forty-two subjects originally enrolled, seventeen (41%) completed 
the four-week study.151 Four patients discontinued due to side effects: sedation (2), constipation 
(1), and weakness (1).151 Patients evaluated their sleep using 5-point Likert scales for: ease of sleep, 
quality of sleep, ease of waking in the morning, and ability to function after waking.151 
Improvements to ease of sleep, quality of sleep, and ability to function were reported as early as 
day one, while ease of waking improved at day five.151 In addition, scores for depression improved 
from the first week, and, for subjects experiencing nausea and vomiting from chemotherapy, 
symptoms improved from the first day of mirtazapine administration.151 
Trazodone was studied in 30 patients with insomnia who were receiving palliative care for 
advanced cancer at Osaka University Hospital between December 2008 and November 2011.152 
Tanimuki et. al. administered a starting dose of 12.5 – 25 mg, and increased to 25 – 50 mg until 
insomnia improved.152 Fifteen patients (50%) achieved improved sleep within seven days without 
requesting a dose increase.152 In addition, of four subjects from the original sample who reported 
experiencing troublesome nightmares, two reported improvements after initiation of trazodone.152 
Between March 2007 and March 2009, Chen et. al. conducted a randomized, placebo-
controlled trial to evaluate melatonin for improvement of mood, sleep, and hot flashes in survivors 
of breast cancer.153 Ninety-five women were randomized to melatonin (3 mg, n = 48) or placebo 
(n = 47) for four months, and 52% of those subjects reported poor sleep in the month preceding 
enrollment (56% on melatonin, 43% on placebo).153 Eighty-six (91%) participants completed the 
study; four from the melatonin group withdrew due to side effects (headaches, insomnia, 
nightmares).153 Sleep was evaluated at baseline and at four months with the Pittsburgh Sleep 
Quality Index (PSQI), which subjectively measures sleep quality, latency, duration, efficiency, and 
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disturbances, as well as hypnotic use and daytime dysfunction during the last month.153 In the 
melatonin group, average overall PSQI score was 1.67 points lower (better), compared to placebo 
(95% CI 0.67–2.66, p = 0.001), and mean changes in PSQI total score were -1.9 and -0.1, 
respectively (p < 0.001).153 No differences were observed for depression or hot flashes.153 
Finally, Palesh et. al. studied the effects of paroxetine on sleep problems in patients 
receiving chemotherapy between June 1997 and April 1999.154 Paroxetine is a serotonin-selective 
reuptake inhibitor (SSRI) antidepressant, and is not commonly used for sleep, as it lacks the 
sedative effects of less selective antidepressants (insomnia is, in fact, a common side effect).155 
Nonetheless, Palesh et. al. found promising results. After a second cycle of chemotherapy, 426 
subjects were randomized to a 60-day supply of paroxetine 20 mg (n = 217) or placebo (n = 209).154 
Sleep was assessed with three questions that asked participants to quantify the number of nights 
they had trouble with: falling asleep, waking in the middle of the night, or waking up too early.154 
Fewer patients in the paroxetine group reported sleep problems (79%) compared to patients on 
placebo (88%, p < 0.05), but overall prevalence of sleep disturbance remained high.154  
These appear to be the only studies to evaluate outcomes associated with hypnotic use in 
persons with cancer, and the paucity of evidence is reflected in published recommendations and 
guidelines for the management of sleep disturbance in this population. 
 
1.2.5.3 Guidelines for hypnotic use in persons with cancer 
The National Comprehensive Cancer Network (NCCN), Multinational Association of 
Supportive Care in Cancer (MASCC), European Society For Medical Oncology (ESMO), and 
American Society of Clinical Oncology (ASCO) have developed supportive care guidelines for 
several cancer symptoms, including pain, fatigue, nausea and vomiting, mucositis, and distress. 
To date, however, only the Oncology Nursing Society (ONS) and the Canadian Partnership 
Against Cancer have published guidelines on the management of sleep disturbance. The 
recommendations of both groups are substantially limited by inconsistent evidence in support of 
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CBT-I interventions and a paucity of experimental data supporting the use of hypnotics.156,157 In 
addition to these guidelines, there have been several published reviews of evidence relating to 
treatment of insomnia in cancer. Two of these, Langford et. al. (2012)158 and Dickerson et. al. 
(2014)111 reviewed only nonpharmacological interventions and will not be discussed further in this 
section. 
In 2002, Hirst and Sloan published a Cochrane review on the use of benzodiazepines and 
BzRAs in palliative care.159 The initial sample of 404 potential studies was reduced to 37 on the 
basis of relevance.159 This selection was further reduced to three studies for issues relating to study 
design and/or level of detail.159 Ultimately, the remaining three studies were excluded due to lack 
of usable data, and the authors were unable to make any recommendations.159 
Since 2002, several publications have reviewed evidence related to management of sleep 
disturbance in persons with cancer. Most conclude that there is sufficient evidence to support the 
use of cognitive behavioral therapies, but evidence related to pharmacological treatment of sleep 
disturbance appears in only a few publications and most offer little or no guidance on the use of 
medications for sleep disturbance in persons with cancer. 
In a review for the Oncology Nursing Society, Page et. al. (2006) found, “no published 
meta-analysis or experimental design study,” examining the efficacy of hypnotics in patients with 
cancer, and assigned hypnotics to the category, “Benefits Balanced with Harms,” indicating that 
clinicians and patients should evaluate risks and benefits on a case by case basis.156 In a follow-up 
review, Berger (2009) also reported that, “no intervention studies have tested the effects of 
prescription sleep drugs in patients with cancer,” and made no recommendations regarding their 
use.160 
A 2007 review by Fiorentino and Ancoli-Israel notes that the National Institutes of Health 
State of the Science Conference on Insomnia determined BzRAs and ramelteon to be safer than 
benzodiazepines, and provides details (e.g., dosing, side effects, cost) for those medications. No 
studies on the effects of hypnotics in patients with cancer are cited, however, and no further 
recommendations regarding their use are made. 161  
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In 2012, Langford, Lee, and Miaskowski published a comprehensive review and meta-
analysis of sleep disturbance interventions in oncology. No pharmacological interventions were 
included.158 
Also in 2012, Palesh et. al. published a review of sleep disturbance (prevalence, causes, 
and management) in patients undergoing chemotherapy.162 The authors reported finding no 
assessment of sleep aids in persons receiving chemotherapy, and cautioned against the possibility 
of harmful drug interactions.162 
A third publication in 2012, by Pachman et. al., reviewed treatments for fatigue, 
neuropathy, and pain, as well as insomnia, in cancer survivors.110 This review included the studies 
on mirtazapine,151 trazodone,152 and paroxetine154 in persons with cancer, but concluded that, 
overall, there was insufficient evidence to recommend any pharmacologic intervention.110 
A review of psychopharmacology in oncology by Caruso et. al. published in 2013 cites two 
investigations of antidepressants for treatment of sleep disturbance, the Tanimukai et. al.152 study 
on trazodone and the Palesh et. al.154 study on paroxetine, both of which had positive, if modest, 
results.163 Use of benzodiazepines is discouraged, due to the potential for respiratory depression, 
and the authors remain equivocal on use of BzRAs, citing lack of evidence.163 
A Pan-Canadian practice guideline for sleep disturbance in adults with cancer was also 
published in 2013, by Howell et. al.164 The guidelines were based upon a systematic review of 
evidence (published separately, in 2014 by the same authors), which included the small, 
randomized controlled trial (RCT) of eszopiclone in patients with mucositis pain.150 The remainder 
of the review, however, cited data from non-cancer populations because, “no RCT data involving 
pharmacological interventions for insomnia in cancer were identified.”157 In the guidelines, Howell 
et. al. advocated for non-pharmacological approaches, such as prevention, supportive education, 
and cognitive behavioral therapy for insomnia (CBT-I), as first line therapy, and recommended 
that pharmacotherapy be reserved for augmentation (e.g., while waiting for CBT-I to take effect) 
or rescue (e.g., for patients too ill to complete CBT-I), and for no more than four weeks.164 No 
recommendations regarding specific medications were made, but clinicians were advised to base 
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their selection on patient-specific factors, such as age, primary sleep complaint, and potential for 
drug interactions.164 
Also in 2014, Davis and Goforth published a review on the effects of, and interventions 
for, insomnia in cancer, and, as with the review by Howell et. al., pharmacotherapy trials cited 
were all conducted in non-cancer populations.165 Nonetheless, Davis and Goforth concluded, 
despite the “weak evidence,” that clinicians should consider multimodal treatment approaches that 
include both nonpharmacological and pharmacological interventions, and observed that many 
medications have additional effects that could provide added benefits for persons with cancer.165  
Finally, a similar conclusion was made by Scalo and Rascati that same year.166 After 
reviewing the therapeutic and adverse effects of sleep disturbance medications, as observed in non-
cancer populations, the authors discussed how each therapy might ameliorate (or exacerbate) the 
unique needs of persons with cancer [Table 1.2].166  
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Table 1.2 Potential benefits and risks of commonly used hypnotics for patients with cancer. 
Drug Class Drugs Potential Benefits Potential Risks 
Benzodiazepines 
(BZDs) 
Estazolam* 
Flurazepam* 
Quazepam* 
Temazepam* 
Triazolam* 
Alprazolam 
Lorazepam 
Clonazepam 
- Anxiolytic 
- Longer duration than BzRAs 
- Significant fall risk 
- Next day residual effects may worsen 
CRF  
- Withdrawal and/or rebound on 
discontinuation 
- Risk of respiratory depression when 
combined with opioid analgesics 
- REM sleep suppression 
Benzodiazepine 
Receptor Agonists 
(BzRAs) 
Eszopiclone* 
Zaleplon* 
Zolpidem* 
- Fewer side effects than BDZs 
- Extended-release, sublingual, and spray 
formulations are available 
- Risk of parasomnias, anterograde 
amnesia 
- Dose-dependent next day residual effects 
- Significant fall risk 
- Withdrawal syndrome 
- REM sleep suppression 
Melatonin 
Agonists 
Melatonin 
Ramelteon* 
- Excellent safety profile 
- Better efficacy in older patients 
- May help to correct circadian rhythms 
- Possibly antioxidant, antiproliferative 
- Low fall risk 
- None documented 
Tricyclic 
Antidepressants 
Doxepin* 
 
 
- Low fall risk  
- May improve neuropathic pain 
- Antidepressant (at higher doses) 
- Risk of cardiac conduction abnormalities 
- Risk of anticholinergic effects  
- Risk of SIADH, hyponatremia  
Other Sedating 
Antidepressants 
Mirtazapine - Low fall risk 
- Preserves sleep architecture 
- Improved appetite and weight gain  
- Minimal risk of anticholinergic effects, 
cardiotoxicity, SIADH, hyponatremia 
- Effective for depression at low doses 
- Anxiolytic & antiemetic 
- May improve neuropathic pain 
- May cause or exacerbate restless leg 
syndrome or periodic limb movements 
 Trazodone - Anxiolytic, antidepressant (high doses) 
- May improve neuropathic pain 
- Risk of SIADH, hyponatremia  
- Risk of cardiac conduction abnormalities  
Sedating 
Antipsychotics 
Olanzapine 
Quetiapine 
- Effective for delirium (Recommended 
for short-term use only) 
- Risk of metabolic syndrome, neuroleptic 
malignant syndrome, and blood 
dyscrasias 
- Risk of SIADH, hyponatremia  
Anticonvulsants Gabapentin 
Pregabalin 
- May improve neuropathic pain - Peripheral edema may exacerbate CHF 
- Rare cases of blood dyscrasias, 
hyponatremia 
Antihistamines Diphen-
hydramine† 
Doxylamine† 
 
By Rx only: 
Hydroxyzine 
Promethazine 
- Antiemetic 
- Anxiolytic 
- Strongly anticholinergic - may exacerbate 
CRF and/or opioid-induced constipation 
- Tolerance can develop with continued use 
- Residual sedation may exacerbate CRF 
Promethazine: 
- Risk of cardiotoxicity, neuroleptic 
malignant syndrome, bone marrow 
suppression 
 
CHF: congestive heart failure, CRF: cancer-related fatigue; REM: rapid eye movement, Rx: prescription, SIADH: syndrome of inappropriate 
diuretic hormone 
*  Prescription medication with FDA approval for treatment of insomnia 
† Non-prescription medication with FDA approval for use as a night-time sleep aid 
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1.3   SECTION III: RATIONALE FOR PROPOSED STUDY 
Sleep disturbance warrants special consideration in patients with cancer. In addition to the 
usual risk factors, oncology patients encounter numerous other sleep disruptors, and the incidence 
of sleep disturbance is high in this setting. Sleep disturbances also have more severe consequences 
for persons with cancer, including exacerbation of other symptoms, diminished quality of life, and 
worsened prognoses. Effective treatment of sleep disturbances is, therefore, an essential 
component of supportive care. 
There is some evidence that nonpharmacologic therapies, which correct beliefs and 
behaviors that interfere with sleep, are effective in persons with cancer. Such therapies may not be 
appropriate, however, for patients with limited time or functional status or for those whose sleep 
disturbance has other causes. Pharmacologic interventions, on the other hand, can offer rapid relief, 
and some may offer therapeutic benefits for other symptoms, such as depression, anxiety, or 
anorexia. There is little known, however, about the safety and efficacy of hypnotic drugs in persons 
with cancer.  
The first rationale for this research is to delineate more clearly the use of hypnotics in 
persons with cancer. Several US studies have measured hypnotic use in oncology prior to the 
1990s. The introduction of benzodiazepine receptor antagonists in the late 20th century, however, 
has dramatically altered prescribing practices in the general US population,145 and it is unclear 
whether this extends to the oncology setting. From the few studies conducted so far, hypnotic use 
appears to be common, with estimates hovering near 30%.82,140-142 Even less is known about the 
distribution of hypnotic use by drug class, but results from one study indicate a relatively high 
reliance on benzodiazepines (39.2% of all hypnotics prescribed).142 Given the potential for adverse 
events, especially in persons with cancer, it is important to obtain current data on how commonly 
benzodiazepines, as well as other hypnotics, are prescribed. The proposed study of hypnotic use 
will have the largest and most diverse population to date (> 2,700 patients from 38 regionally 
dispersed sites), which will improve generalizability. In addition, the data set includes an 
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abundance of variables describing patient characteristics and outcomes, which will allow patterns 
of hypnotic use in sub-samples to be described as well.   
The second rationale is the need for more data on outcomes associated with hypnotic use 
in oncology. Despite the prevalence of sleep disturbance and hypnotic use in persons with cancer, 
there is, to date, little guidance on the pharmacologic management of sleep disturbance in this 
population. Recommendations are substantially limited by the paucity of experimental data.156,157 
The proposed study will contribute to the literature as a comprehensive exploration of symptom 
burden and quality of life outcomes associated with hypnotic use in patients with cancer. The data 
available for analysis will allow comparisons of outcomes between subjects using and not using 
hypnotics, with outcomes variables that are scaled in intensity. Although the retrospective design 
of this study will limit what conclusions can be drawn, the findings may reveal drug–outcome 
relationships that should be further explored in prospective trials. 
Finally, this study is motivated by the need to better understand relationships between sleep 
and other symptoms. Many cancer symptoms occur concomitantly and interactions between them 
have been observed.90,167,168 Understanding how these symptoms influence each other is key to 
optimizing symptom management. Cancer-related pain, fatigue, and depression have commonly 
been associated with sleep disturbance, but given the multifarious somatic effects of sleep, it is 
reasonable to hypothesize that relationships exist between sleep and other cancer symptoms that 
are less frequently measured (e.g., cognitive function, appetite loss).169 Studies testing this 
hypothesis may help to uncover important causal pathways to target therapeutically.  
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Chapter 2: Methodology 
 
CHAPTER OVERVIEW 
This chapter documents the methodology that was used to evaluate hypnotic use and 
associated outcomes in persons with cancer, beginning with a listing of the specific aims and 
hypotheses. The general study design is outlined, followed by detailed descriptions of the data 
source and study variables, the analysis plans for each specific aim, and the sample size 
requirements for each analysis. A discussion of study limitations closes the chapter. 
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2.1 SECTION I:  SPECIFIC AIMS  
 
For a population of patients with cancer, the aims of this study are: 
 
1. To quantify the prevalence of reported sleep disturbances and evaluate whether or not 
demographic characteristics, disease characteristics, treatment characteristics, symptom 
burden, or medication use are related to sleep disturbance. 
 
2. To quantify the prevalence of hypnotic use and evaluate whether or not demographic 
characteristics, disease characteristics, treatment characteristics, symptom burden, or 
medication use are related to hypnotic use.  
 
3. To quantify reported change in sleep disturbance and evaluate whether or not demographic 
characteristics, disease characteristics, treatment characteristics, symptom burden, or 
medication use are related to change in sleep disturbance. 
 
4. To evaluate whether or not symptom burden and health-related quality of life outcomes 
differ on the basis of sleep disturbance or hypnotic use, controlling for demographic, 
disease, and treatment characteristics.  
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2.2 SECTION II:  HYPOTHESES  
2.2.1 Specific Aim 1 
To quantify the prevalence of sleep disturbance and evaluate whether or not demographic 
characteristics, disease characteristics, treatment characteristics, symptom burden, or medication 
use are related to sleep disturbance in the study cohort. 
 
H0 (1a): Demographic characteristics (age, sex, race, employment status, driver status, history of 
depression) will not differ significantly when cohort is ranked by severity of reported sleep 
disturbance. 
H0 (1b): Disease characteristics (cancer site, cancer stage, age at diagnosis, time since diagnosis, 
progression status, performance status, weight loss) will not differ significantly when 
cohort is ranked by severity of reported sleep disturbance. 
H0 (1c): Treatment characteristics (current chemotherapy, current radiotherapy, clinician type, 
opioid analgesia, clinician assessments of symptom burden and quality of life, difficulty to 
treat, medication use for symptom management) will not differ significantly when cohort 
is ranked by severity of reported sleep disturbance.  
H0 (1d): Symptom burden (pain, fatigue, nausea, vomiting, distress, shortness of breath, cognitive 
difficulty, anorexia/cachexia, drowsiness, dry mouth, depression, numbness/tingling, 
diarrhea, constipation, sore mouth, rash/itching, hair loss, cough) will not differ 
significantly when cohort is ranked by severity of reported sleep disturbance.  
H0 (1e): Demographic characteristics, disease characteristics, treatment characteristics, and 
symptom burden are not related to level of reported sleep disturbance [scale: 0 = “not 
present” to 10 = “as bad as you can imagine”].  
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2.2.2 Specific Aim 2 
To quantify the prevalence of hypnotic use and evaluate whether or not demographic 
characteristics, disease characteristics, treatment characteristics, symptom burden, or medication 
use are related to hypnotic use in the study cohort. 
 
H0 (2a): Demographic characteristics (age, sex, race, employment status, driver status, history of 
depression) will not differ significantly when cohort is dichotomized as users/nonusers of 
hypnotics or categorized by type of hypnotic used. 
H0 (2b): Disease characteristics (cancer site, cancer stage, age at diagnosis, time since diagnosis, 
progression status, performance status, weight loss) will not differ significantly when 
cohort is dichotomized as users/nonusers of hypnotics or categorized by type of hypnotic 
used. 
H0 (2c): Treatment characteristics (current chemotherapy, current radiotherapy, clinician type, 
opioid analgesia, clinician assessments of symptom burden and quality of life, difficulty to 
treat, medication use for symptom management) will not differ significantly when cohort 
is dichotomized as users/nonusers of hypnotics or categorized by type of hypnotic used.  
H0 (2d): Symptom burden (pain, fatigue, nausea, vomiting, distress, shortness of breath, cognitive 
difficulty, anorexia/cachexia, drowsiness, dry mouth, depression, numbness/tingling, 
diarrhea, constipation, sore mouth, rash/itching, hair loss, cough) will not differ 
significantly will not differ significantly when cohort is dichotomized as users/nonusers of 
hypnotics or categorized by type of hypnotic used.  
H0 (2e): Demographic characteristics, disease characteristics, treatment characteristics, and 
symptom burden are not related to use of hypnotics or the use of a specific class of 
hypnotic.  
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2.2.3 Specific Aim 3 
To quantify change in sleep disturbance and evaluate whether or not demographic 
characteristics, disease characteristics, treatment characteristics, symptom burden, or medication 
use are associated with change in sleep disturbance in the study cohort. 
 
H0 (3a): Demographic characteristics (age, sex, race, employment status, driver status, history of 
depression) will not differ significantly when cohort is categorized by change in level of 
reported sleep disturbance. 
H0 (3b): Disease characteristics (cancer site, cancer stage, age at diagnosis, time since diagnosis, 
progression status, performance status, weight loss) will not differ significantly when 
cohort is categorized by change in level of reported sleep disturbance. 
H0 (3c): Treatment characteristics (current chemotherapy, current radiotherapy, clinician type, 
opioid analgesia, clinician assessments of symptom burden and quality of life, difficulty to 
treat, medication use for symptom management) will not differ significantly when cohort 
is categorized by change in level of reported sleep disturbance. 
H0 (3d): Symptom burden (pain, fatigue, nausea, vomiting, distress, shortness of breath, cognitive 
difficulty, anorexia/cachexia, drowsiness, dry mouth, depression, numbness/tingling, 
diarrhea, constipation, sore mouth, rash/itching, hair loss, cough) will not differ 
significantly when cohort is categorized by change in level of reported sleep disturbance. 
H0 (3e): Demographic characteristics, disease characteristics, treatment characteristics, and 
symptom burden are not associated with change in level of reported sleep disturbance.  
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2.2.4 Specific Aim 4 
To evaluate whether or not symptom burden and health-related quality of life outcomes 
differ on the basis of sleep disturbance or hypnotic use, controlling for demographic, disease, and 
treatment characteristics. 
H0 (4a): Symptom burden outcomes (pain, fatigue, nausea, being distressed, dyspnea, cognitive 
difficulties, anorexia/cachexia, drowsiness, dry mouth, sad/depressed, vomiting, 
numbness/tingling, diarrhea, constipation, sore mouth, rash/pruritus, hair loss, coughing) 
will not differ significantly on the basis of level of reported sleep disturbance.  
H0 (4b): Quality of life outcomes (based on six domains: general activity, mood, work, relations 
with other people, walking, and enjoyment of life) will not differ significantly on the basis 
of level of reported sleep disturbance. 
H0 (4c): Symptom burden outcomes (pain, fatigue, nausea, being distressed, dyspnea, cognitive 
difficulties, anorexia/cachexia, drowsiness, dry mouth, sad/depressed, vomiting, 
numbness/tingling, diarrhea, constipation, sore mouth, rash/pruritus, hair loss, coughing) 
will not differ significantly on the basis of level of reported hypnotic use. 
H0 (4d): Quality of life outcomes (based on six domains: general activity, mood, work, relations 
with other people, walking, and enjoyment of life) will not differ significantly on the basis 
of level of reported hypnotic use. 
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Table 2.1 Hypotheses for Specific Aim 1      
Hypothesis DV Level IV Level Statistical Test 
Specific Aim 1: To quantify the prevalence of sleep disturbance and evaluate whether or not demographic characteristics, disease characteristics, treatment 
characteristics, symptom burden, or medication use are related to sleep disturbance in the study cohort. 
H0 (1a):  
Demographic characteristics will not 
differ significantly when cohort is 
ranked by severity of reported sleep 
disturbance. 
Ranked sleep 
disturbance 
severity 
score  
Continuous Age 
Sex  
Race  
Employment status  
Driver status 
History of depression 
Categorical 
Binary 
Categorical 
Categorical 
Binary 
Binary 
Welch’s ANOVA 
H0 (1b):  
Disease characteristics will not differ 
significantly when cohort is ranked by 
severity of reported sleep disturbance. 
Ranked sleep 
disturbance 
severity 
score  
Continuous Cancer site 
Cancer stage 
Age at diagnosis 
Time since diagnosis 
Progression status 
Performance status 
Weight loss 
Categorical 
Categorical 
Categorical 
Categorical 
Categorical 
Categorical 
Categorical 
Welch’s ANOVA 
H0 (1c):  
Treatment characteristics will not differ 
significantly when cohort is ranked by 
severity of reported sleep disturbance. 
Ranked sleep 
disturbance 
severity 
score  
Continuous Current chemotherapy 
Current radiotherapy 
Clinician type 
Opioid analgesia 
Clinician assessments of symptom burden 
and quality of life 
Difficulty to treat 
Medication use for symptom management 
Binary 
Binary 
Categorical 
Binary 
Ordinal 
 
Ordinal 
Categorical 
Welch’s ANOVA 
H0 (1d):  
Symptom burden will not differ 
significantly when cohort is ranked by 
severity of reported sleep disturbance. 
Ranked sleep 
disturbance 
severity 
score  
Continuous Pain 
Fatigue 
Nausea 
Vomiting 
Distress 
Shortness of breath 
Cognitive difficulty 
Anorexia/cachexia 
Drowsiness 
Dry mouth 
Depression 
Numbness/tingling 
Diarrhea 
Constipation 
Sore mouth 
Rash/itching 
Hair loss 
Cough 
Ordinal / 
Continuous  
Welch’s ANOVA  
H0 (1e):  
Demographic characteristics, disease 
characteristics, treatment characteristics, 
and symptom burden are not related to 
the level of reported sleep disturbance 
[scale: 0 = “not present” to 10 = “as bad as 
you can imagine”]. 
Sleep 
disturbance 
severity 
score 
Continuous Multiple, from dependent variables above Mixed: 
may be  
continuous, 
ordinal, 
categorical, or 
binary  
Linear regression 
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Table 2.2 Hypotheses for Specific Aim 2         
Hypothesis IV Level DV Level Statistical Test 
Specific Aim 2: To quantify the prevalence of hypnotic use and evaluate whether or not demographic characteristics, disease characteristics, treatment 
characteristics, symptom burden, or medication use are related to hypnotic use in the study cohort. 
H0 (2a):  
Demographic characteristics will not 
differ significantly when cohort is 
dichotomized as users/nonusers of 
hypnotics or categorized by type of 
hypnotic used. 
Hypnotic use 
(yes/no) 
Binary Age 
Sex  
Race  
Employment status  
Driver status 
History of depression 
Categorical 
Binary 
Categorical 
Categorical 
Binary 
Binary 
Pearson chi-square  
 
H0 (2b):  
Disease characteristics will not differ 
significantly when cohort is 
dichotomized as users/nonusers of 
hypnotics or categorized by type of 
hypnotic used. 
Hypnotic use 
(yes/no) 
Binary Cancer site 
Cancer stage 
Age at diagnosis 
Time since diagnosis 
Progression status 
Performance status 
Weight loss 
Categorical 
Categorical 
Categorical 
Categorical 
Categorical 
Categorical 
Categorical 
Pearson chi-square  
 
H0 (2c):  
Treatment characteristics will not differ 
significantly when cohort is 
dichotomized as users/nonusers of 
hypnotics or categorized by type of 
hypnotic used. 
Hypnotic use 
(yes/no) 
Binary Current chemotherapy 
Current radiotherapy 
Clinician type 
Opioid analgesia 
Clinician assessments of symptom burden 
and quality of life 
Difficulty to treat 
Medication use for symptom management 
Binary 
Binary 
Categorical 
Binary 
 
Ordinal 
Ordinal 
Categorical 
Pearson chi-square  
 
H0 (2d):  
Symptom burden will not differ 
significantly when cohort is 
dichotomized as users/nonusers of 
hypnotics or categorized by type of 
hypnotic used. 
Hypnotic use 
(yes/no) 
Binary Pain 
Fatigue 
Nausea 
Vomiting 
Distress 
Shortness of breath 
Cognitive difficulty 
Anorexia/cachexia 
Drowsiness 
Dry mouth 
Depression 
Numbness/tingling 
Diarrhea 
Constipation 
Sore mouth 
Rash/itching 
Hair loss 
Cough 
Ordinal / 
Continuous 
 
Pearson chi-square  
 
H0 (2e):  
Demographic characteristics, disease 
characteristics, treatment characteristics, 
and symptom burden are not related to 
the use of hypnotics or the use of a 
specific class of hypnotic.  
Hypnotic use 
(yes/no) 
Binary Multiple, from dependent variables above Mixed: 
may be  
continuous, 
ordinal, 
categorical, or 
binary 
Logistic regression 
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Table 2.3 Hypotheses for Specific Aim 3         
Hypothesis IV Level DV Level Statistical Test 
Specific Aim 3: To quantify change in sleep disturbance and evaluate whether or not demographic characteristics, disease characteristics, treatment 
characteristics, symptom burden, or medication use are related to change in sleep disturbance in the study cohort. 
H0 (3a):  
Demographic characteristics will not 
differ significantly when cohort is 
categorized by change in level of 
reported sleep disturbance. 
Sleep 
disturbance 
change 
group 
Continuous Age 
Sex  
Race  
Employment status  
Driver status 
History of depression 
Categorical 
Binary 
Categorical 
Categorical 
Binary 
Binary 
Welch’s ANOVA 
H0 (3b):  
Disease characteristics will not differ 
significantly when cohort is categorized 
by change in level of reported sleep 
disturbance. 
Sleep 
disturbance 
change  
group 
Continuous Cancer site 
Cancer stage 
Age at diagnosis 
Time since diagnosis 
Progression status 
Performance status 
Weight loss 
Categorical 
Categorical 
Categorical 
Categorical 
Categorical 
Categorical 
Categorical 
Welch’s ANOVA 
H0 (3c):  
Treatment characteristics will not differ 
significantly when cohort is categorized 
by change in level of reported sleep 
disturbance. 
Sleep 
disturbance 
change 
group 
Continuous Current chemotherapy 
Current radiotherapy 
Clinician type 
Opioid analgesia 
Clinician assessments of symptom burden 
and quality of life 
Difficulty to treat 
Medication use for symptom management 
Binary 
Binary 
Categorical 
Binary 
 
Ordinal 
Ordinal 
Categorical 
Welch’s ANOVA 
H0 (3d):  
Symptom burden will not differ 
significantly when cohort is categorized 
by change in level of reported sleep 
disturbance. 
Sleep 
disturbance 
change 
group 
Continuous Pain 
Fatigue 
Nausea 
Vomiting 
Distress 
Shortness of breath 
Cognitive difficulty 
Anorexia/cachexia 
Drowsiness 
Dry mouth 
Depression 
Numbness/tingling 
Diarrhea 
Constipation 
Sore mouth 
Rash/itching 
Hair loss 
Cough 
Ordinal  Welch’s ANOVA  
H0 (3e):  
Demographic characteristics, disease 
characteristics, treatment characteristics, 
and symptom burden are not related to 
change in level of reported sleep 
disturbance.  
Change in 
sleep 
disturbance 
severity 
score 
Continuous Multiple, from dependent variables above Mixed: 
may be  
continuous, 
ordinal, 
categorical, or 
binary 
Linear regression 
 
 
 
37 
Table 2.4 Hypotheses for Specific Aim 4      
Hypothesis IV Level DV Level Statistical Test 
Specific Aim 4: To evaluate whether or not symptom burden and quality of life outcomes differ on the basis of sleep disturbance or hypnotic use, controlling 
for demographic, disease, and treatment characteristics. 
H0 (4a):  
Symptom burden outcomes 
will not differ significantly on 
the basis of level of reported 
sleep disturbance [scale: 0 = 
“not present” to 10 = “as bad as 
you can imagine”]. 
Change in sleep 
disturbance score 
 
Continuous  Pain 
Fatigue 
Nausea 
Vomiting 
Distress 
Shortness of breath 
Cognitive difficulty 
Anorexia/cachexia 
Drowsiness 
Dry mouth 
Depression 
Numbness/tingling 
Diarrhea 
Constipation 
Sore mouth 
Rash/itching 
Hair loss 
Cough 
Continuous  Linear regression 
H0 (4b):  
Quality of life outcomes will 
not differ significantly on the 
basis of level of reported sleep 
disturbance [scale: 0 = “not 
present” to 10 = “as bad as you 
can imagine”]. 
Change in sleep 
disturbance score 
 
Continuous  General activity 
Mood 
Work (including around the house) 
Relations with other people 
Walking 
Enjoyment of life 
Continuous  Linear regression 
H0 (4c):  
Symptom burden outcomes 
will not differ significantly on 
the basis of the use of 
hypnotics or the use of a 
specific class of hypnotic. 
Hypnotic use/non-use  Binary Pain 
Fatigue 
Nausea 
Vomiting 
Distress 
Shortness of breath 
Cognitive difficulty 
Anorexia/cachexia 
Drowsiness 
Depression 
Numbness/tingling 
Diarrhea 
Constipation 
Sore mouth 
Rash/itching 
Hair loss 
Cough 
Continuous  Hotelling’s T2, 
corrected for 
heteroscedasticity 
H0 (4d):  
Quality of life outcomes will 
not differ significantly on the 
basis of the use of hypnotics or 
the use of a specific class of 
hypnotic. 
Hypnotic use/non-use  Binary General activity 
Mood 
Work (including around the house) 
Relations with other people 
Walking 
Enjoyment of life 
Continuous  Hotelling’s T2, 
corrected for 
heteroscedasticity 
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2.3 SECTION III:  INSTITUTIONAL REVIEW BOARD APPROVAL 
The Institutional Review Board (IRB) of The University of Texas at Austin 
(Federalwide Assurance #2030) has determined that this study does not meet the criteria 
for human subjects research as defined in the Common Rule (45 CFR 46) or FDA 
Regulations (21 CFR 56), and, therefore, does not require IRB oversight. Specifically, 
IRB review and oversight is not required because the study activities involve secondary 
use of a de-identified data set that has no direct identifiers or links to identifiers. 
 
2.4 SECTION IV:  STUDY DESIGN 
The study was a secondary analysis of data from the Symptom Outcomes and 
Practice Patterns (SOAPP) study (ECOG E2Z02, NCT00303914), a prospective 
observational study with a primary objective of gathering reliable data on how cancer 
symptoms affect patients and how those symptoms are treated.170 The SOAPP study 
took place over two clinic visits, approximately four weeks apart, during which patients 
and clinicians were surveyed. The patient survey included assessments of nineteen 
cancer-related symptoms and six items measuring the extent to which symptoms 
interfered with health-related quality of life.  
Specific Aims 1 and 2 were cross-sectional evaluations of the prevalence and 
correlates of sleep disturbance and hypnotic use, respectively. Specific Aim 3 evaluated 
correlates of longitudinal change in sleep disturbance. Specific Aim 4 evaluated 
longitudinal change in symptom burden and quality of life outcome measures 
associated with sleep disturbance and hypnotic use. 
 
2.5 SECTION V:  DATA SOURCE 
Data for the study were originally collected during the Symptom Outcomes and 
Practice Patterns (SOAPP) study (ECOG E2Z02, NCT00303914) conducted by the 
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Eastern Cooperative Oncology Group (ECOG).170 ECOG, one of the largest clinical 
cancer research organizations, is a collaboration of public and private clinics and 
research institutes in the United States and abroad. The study was chaired by Michael 
J. Fisch, MD, MPH, Chair of the Department of General Oncology, Division of Cancer 
Medicine, The University of Texas MD Anderson Cancer Center, and by Charles S. 
Cleeland, PhD, McCullough Professor of Cancer Research, Department of Symptom 
Research, Division of Internal Medicine, The University of Texas MD Anderson 
Cancer Center.170 Permission to use the SOAPP data has been generously granted by 
Dr. Fisch and his collaborators, including Judith Manola and Fengmin Zhao, who were 
instrumental in providing the data. 
 
2.5.1 Study population and data collection 
The SOAPP study was conducted at multiple, randomly selected sites that 
agreed to participate.170 From March 3, 2006 to May 19, 2008, the SOAPP study 
enrolled adult patients receiving care for lung, breast, prostate, or colorectal cancer at 
academic centers and community oncology clinics in Illinois, Indiana, Iowa, Michigan, 
and South Dakota.170 To reduce selection bias, each site devised a system for recruiting 
participants.170 Of the 38 participating sites, 13 had at least 40 percent minority 
participation.171  
Patients were recruited for the SOAPP study upon checking in for a scheduled 
appointment, and those that agreed to participate completed baseline symptom 
assessment surveys prior to meeting with their clinician.170 Demographic and clinical 
information was also collected from patients at this time.170  
After the visit, clinicians provided additional clinical information, and were also 
surveyed on their evaluation of the patient’s symptom burden and quality of life.170 
Symptom surveys were repeated, for both patients and clinicians, at a follow-up visit 
four to five weeks later.170 
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Table 2.5 Overview of cohort characteristics – SOAPP study respondents with sleep 
disturbance scores (N = 2,748) 
 
SOAPP: Symptom Outcomes and Practice Patterns 
SD: standard deviation 
 
Inclusion Criteria: Outpatients who were at least 18 years of age, at any stage 
of care for invasive breast, lung, prostate, or colorectal cancer, and willing to take the 
follow-up survey were eligible to participate in the SOAPP study.171,172  
Exclusion Criteria: Patients with inadequate cognitive function, as assessed by 
a study screener, were excluded from the original SOAPP study.172 For the present 
study, subjects missing a score on the sleep disturbance item at either the first or second 
visit were also excluded. 
Characteristic Mean SD 
Age 61.16 12.3 
Age at diagnosis 58.20 12.3 
   
Characteristic N % 
Sex   
Female 1926 70.1 
Male 822 29.9 
 
Race   
White 2349 86.5 
Black 314 11.6 
Other 52 1.9 
 Missing = 33  
 
Ethnicity   
Non-Hispanic 2273 89.7 
Hispanic 251 9.9 
Refused 11 0.4 
 Missing = 213  
   
Primary Disease Site   
Breast 1367 49.8 
Colorectal 647 23.5 
Lung 449 16.3 
Prostate 285 10.4 
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The final sample size of the SOAPP study was 3,106.171 After exclusion of 
subjects with missing sleep disturbance scores, the sample for the present study was 
2,748. Table 2.5 provides an overview of cohort characteristics. 
 
2.5.2 Survey instruments 
2.5.2.1 Patient survey 
MDASI 
 The MD Anderson Symptom Inventory (MDASI) is a validated instrument 
measuring the intensity of 13 cancer symptoms, including disturbed sleep, during the 
past 24 hours.173 Development of the MDASI began with an initial list of 26 symptoms 
and interference items collected from panels of clinicians.173 Clinical judgment, along 
with cluster and factor analyses, were used to identify the core items that represented 
overall symptom burden for patients with cancer.173 The final 13 core items are: pain, 
fatigue, nausea, disturbed sleep, distress (upset), shortness of breath, memory problems, 
lack of appetite, feeling drowsy, dry mouth, feeling sad, vomiting, and numbness or 
tingling.173 For each core symptom, there is one item on the MDASI survey.173 Patients 
rate each symptom on an 11-point Likert-type scale (0 = “not present” to 10 = “as bad 
as you can imagine”).173 
The MDASI also includes six items measuring the interference of overall 
symptom burden with health-related quality of life (HRQoL) items: general activity, 
mood, work (including around the house), relations with other people, walking, and 
enjoyment of life.173 The interference items are measured on a similar 11-point scale (0 
= “did not interfere”, 10 = “interfered completely”).173  
In initial testing, the thirteen symptoms measured by the MDASI accounted for 
64% of the variability in HRQoL interference.173 Construct validity was tested with 
principal axis factor analysis, which yielded two factors (general symptoms and 
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gastrointestinal symptoms) onto which the thirteen symptoms loaded.173 These two 
factors, along with the HRQoL interference items, were tested for internal consistency 
in two different samples.173 Cronbach’s alpha values ranged from 0.82 to 0.94, 
indicating high internal consistency (reliability).173 To test sensitivity, subjects were 
dichotomized by severity of disease, as measured by performance status (‘good’ or 
‘poor’); differences were observed for both mean symptom severity (2.36 vs. 3.62; p < 
0.001) and mean symptom interference (2.95 vs. 5.31; p < 0.001).173 Sensitivity to 
treatment was examined by comparing patients who had not received cancer treatment 
in the previous three months against a group undergoing bone marrow transplantation 
and a group receiving chemotherapy.173 No difference in overall mean symptom 
severity was detected, but overall mean symptom interference was greater in the 
transplant and chemotherapy groups than in the group not currently receiving cancer 
treatment (5.22 vs. 4.43 vs. 3.23, p < 0.01).173  
In 2014, the National Cancer Institute's Symptom Management and Health-
Related Quality of Life Steering Committee published a consensus statement 
recommending a core set of symptoms that should be measured in trials of cancer 
treatments (in adults).174 The list was developed through a multi-step process that 
included systematic literature review, analysis of six large datasets with symptom 
measures, and multi-stakeholder review by a panel of experts and patient 
representatives.174 The MDASI instrument contains all recommended core items 
except: constipation, and diarrhea. The SOAPP study added those two symptoms, along 
with four more (sore mouth, hair loss, cough, and rash/itching).  
Standard interpretations of the MDASI have yet to be established in the 
literature, but the authors suggest that a change of about one point can be considered a 
minimally important (i.e., clinically significant) difference (MID).175 The rationale for 
this is that one-half standard deviation has been commonly used as an MID threshold, 
and, in initial validation studies, the standard deviations for the 13 core symptoms 
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ranged from 1.95 to 2.31.175 In a systematic review of health-related quality of life 
studies, Norman, Sloan, and Wyrwich (2003) concluded that, in most cases, the 
detection threshold for meaningful change was approximately one-half standard 
deviation.176 Other authors have argued, however, that no ideal method for determining 
MID has yet been identified, and, even with a consistent method, results may differ 
across subpopulations.177,178 Nonetheless, for the purposes of the present study, the 
suggested MID of one point will be used. 
Interpretation of symptom severity using MDASI scores is also not fully 
defined, to date. Based on instruments previously developed by the MDASI authors, 
cut points have been established for pain and fatigue. The pain179 and fatigue180 
instruments were scaled the same way as the MDASI (0 = “none” to 10 = “as bad as 
you can imagine”), and optimal cut points for both were 1 – 4 for mild, 5 – 6 for 
moderate, and 7 – 10 for severe.179,181  Although prior findings are not conclusive, cut-
points of 5 and 7 are also often associated with clinically meaningful differences for 
other 0 to 10 scales used for symptom assessment in oncology (e.g., Edmonton 
Symptom Assessment Scale, the Brief Fatigue Inventory, and the Brief Pain 
Inventory).179,180,182 Therefore, this study used the same cut points, checked against 
histograms.  
Appendix A contains a copy of the patient survey. 
 
2.5.2.2 Clinician survey 
Clinician Survey 
 After indicating what type of clinician is completing the survey (attending 
physician, resident or fellow, advanced practice nurse or nurse practitioner, physician 
assistant, or other), the clinicians were asked to provide clinical information about the 
patient, including: cancer site, cancer stage, age at diagnosis, time since diagnosis, 
performance status, and whether the patient is undergoing radiotherapy or 
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chemotherapy. Then, mirroring the patient’s non-MDASI items, clinicians were asked 
to rate (0 to 5) the patient’s overall quality of life, and the extent to which the patient is 
bothered by difficulties relating to: cancer, other diseases, cancer treatments, symptom 
management medications, and weight change. Finally, clinicians are asked to rate the 
difficulty of caring for the patient (1=”very difficult”, 2=”difficult”, 3=”average”, 
4=”easier than average”, 5=”much easier than average”).170 
Appendix B contains a copy of the clinician survey.  
 
2.5.3 Study variables 
2.5.3.1 Dependent variables 
Specific Aims 1a, 1b, and 1c, sleep disturbance score (0 = “none” to 10 = “as 
bad as you can imagine”), was ranked prior to bivariate analysis to correct for a strong 
zero bias in the distribution. Specific Aim 1d used the original sleep disturbance 
severity score as a continuous variable. Non-parametric models (including Poisson, 
zero-inflated Poisson, ordinal logistic, and zero-inflated beta) were initially evaluated, 
but linear regression analysis, treating sleep disturbance severity score as a continuous 
variable, produced the best-fitting models. 
For Specific Aim 2, subjects were dichotomized on the basis of hypnotic use 
(yes / no); sample size did not permit categorization by hypnotic class. In the original 
SOAPP study, clinicians identified patient medication use by category. The ‘hypnotics’ 
category was subdivided into benzodiazepines (BZDs), and non-BZDs. Examples listed 
for non-BZD hypnotics were zolpidem (a BZD receptor agonist) and chloral hydrate. 
Chloral hydrate is not commonly used in recent studies of the general population nor in 
oncology studies dating just before the introduction of BZD receptor agoninsts 
(BzRAs). Therefore, this study assumed ‘non-benzodiazepine hypnotics’ to represent 
mainly BzRAs. BZDs were further partitioned into long- / intermediate-acting (e.g, 
clonazepam, clorazepate, flurazepam, lorazepam) and short-acting (e.g., oxazepam, 
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triazolam, alprazolam) because short-acting BZDs are sometimes used for anxiety, 
independently of sleep disturbance. Categorization by duration of action is not 
consistent in the literature, however, and SOAPP clinicians may have assigned BZDs 
differently. 
 
Table 2.6 Definitions of dependent variables 
Dependent Variables Level Definition 
Specific Aim1: To quantify the prevalence of sleep disturbance and evaluate whether or not 
demographic characteristics, disease characteristics, treatment characteristics, symptom burden, 
or medication use are related to sleep disturbance in the study cohort.  
Sleep disturbance score Continuous 0: Not present  
–to–  
10: As bad as you can imagine 
Specific Aim 2: To quantify the prevalence of hypnotic use and evaluate whether or not 
demographic characteristics, disease characteristics, treatment characteristics, symptom burden, 
or medication use are related to hypnotic use in the study cohort. 
Hypnotic use  Binary 0: No 
1: Yes 
Specific Aim 3: To quantify change in sleep disturbance and evaluate whether or not 
demographic characteristics, disease characteristics, treatment characteristics, symptom burden, 
or medication use are associated with change in sleep disturbance in the study cohort. 
Change in sleep disturbance severity  Continuous Visit 2 score – visit 1 score 
Range: -10 to +10 
Specific Aim 4: To evaluate whether or not symptom burden and quality of life outcomes differ 
on the basis of sleep disturbance or hypnotic use. 
Change in severity of: pain, fatigue, 
nausea, being distressed, dyspnea, 
cognitive difficulties, anorexia/cachexia, 
drowsiness, dry mouth, sad/depressed, 
vomiting, numbness/tingling, diarrhea, 
constipation, sore mouth, rash/pruritus, 
hair loss, coughing 
Continuous Visit 2 score – visit 1 score 
Range: -10 to +10 
Change in interference with: general 
activity, mood, work, relations with other 
people, walking, and enjoyment of life 
Continuous Visit 2 score – visit 1 score 
Range: -10 to +10 
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Specific Aims 3a, 3b, 3c, and 3d, evaluated change in sleep disturbance severity 
score from the first to second visit (range: -10 to + 10). For bivariate analyses, change 
in sleep disturbance score was binned into  
Dependent variables for Specific Aims 4a and 4c, were the changes in symptom 
severity scores from the first to second visit (range: -10 to + 10). Specific Aims 4b and 
4d evaluated changes in symptom interference scores for the six health-related quality 
of life items from the first to second visit (range: -10 to + 10). 
Definitions of classification variables can be found in Table 2.6.  
 
2.5.3.2 Proposed correlates of sleep disturbance and hypnotic use 
Variables that were evaluated as correlates of sleep disturbance and hypnotic 
use are defined in Table 2.7. Selection of variables was based, in part, on the ‘3P' model 
of insomnia, which characterizes risk factors as predisposing, precipitating, and/or 
perpetuating.* Predisposing factors for insomnia include physiological, psychological, 
or social circumstances that increase one’s vulnerability to sleep disruption; 
precipitating factors are life events that trigger acute insomnia; and perpetuating factors 
inhibit one’s ability to adapt and resume normal sleeping patterns.183 The SOAPP study 
measured numerous variables, allowing for broad exploration of potential sleep 
disturbance correlates. Interpretation is limited, however, by lack of information 
pertaining to timing. For example, initiation of treatment (e.g., chemotherapy, 
corticosteroids) may precipitate sleep disturbance, while continued treatment may 
perpetuate sleep disturbance. Because timing data (initiation and duration) are mostly 
unavailable in this study, distinctions between precipitation and perpetuation cannot be 
made, nor can causality be inferred. Therefore, factors will be treated as correlates only.  
                                                
* The terms sleep disturbance and insomnia are often used interchangeably. It should be noted, 
however, that the term sleep disturbance may encompass a wider range of complaints (e.g., restless leg 
syndrome, obstructive sleep apnea). 
 47 
Demographic variables are: age, sex, race, employment status, driver status, and 
history of depression [Table 2.7.a]. Disease characteristics are: cancer site, cancer 
stage, age at diagnosis, time since diagnosis, progression status, performance status, 
and weight loss [Table 2.7.b]. Treatment characteristics are: current chemotherapy, 
current radiotherapy, clinician type, opioid analgesia, clinician assessments of symptom 
burden and quality of life, clinician assessment of difficulty to treat, and medications 
used for symptom management [Table 2.7.c]. Among medications used to manage 
cancer symptoms, this study included those known or suspected to have effects on 
sleep: long-, mid-, and short-acting benzodiazepines, benzodiazepine receptor agonists, 
steroids, tricyclic antidepressants, antiepileptics for pain, antidepressants for pain, phenergan, 
neurokinin-1 inhibitors, reglan, and 5-ht3 antagonists [Table 2.7.d]. Symptom burden 
variables are: pain, fatigue, nausea, vomiting, distress, shortness of breath, cognitive 
difficulty, anorexia/cachexia, drowsiness, dry mouth, depression, numbness/tingling, 
diarrhea, constipation, sore mouth, rash/itching, hair loss, and cough [Table 2.7.e].  
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Table 2.7 Definitions of correlate variables 
Table 2.7.a Demographic characteristics 
Variable Level Definition 
Age Continuous Age at registration 
Sex  Binary 1: Male 
2: Female 
Race  Categorical 1: White 
2: Black 
3: Others 
Ethnicity  Categorical 1: Hispanic 
2: Non-Hispanic 
10: Patient refusal 
11: Site refusal 
Employment status Categorical 1: Working Full-Time 
2: Working Part-Time 
3: Not in workforce (e.g., retired, 
disabled, student, homemaker) 
Employment change Binary 1: No 
2: Yes 
Drive within the past 4 weeks  Binary 1: No 
2: Yes 
Personal history of depression  Binary 1: No 
2: Yes 
Family history of depression  Binary 1: No 
2: Yes 
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Table 2.7.b Disease characteristics 
Variable Level Definition 
Disease characteristics 
Independent Variable Level Definition 
Disease site Categorical 1: Breast 
2: Colorectal 
3: Prostate 
4: Lung 
Current stage of disease Categorical 1: No evidence of disease 
2: Local/regional 
3: Metastatic 
4: Local/regional and met 
Diagnosis age Continuous Age at first diagnosis of cancer 
Diagnosis months Continuous Months since cancer diagnosis at 
registration 
Current status of disease Categorical 1: Complete Disappearance of 
Lesions 
2: Partial Response 
3: Stable 
4: Progression 
ECOG performance status Categorical 
 
or 
 
Ordinal 
0: Fully active, all pre-disease ability 
without restriction  
1: Restricted in physically strenuous 
activity but ambulatory  
2: Ambulatory and capable of all self 
care but unable to carry out any 
work activities  
3: Capable of only limited self care, 
confined to bed or chair more than 
50% of waking hours  
4: Completely disabled  
Weight loss in previous 6 months Categorical 
or 
Ordinal 
1:  <5% of body weight 
2: 5 to <10% of body weight  
3: 10 to <20% of body weight 
4:  ≥20% of body weight 
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Table 2.7.c Treatment characteristics 
Variable Level Definition 
Current  
chemotherapy  
Binary 1: No   
2: Yes 
Current radiation therapy Binary 1: No 
2: Yes 
Type of clinician  1: Attending Physician 
2: Resident or fellow 
3: Advanced practice nurse or nurse 
practitioner  
4: Physician assistant 
5: Other  
Systemic opioids for treating pain Binary 1: No 
2: Yes 
Support group  Binary 1: No 
2: Yes 
Counseling   Binary 1: No 
2: Yes 
Clinician assessments of patient’s 
level of difficulty relating to:  
- Comorbidity 
- Cancer 
- Cancer treatment 
- Symptom management 
medications 
- Weight change	
Ordinal 0: Not at all  
1: A little bit  
2: Moderately  
3: Quite a bit 
4: Extremely 
Clinician assessment of patient’s 
overall quality of life  
Ordinal 1: Very poor  
2: Poor  
3: Fair  
4: Good  
5: Excellent 
Clinician assessment of difficulty in 
caring for patient  
Ordinal 1: Very difficult 
2: Difficult 
3: Average 
4: Easier than average  
5: Much easier than average 
 
 
 
  
 51 
Table 2.7.d Medications used for symptom management 
Variable Level Definition 
Long-acting benzodiazepines Binary 0: No 
1: Yes Mid-acting benzodiazepines 
Short-acting benzodiazepines 
Benzodiazepine receptor agonists 
Steroids 
Tricyclic antidepressants 
Antiepileptics for pain 
Antidepressants for pain 
Phenergan 
Neurokinin-1 inhibitors 
Reglan 
5-HT3 antagonists 
 
Table 2.7.e Cancer symptoms other than disturbed sleep 
Independent Variable Level Definition 
Pain Ordinal or 
Continuous 
0: Not present  
 
–to–  
 
10: As bad as you can imagine 
Fatigue 
Nausea 
Disturbed sleep 
Being distressed 
Dyspnea 
Cognitive difficulties 
Anorexia/cachexia 
Drowsiness 
Dry mouth 
Sad/depressed 
Vomiting 
Numbness/tingling 
Diarrhea 
Constipation 
Sore mouth 
Rash/pruritus 
Hair loss 
Coughing 
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2.6 SECTION VI:  ANALYSIS PLAN 
Statistical analyses were conducted using the following software: Stata 
(StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: 
StataCorp LP.), SAS (SAS Institute. 2015. The SAS system for Windows. Release 9.4. 
SAS Institute, Cary, NC.), Excel (Microsoft®. 2015. Excel for Mac. Version 15), 
IVEware (University of Michigan. 2002. IVEware: Imputation and Variance 
Estimation Software), and the Stata module PSMATCH2 (version 4.0.11, 2014).184 
All regression analyses and statistical tests for significant difference were two-
tailed, with an alpha (a, acceptable probability of type I error) of 0.01.  
In biomedical research, an alpha of 0.05 is the general standard; that is, a 5 
percent chance of a statistical test falsely finding a significant difference is generally 
considered acceptable. When multiple tests are conducted on a sample, however, the 
probability of type I error from each study accumulates, resulting in an increased error 
rate of 1 – (1 – a)n for the study as a whole (where n = the number of statistical tests 
performed).185 For example, if ten tests are performed with an alpha of 0.05, then the 
probability of type I error for all ten tests (i.e., the family-wise error rate) is 40 percent. 
One way to reduce the family-wise error rate is to assign a smaller alpha to the 
individual tests. For example, ten tests with an alpha of 0.01 produce a family-wise 
error rate of ten percent. While this approach reduces the probability of type I error, its 
cost is an increase in the probability of type II error. That is, as the chance of an overall 
family-wise false positive result decreases, so does the power of each individual test to 
detect a true difference.  
When interpreting statistical results, the family-wise error rate can be more 
meaningful than the results of individual tests. For example, when testing the “universal 
null” hypothesis that groups are identical in all variables, or when performing the same 
test repeatedly in subsamples (e.g., batches of manufactured items) for the purpose of 
rejecting or retaining the subsample.186 It has been argued, however, that in 
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epidemiological and biomedical studies it does not always make sense to interpret 
multiple endpoints with a “family” level of significance. Adjusting the alpha level can 
bias studies with multiple endpoints. For example, a clinical trial may miss a true 
treatment effect if the corresponding statistical test is interpreted with an alpha that was 
reduced to account for testing the entire family of primary and secondary endpoints.186 
Furthermore, the multiple endpoints of a given study are often chosen arbitrarily and 
do not necessarily constitute a “family” that should be interpreted using a combined 
measure of error.187  
Nonetheless, in the present study, alpha was set to 0.01 based on the following 
considerations. The proposed study includes a large number of variables, many of 
which will be tested multiple times. Many of the MDASI symptom burden and quality 
of life items are intercorrelated, and may conceivably represent families of repeated 
measures on each subject.188 Finally, the large sample size provided by the SOAPP 
study should ensure sufficient power, even with a reduced alpha.  
 
2.6.1 Missing data 
Preliminary analysis of the data revealed the low proportions (< 5%) of missing 
values for most independent variables, except current immunotherapy (49.2%). With a 
large number of variables, however, list-wise deletion would reduce the sample by 
about 25%. To preserve the sample, missing data was estimated using multiple 
imputation.  
Imputation is the process of replacing missing values with reasonable estimates. 
The motivations for imputation are to preserve the sample and to maximize the validity 
of statistical analyses. If cases with missing values are simply dropped from statistical 
analyses, the attrition can reduce power and limit the generalizability of results. In 
addition, analysis of only complete cases can introduce selection bias if groups with 
missing data differ from those with complete data.189 Filling in missing data can also 
 54 
introduce bias, however, and carries the risk of underestimating uncertainty and 
increasing Type I error.190 For example, a simple approach to imputation is to replace 
all missing values of a variable with the mean of the existing values. The resulting 
sample will be biased toward the ‘non-missing’ mean value, which may not reflect the 
original sample population. To reduce this bias, a regression model conditioned on 
other variables can be used to produce different values for different individuals. 
Although this approach reduces inflation of a single value, a remaining concern is the 
increased probability of Type I error because the predicted values do not take into 
account uncertainty in the predictive model. Combining point estimates from multiple 
imputed datasets (using “Rubin’s rules”)191 introduces variability, which, in turn, 
accounts for some degree of uncertainty related to estimating the missing values.192  
 
Mechanisms that cause missing data are classified as: missing at random 
(MAR), missing completely at random (MCAR), and missing not at random 
(MNAR).192,193 For data that are MCAR, the mechanism for missingness has no 
relationship with any observable variable. This could be the result of, for example, wind 
scattering and blowing away random sheets from a collection of surveys that were 
dropped on the ground. Imputation is generally not needed for MCAR data, as list-wise 
deletion will not bias results, but loss of power may be a concern. Data are MNAR if 
the reason for missingness is unknown or related to the variables itself. For example, 
respondents with a particular disease may be unwilling to report it on a survey. In this 
case, list-wise deletion would bias the sample, and imputation would require an a priori 
model to represent the mechanism for missingness. In MAR data, missingness of a 
value is related to an observable variable or variables, other than the variable itself. In 
this case, the related variables can be used to predict the missing value, assuming those 
variables are represented in the dataset.  
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Little (1998) proposed a chi-square test for MCAR.194 Subjects are 
dichotomized as either having no missing values or at least one missing value, and these 
groups are then assessed for differences in key variables. Data are assumed to be MCAR 
if the p-value for Little’s test is not significant (p > 0.05). The SOAPP data failed 
Little’s test (Χ2= 32.07, df = 18, p = 0.022) with the following variables: sleep score at 
first visit, hypnotic use at first visit, age group, sex, race, ethnicity, cancer site, months 
since diagnosis, cancer status, and functional status. There is no established test to 
determine that data are MAR, but it is a reasonable assumption for the SOAPP data, 
which include a large number of observed variables and a generally low proportion of 
missing values.195,196 It is difficult to evaluate whether data are MNAR, rather than 
MAR, without additional information, but multiple imputation usually produces 
unbiased estimates with NMAR data.197 
The number of imputations required depends, in part, on the fraction of missing 
information, λ. The fraction of missing information represents, for a given estimate 
based on m imputed datasets, the amount of information missing due to missing values. 
The formula for λ, adapted from Schafer and Olson (1998)198, is 
 ! = # + 2 & + 31 + #  
 
where r is the relative increase in variance due to missing data 
 # = 1 + 1) *+,-++.	0)12,3,04.	53#03.6+-0,ℎ0.	0)12,3,04.	53#03.6+  
and ν is the degrees of freedom 
 8 = ) − 1 1 + *+,-++.	0)12,30,4.	53#03.6+1 + :; 	-0,ℎ0.	0)12,3,04.	53#03.6+
<
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In the present study, the fraction of missing information was less than 5% for all 
variables, except current immunotherapy, which had 41% missing information. 
Early recommendations suggested that the number of imputations needed could 
be determined by relative efficiency, a comparison of the variance for an estimate based 
on m imputed datasets relative to the variance based on an infinite number of 
imputations, as a metric.199 Relative efficiency is approximated as => = (1 + !/)) −1, where λ is the fraction of missing information. In many cases, there will be little 
change after five imputations. For example, if starting with 50% missing information, 
the relative efficiency for an estimate based on five imputed datasets is 1.049, meaning 
that standard deviations for m=5 estimates increase 5% over m= estimates. Newer 
recommendations take statistical power into account, in addition to variance. In a study 
that tested several multiple imputation models with varying ! and m, Graham, 
Olchowski, and Gilreath (2007) showed that power to detect small effect sizes 
decreased markedly with fewer imputations.200 From these findings, they recommend 
that for ! < 0.1, five imputations are needed. 
Among the various methods of imputation, one of the more common approaches 
is to construct regression models that allow missing values to be predicted conditional 
on the values of other variables. The simplest approach is to assume a joint model, such 
as multivariate normality, for all variables. In datasets that include a diversity of 
distributions, however, joint modeling can produce biased estimates.201 Fully 
conditional specification (FCS), on the other hand, incorporates a distribution-specific 
model for each missing variable into the overall multivariate model.202 This method is 
also known as multiple imputation by chained equations,203 and sequential multiple 
regression imputation.201 
FCS is useful for imputation of survey data, as it accommodates variables with 
varied measurement levels (e.g., continuous, categorical, ordinal) and distribution 
forms (e.g, parametric, non-parametric, Poisson). Imputing values on a variable-by-
 57 
variable basis from a sequence of multiple regression models matched to the variable 
type, and conditioned on all other variables, reduces the risk that imputations of one 
variable may be inconsistent with others. FCS also allows for imposing restrictions and 
bounds, and accommodates five types of variables: 1) continuous, 2) dichotomous, 3) 
categorical with three or more categories, 4) counts, and 5) mixed.203 Mixed variables 
are defined as continuous variables with a probability mass at zero. Ordinal data are 
treated as continuous, but with restrictions imposed to limit the range of values imputed 
and exclude non-integer values.204 
Using SAS software (SAS Institute. 2015. The SAS system for Windows. 
Release 9.4. SAS Institute, Cary, NC.) and a callable routine built with IVEWare 
(University of Michigan. 2002. IVEware: Imputation and Variance Estimation 
Software), missing values were multiply-imputed (m=5) through sequential multiple 
regression by chained equations to accommodate heterogeneity of variable type and 
distribution.201-203 In addition to the planned study variables, auxiliary variables were 
included in the multiple imputation models, to provide more information for modeling.  
Pooling of the results from ANOVA, 205 chi-squared,191 and regression191 
analyses was performed with Excel (Microsoft®. 2015. Excel for Mac. Version 15) 
spreadsheets for ANOVA and chi-square results, and the mi estimate command in Stata 
(StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: 
StataCorp LP.) for regression analyses.  
Comparison of imputed datasets by analysis of variance (ANOVA) revealed no 
differences for any variables, except current hormone therapy (F=5.54 [1,13903], p = 
0.0186). Final analyses were, therefore, performed on a singly-imputed dataset, to 
permit use of additional analytic procedures, including regression diagnostics.  
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2.6.2 Statistical analyses 
2.6.2.1 Specific Aim 1: Correlates of Sleep Disturbance Severity 
The sample was subdivided by cancer type and subsample characteristics were 
evaluated using ANOVA and chi-squared tests. Regression analysis was used to 
identify correlates of sleep disturbance severity (SDS). Because SDS scores were 
discrete and their distribution strongly skewed toward zero, non-parametric models 
(including Poisson, zero-inflated Poisson, ordinal logistic, and zero-inflated beta) were 
initially evaluated, but linear regression analysis produced the best-fitting models. The 
final linear regression model was subjected to diagnostic tests for multicollinearity 
(variance inflation factors < 3.0 for all variables), outliers and highly influential 
observations (largest Cook’s distance = 0.018), normality of residuals (kernel density 
plot, Appendix C) and homoscedasticity (Breusch-Pagan test, p<0.001). The test for 
homoscedasticity failed; therefore, robust standard errors were computed for improved 
validity.206 Saturated models were reduced based on significance level for each 
correlation coefficient and model fit was evaluated with Bayesian Information Criterion 
values. After modeling the total sample, cancer site-specific models were evaluated 
using the same methods.  
 
2.6.2.2 Specific Aim 2: Correlates of Hypnotic Use 
The sample was dichotomized by hypnotic use and subsample characteristics 
were evaluated using chi-squared tests. Starting with a saturated model, binary logistic 
regression was used to identify correlates of hypnotic use. Models were reduced based 
on significance level for each correlation coefficient, and model fit was evaluated with 
Bayesian Information Criterion values. Probability of hypnotic use was estimated for 
each factor level and standardized to the total group (covariates controlled using 
weighted averages).207,208 After modeling the total sample, cancer site-specific models 
were evaluated using the same methods.  
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3.6.2.3 Specific Aim 3: Correlates of Change in Sleep Disturbance Severity 
Change in sleep disturbance severity (SDS) was calculated as: SDS Change = 
Visit 2 SDS score – Visit 1 SDS score. Bivariate analyses were performed with Welch’s 
ANOVA. Starting with a saturated model, linear regression was used to identify 
correlates of change in SDS score. Models were reduced based on significance level for 
each correlation coefficient. No further analysis was conducted, as there was no model 
that met statistical significance.  
 
2.6.2.4 Specific Aim 4: Outcomes Associated with Sleep Disturbance and Hypnotic 
Use 
Participants not using hypnotics were matched to hypnotic users on the basis of 
Mahalanobis distance within calipers of 0.2 standard deviations of a propensity score.209 
Propensity scores, representing the probability of being in the treatment group were 
estimated with a probit model of baseline characteristics thought to predict treatment.210 
The Mahalanobis metric is a multidimensional measure of distance between two 
observations.211 Each estimate can be used alone to select matches, but use of both, first 
identifying candidates whose propensity scores are within calipers, then selecting from 
those based on minimal Mahalanobis distance, appears to provide more balanced 
samples than either method alone.209 Average outcomes in the hypnotics group were 
estimated based on the average of differences across matched cases, and conditional 
variance was estimated using fifty neighbors (~12.5% of the group size) to produce 
heteroscedasticity-consistent standard errors.212 Matching was conducted to reduce the 
effects of selection bias (where covariates can have confounding effects on 
outcomes),210 and to reduce Type-I error risk from heteroscedasticity (exacerbated by 
unequal group sizes).213 
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Changes in symptom severity and HRQoL between hypnotic users and non-
users were compared using Hotelling’s T2 test (an omnibus version of the paired t-
test214), with degrees of freedom corrected for heteroscedasticity.215 Following a 
statistically significant multivariate result, individual symptoms were evaluated with 
post-hoc two-sided t-tests (with Welch’s approximation of degrees of freedom for 
unequal variance). Multivariate regression, controlling for hypnotic use, was conducted 
to evaluate how change in severity of sleep disturbance related to changes in other 
cancer symptoms and HRQoL.  
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2.7 SECTION VII:  SAMPLE SIZE REQUIREMENTS 
Statistical power is the probability of a study detecting a difference that truly 
exists. Although it is defined as 1-b, there are four variables that influence power: 1) 
the probability of type I error (alpha, or a); 2) the probability of type II error (beta, or 
b); 3) the sample size (n); and 4) the magnitude of difference or change to be detected 
(effect size).216 For all analyses in this study, values for a and b are set to 0.01 and 0.2, 
respectively. Samples size requirements are summarized in table 2.8. 
 
2.7.1 Specific Aim 1: Correlates of sleep disturbance 
Correlates of sleep disturbance were evaluated using multiple linear regression, 
with the null hypothesis (H0) that cancer-related variables are not associated with 
severity of sleep disturbance. Assuming a small effect size (f2 = 0.02) and a maximum 
of 25 correlates, a total of 1,551 cases are required (Figure 2.1). 
 
Figure 2.1 
G*Power 
calculation of 
required sample 
size for multiple 
regression with 
25 correlates 
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2.7.2 Specific Aim 2: Correlates of hypnotic use 
The effect size for this analysis is the odds ratio of hypnotic use associated with 
each factor. The odds ratio (OR) for a binary outcome is the ratio of the odds of H1 (an 
event X occurring in the presence of factor Y) over the odds of H0 (event X occurring 
when factor Y is not present). The formula for OR is 
 E= = 	F:G# H = 1|J = 1FKG# H = 1|J = 0  
For Specific Aim 2, the null hypothesis (H0) is that cancer-related variables are 
not associated with use of a hypnotic. The event rate for sleep disturbance under the 
null hypothesis (H0) was set to five percent. A recent study by Bertisch et. al. estimated 
that about three percent of Americans use a prescription sleep-aid (including 
medications used off-label).145 For persons over sixty years of age, prevalence of 
hypnotic use ranged from 3.86 percent (ages 60 to 69 years) to 5.26 percent (ages ≥ 80 
years).145  
The alternative hypothesis (H1) is that cancer-related variables are associated 
with use of hypnotics. The event rate for the alternative hypothesis was set to twenty 
percent. Although data for patients with cancer are limited, estimates range from about 
twenty percent of patients at various stages,89 to about sixty percent of patients with 
advanced cancer.138 The resulting odds ratio is 8.08. 
 E= = 	F:G# H = 1|J = 1FKG# H = 1|J = 0 = 	 0.20/0.80H0.03/0.97 = 8.08 
 
To account for correlations among covariates, a large correlation (r = 0.50) was 
assumed, and R2 was set to 0.25. To account for all possible variable types, estimations 
of total sample size required were carried out using G*Power and assuming a normal 
distribution for X (Total N = 100), an exponential distribution of X (Total N = 56), and 
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a binary distribution of X (Total N = 258), as shown in Figures 2.2.a, b, and c, 
respectively.  
Alternatively,217 estimating a maximum of twenty-five covariates, and 
considering intercorrelations among variables and unequal distribution of variables, the 
required sample size to have fifty cases per variable would be 1,250. 
 
 
 
Figure 2.2.a 
G*Power calculation 
of required sample 
size for logistic 
regression where X 
follows a normal 
distribution 
  
 64 
 
 
Figure 2.2.b G*Power 
calculation of required 
sample size for logistic 
regression where X 
follows an exponential 
distribution 
 
 
 
 
 
 
Figure 2.2.c G*Power 
calculation of required 
sample size for 
logistic regression 
where X follows a 
binomial distribution 
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2.7.3 Specific Aim 3: Correlates of change in sleep disturbance 
Correlates of change in sleep disturbance were evaluated using multiple linear 
regression, with the null hypothesis (H0) that cancer-related variables are not associated 
with change in sleep disturbance. Assuming a small effect size (f2 = 0.02) and a 
maximum of twenty-five covariates, a total of 1,551 cases are required (Figure 2.3). 
 
 
Figure 2.3 G*Power 
calculation of 
required sample size 
for multiple 
regression with 25 
correlates 
 
 
 
 
 
 
2.7.4 Specific Aim 4: Outcomes associated with sleep disturbance and hypnotic 
use 
Multivariate linear regression was used to assess associations between changes 
in sleep disturbance severity and changes in severity of other cancer symptoms. 
Assuming a small effect size (f2 = 0.02) and a maximum of eighteen response variables, 
a total of 1,374 cases are required (Figure 2.4.a). 
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Figure 2.4.a 
G*Power calculation 
of required sample 
size for multivariate 
F test with eighteen 
dependent variables 
 
 
 
 
 
 
 
 
Figure 2.4.b 
G*Power calculation 
of required sample 
size for multivariate 
F test with six 
dependent variables 
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Multivariate linear regression was also used to evaluate associations between 
changes in sleep disturbance severity and changes in the degree to which symptom 
burden interfered with health-related quality of life. Assuming a small effect size (f2 = 
0.02) and a maximum of six response variables, a total of 954 cases are required (Figure 
2.4.b). 
Hotelling’s T2 test was used to assess associations between hypnotic use and 
changes in severity of cancer symptoms other than sleep disturbance. Assuming a small 
effect size (mean change = 0.25) and a maximum of eighteen response variables, each 
group requires 877 cases (Figure 2.4.c). 
Hotelling’s T2 test was also used to evaluate associations between hypnotic use 
and changes in the degree to which symptom burden interfered with health-related 
quality of life. Assuming a small effect size (f2 = 0.02) and a maximum of six response 
variables, each group requires 609 cases (Figure 2.4.d). 
 
 
Figure 2.4.c G*Power 
calculation of 
required sample size 
for Hotelling’s T2 test 
with eighteen 
dependent variables 
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Figure 2.4.d G*Power 
calculation of required 
sample size for 
Hotelling’s T2 test 
with six dependent 
variables 
 
 
 
 
 
 
 
Table 2.8 Summary table of sample size requirements 
Specific Aim Statistical Test Effect Size Model Variable Assumptions 
Total 
Required 
1: Correlates of SDS Linear regression 
f2 = 0.02 
(small) ≤ 25 independent variables 1551 
2: Correlates of hypnotic 
use 
Logistic 
regression OR= 8.08 
Normal distribution, r = 0.50 100 
Exponential distribution, r = 
0.50 56 
Binomial distribution, r = 0.50 258 
≤ 25 independent variables, r = 
0.50, unequal distributions 1250 
3: Correlates of SDS 
change 
Linear 
regression 
f2 = 0.02 
(small) ≤ 25 independent variables 1551 
4: Symptom changes 
associated with SDS 
change 
Multivariate 
regression 
f2 = 0.02 
(small) ≤ 18 dependent variables 1374 
4: HRQoL change 
associated with SDS 
change 
Multivariate 
regression 
f2 = 0.02 
(small) ≤ 6 dependent variables 954 
4: Symptom change 
associated with hypnotic 
use 
Hotelling’s T2 ΔO= 0.25 (small) ≤ 18 dependent variables 1754 
4: HRQoL changes 
associated with hypnotic 
use 
Hotelling’s T2 ΔO= 0.25 (small) ≤ 6 dependent variables 1218 
SDS: sleep disturbance severity; HRQoL: health-related quality of life  
 69 
2.8 SECTION VIII:  STRENGTHS AND LIMITATIONS 
2.8.1 Strengths 
One of the primary strengths of this study is that it addresses substantial gaps in 
the literature. Literature on the prevalence and correlates of sleep disturbance in 
oncology is ample, but difficult to synthesize because of considerable heterogeneity in 
study populations, methods, covariates, definitions, and measurements. This study 
allows methodology-consistent comparisons sleep disturbance correlates across cancer 
types. Furthermore, despite the high prevalence of sleep disturbance in patients with 
cancer, there is little recent evidence regarding hypnotic use in this population. Patterns 
of hypnotic use have not been well characterized since the introduction of the current 
standard-of-care drugs, and there is virtually no evidence regarding their safety and 
efficacy in persons with cancer. This study provides much needed data that can serve 
as a point of departure for future research of hypnotics for patients with cancer. Finally, 
this study adds to the literature on sleep-related symptom clusters by including 
assessments of symptoms that are less frequently evaluated. Relationships between 
sleep disturbance and fatigue, pain, and depression are well documented, but there is 
still much to understand about how other symptoms might relate to sleep. Elucidating 
these relationships is vital to developing effective and efficient symptom management 
strategies. 
Use of the SOAPP study data provides several advantages, starting with the 
large and diverse sample size, which will improve the generalizability of findings. At 
the same time, meaningful comparisons can be made across subpopulations; this has 
not been possible to date with studies using narrowly defined populations and varied 
methodologies. The SOAPP data include numerous symptom and health-related quality 
of life measures that provide for comprehensive and nuanced characterizations of 
outcomes associated with both sleep disturbance and hypnotic use. A unique feature of 
the SOAPP study was the inclusion of clinician’s assessments of their patients’ 
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symptoms and quality of life. This information may prove consequential in analyses of 
hypnotic use patterns. Finally, the two-visit, prospective design of the SOAPP study 
allows not only for cross-sectional evaluation, but also for assessment of symptom 
burden changes over a short period of time. 
 
2.8.2 Limitations 
Along with the many advantages conferred by the SOAPP study data, there are 
also some disadvantages. Most notable is the limited detail in characterizing sleep 
disturbance. The single subjective sleep disturbance measure likely captured a wide 
variety of sleep disturbances (e.g., restless limbs, apnea, delayed onset, early waking, 
feeling unrestored), but did not permit distinctions among them. Thus, the outcomes 
associated with hypnotics can be assessed only in terms of symptom burden and quality 
of life, rather than sleep-specific parameters. 
Detail is also lacking in the documentation of medication use. Among 
medications commonly used for sleep disturbance, only benzodiazepines and 
benzodiazepine receptor agonists (BzRAs) are clearly listed. Antidepressants and 
anticonvulsants are identified as treatments for pain, and the two categories are not 
broken down into subclasses (e.g., tricyclic antidepressants versus serotonin selective 
reuptake inhibitors); ramelteon is not listed at all. As a result, only benzodiazepines and 
BzRAs were included in this study.  
Because this is a retrospective, secondary analysis, selection bias cannot be 
ruled out. Furthermore, although selection of correlates of sleep disturbance was based 
on a causal model, the cross-sectional design and unknown duration of sleep 
disturbance (and other variables) prohibit causal inference. Cancer-specific subgroups 
were not matched in size or demographic characteristics, and important relationships 
may have gone undetected in the smaller groups due to loss of power. Generalizability 
of results may be limited to ambulatory patients with solid tumors treated by an Eastern 
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United States oncology group, and cluster bias could not be controlled for because the 
data did not identify treatment sites.  
The MDASI survey items have been validated in cancer populations, but 
minimal important differences and severity cut points have not yet been well defined. 
In addition, the sensitivity of the MDASI survey instrument to assess changes in 
HRQoL related to sleep has not been evaluated, and surveys are subject to recall bias. 
Participants were evaluated during the course of treatment, rather than at initiation. This 
may help to explain the small sizes of change from visit one to visit two as well as the 
strong bias toward zero in the MDASI response variables.  
Finally, it was not possible to determine whether medications prescribed were 
actually taken, and results may be confounded by undocumented use of other sleep aids, 
including over-the-counter medications, off-label drugs, and alcohol, or by non-
adherence to prescribed hypnotics.  
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Chapter 3:  Manuscripts 
This chapter provides three manuscripts that represent the work undertaken for 
completion of this dissertation project. The three manuscripts report the results from 
Specific Aims 1, 2, and 4, respectively. Analyses from Specific Aim 3 are not 
represented, as they yielded no statistically significant model. Only a single level of one 
variable (primary cancer site: colorectal cancer) correlated significantly with change in 
sleep disturbance, and it explained only 0.3% of variance. The study may have been 
underpowered to evaluate the rather small mean change in sleep disturbance (-0.11, on 
a scale from 0 to 10). This chapter closes with a table of relevant journals to which these 
manuscripts may be submitted. 
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3.1 SECTION I: MANUSCRIPT 1 
Sleep Disturbance Prevalence and Correlates in Solid Tumor Cancers 
Introduction 
Disturbed sleep is among the commonest and most severe symptoms reported 
by patients with cancer.82,90,110 In addition to reducing health-related quality of life,87,91,111 
disturbed sleep can exacerbate other cancer symptoms81,137 and may worsen 
prognoses.88,89 For well over a decade, oncology clinicians and researchers have 
recognized sleep disturbance to be widespread and impactful for their patients,218,219 yet 
to date, evidence to guide treatment is scant.156,164 
Many risk factors for sleep disturbance in the oncology setting have been 
identified,166 but the relative importance of these factors is not well characterized and 
the pathophysiology remains undetermined.219 Literature on the prevalence and 
correlates of sleep disturbance in oncology is ample, but difficult to synthesize because 
of considerable heterogeneity in study populations, methods, covariates, definitions, 
and measurements. Recent study samples, for example, include twenty-nine newly 
diagnosed breast cancer patients,220 fifty patients with lung cancer,221 440 patients 
receiving palliative care for advanced cancer,222 and 105 patients scheduled to receive 
radiotherapy.223 No two studies used the same sleep disturbance measures, nor were 
covariate selection and measurement consistent. Findings from these studies further 
exemplify interpretive challenges: Nishiura et. al. found sleep disturbance associated 
with chemotherapy in patients with lung cancer,221 while Yennurajalingam et. al. found 
no such association in patients with advanced cancer.222 Because neither analysis 
controlled for covariates, it is difficult to evaluate whether other characteristics in these 
disparate samples might explain the contradiction.   
Many disease and treatment characteristics (e.g., pain, fatigue, chemotherapy) 
are fairly ubiquitous among solid tumor cancers, but some are specific to certain cancer 
types (e.g., hormone therapy for breast or prostate cancer). Accordingly, one can expect 
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sleep disturbance correlates to be similarly distributed in the oncology setting. 
Distinguishing cancer type-specific sleep disturbance factors from those that are 
universal may shed light on underlying mechanisms and inform both general guidelines 
and patient-specific interventions. Data and analyses that are comparable across cancer 
subtypes are integral to building such understanding.  
This study aims to identify – from a large number of demographic, clinical, 
treatment, and symptom variables – the most significant correlates of sleep disturbance 
in a large diverse sample of persons with cancer, and to replicate the analyses in cancer-
specific subgroups.  
 
Methods 
This was a secondary analysis of the Symptom Outcomes and Practice Patterns 
(SOAPP) study conducted from March 3, 2006 to May 19, 2008 in about 40 clinics 
located primarily in the Eastern United States. Outpatients at least 18 years of age at 
any stage of care for invasive breast, lung, prostate, or colorectal cancer were eligible 
to participate; respondents with inadequate cognitive function (assessed by a study 
screener) were excluded.171 At the first visit, clinicians and patients provided, 
respectively, clinical and demographic data. Additionally, patients scored their baseline 
symptom severity for nineteen cancer symptoms. For the present analysis, cases 
missing a severity score for sleep disturbance were excluded. 
 
Study variables 
Sleep disturbance. The SOAPP study used an expanded (19-item, see Table 
3.1) version of the 13-item MD Anderson Symptom Inventory (MDASI), which asks 
patients to rate symptoms (including ‘disturbed sleep’) at their worst in the last 24 
hours.224 Symptom severity is scaled from 0=‘Not present’ to 10=‘As bad as you can 
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imagine,’ and standard deviations ranged from 1.95 to 2.31 in validation studies, and 
the MDASI developers suggest a 1-point change may be minimally important (i.e., 
clinically significant).175 In a systematic review of health-related quality of life studies, 
the detection threshold for meaningful change was, in many cases, one-half standard 
deviation.176 There is no consensus yet, however, on an ideal method for determining 
clinical significance, and even a consistent method may yield different results across 
subpopulations.177,225 Nevertheless, the present study assumes a 1-point difference in 
symptom severity to be clinically meaningful. 
Correlates of sleep disturbance. Selection of correlates was based on the ‘3P' 
model of insomnia, which characterizes risk factors as predisposing, precipitating, 
and/or perpetuating.† Predisposing factors for insomnia include physiological, 
psychological, or social circumstances that increase one’s vulnerability to sleep 
disruption; precipitating factors are life events that trigger acute insomnia; and 
perpetuating factors inhibit one’s ability to adapt and resume normal sleeping 
patterns.183 The SOAPP study measured numerous variables, allowing for broad 
exploration of potential sleep disturbance correlates. Interpretation is limited, however, 
by lack of information pertaining to timing. For example, initiation of treatment (e.g., 
chemotherapy, corticosteroids) may precipitate sleep disturbance, while continued 
treatment may perpetuate sleep disturbance. Because timing data (initiation and 
duration) are mostly unavailable in this study, distinctions between precipitation and 
perpetuation cannot be made, nor can causality be inferred. Therefore, factors will be 
treated as correlates only. Table 3.1 lists study variables included in saturated models.  
 
  
                                                
† The terms sleep disturbance and insomnia are often used interchangeably to describe difficulty falling 
asleep, staying asleep, and/or dissatisfaction with one's sleep quality. It should be noted, however, that 
diagnostic criteria for insomnia are more specific, and include daytime sequelae, while the term sleep 
disturbance may encompass a wider range of complaints (e.g., restless leg syndrome, obstructive sleep 
apnea). 
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Statistical methods 
Software. Statistical analyses were conducted using the following software: 
Stata (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: 
StataCorp LP.), SAS (SAS Institute. 2015. The SAS system for Windows. Release 9.4. 
SAS Institute, Cary, NC.), Excel (Microsoft®. 2015. Excel for Mac. Version 15) and 
IVEware (University of Michigan. 2002. IVEware: Imputation and Variance 
Estimation Software). 
Data reduction. For visualization and bivariate analysis, but not regression 
modeling, participants were grouped by reported sleep disturbance severity: None (0), 
Mild (1-4), Moderate (5-6), and Severe (7-10). Although prior findings are not 
conclusive, cut-points of 5 and 7 are often identified as clinically meaningful thresholds 
for cancer symptom assessments using 0 to 10 scales (e.g., Edmonton Symptom 
Assessment Scale, Brief Fatigue Inventory, Brief Pain Inventory).179,180,182  
Missing data analysis. The percentage of missing values was low (<4%) for 
most independent variables, except ethnicity (7.18%), current hormone therapy 
(16.25%), and current immunotherapy (18.35%). With a large number of variables, 
however, list-wise deletion would reduce the sample by about 25%. Using SAS 
software and a callable routine built with IVEWare, values were multiply-imputed 
(m=5) through sequential multiple regression by chained equations to accommodate 
heterogeneity of variable type and distribution.201-203 Results of statistical tests were 
pooled using Excel spreadsheets for ANOVA,226 and the mi estimate command in Stata 
for regression analysis. Comparison of imputed datasets by analysis of variance 
(ANOVA) revealed no differences for any variables, except current hormone therapy 
(F=5.54 [1,13903], p = 0.0186). Final regression analyses were, therefore, performed 
on a singly-imputed dataset, to permit use of additional analytic procedures, including 
regression diagnostics. 
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Table 3.1 Correlates included in saturated regression models  
Demographic variables Clinical variables Treatment variables Symptom care medications 
Age  Primary site Clinician Long- & mid- acting benzodiazepines 
Sex Breast Attending Physician Short-acting benzodiazepines 
Male Colorectal Resident or fellow Benzodiazepines receptor agonists 
Female Prostate Advanced practice nurse / nurse practitioner Steroids 
Race Lung Physician assistant Tricyclic antidepressants 
White Months since diagnosis Other Anticonvulsants for pain 
Black Cancer stage Prior radiotherapy Antidepressants for pain 
Other* No evidence of disease Current radiotherapy Promethazine 
Ethnicity Local/regional Prior number of regimens Neurokinin-1 inhibitors 
Hispanic Metastatic None Metoclopramide 
Non-Hispanic Local/regional/metastatic 1 5-HT3 antagonists 
Employment status Cancer status 2 Allergy medications 
Part-time Disappearance 3 or more Misc anxiolytics / antidepressants 
Full-time Partial response Current chemotherapy  
Not employed Stable None Symptom severity scores 
Employment change in last 4 
weeks 
Progression Systemic single Alopecia (hair loss) 
ECOG performance status Systemic multi Anorexia (lack of appetite) 
Driving in last 4 weeks 0 Nonsystemic / Noncytotoxic Cognitive difficulty (remembering) 
History of depression 1 Current immunotherapy Constipation 
Family history of depression 2 Current hormone therapy Cough 
 3 & 4 Current treatment stage Depressed (feeling sad) 
 Cognitive function None Diarrhea (loose stools) 
 No impairment Adjuvant Distressed (upset) 
 Partial impairment Non-metastatic Drowsy (sleepy) 
 Pain mechanism Metastatic Dyspnea (shortness of breath) 
 None Attending support group Fatigue (tiredness) 
 Nociceptive Attending counseling Nausea 
 Neuropathic  Pain treatment Neuropathy (numbness & tingling) 
 Psychological distress None Pain 
  Opioids Stomatitis (mouth sores) 
  Non-opioids Urticaria (skin rash) 
  Combination Vomiting 
   Xerostomia (dry mouth) 
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Statistical analyses. Summary statistics are reported for the overall sample and 
for each sleep disturbance severity (SDS) group. The sample was then subdivided by 
cancer type and subsample characteristics were evaluated using ANOVA and chi-
squared tests. Because SDS scores are discrete and strongly skewed toward zero, non-
parametric models (including Poisson, zero-inflated Poisson, ordinal logistic, and zero-
inflated beta) were initially evaluated, but linear regression analysis produced the best-
fitting models. The final linear regression model was subjected to diagnostic tests for 
multicollinearity (variance inflation factors < 3.0 for all variables), outliers and highly 
influential observations (largest Cook’s distance = 0.018), normality of residuals 
(kernel density plot, Appendix A and homoscedasticity (Breusch-Pagan test, p<0.001). 
The test for homoscedasticity failed; therefore, robust standard errors were computed 
for improved validity.206 Saturated models were reduced based on significance level for 
each correlation coefficient and model fit was evaluated with Bayesian Information 
Criterion values. After modeling the total sample, cancer site-specific models were 
evaluated using the same methods. To mitigate Type I error risk from multiple analyses, 
we used a significance cutoff of p <0.01.  
 
Results 
Sample characteristics 
Overall sample. Of 3,106 participants in the SOAPP study, 2,382 had sleep 
disturbance severity (SDS) scores. The sample was 71% female, 86% white, and mean 
age was 61 years (range, 23 to 93 years). The majority (62.8%) reported some degree 
of disturbed sleep [Figure 3.2], with about one quarter (26.2%) scoring the severity as 
moderate to severe (SDS≥5). Table 3.2 shows sample characteristics overall and by 
sleep disturbance severity group.  
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Figure 3.1 Distribution of 
subjective scores for severity 
of disturbed sleep at its worst 
in the last 24 hours: None 
(rating=0), Mild (rating=1-4), 
Moderate (rating=5-6), and 
Severe (rating=7-10) 
 
 
 
Cancer site-specific groups. Primary cancer sites were: breast (51%), colorectal 
(24%), lung (15%), and prostate (10%). Table 3.3 shows subsample characteristics for 
each cancer site. On average, breast cancer patients were youngest (57.6 ± 11.4 years), 
and prostate cancer patients were oldest (71.0 ± 9.5 years; F[3,2378]=109.47; 
p<0.001). No gender difference was detected between lung and colorectal cancer 
(evaluated separately from breast and prostate cancer). Groups differed by 
Hispanic/non-Hispanic ethnicity (X2[3]=23.96;p<0.001), but not race. Cancer 
disappearance was most common for breast cancer, while lung and prostate cancer had 
higher frequencies of partial response, progression, and stable disease 
(X2[9]=308.43;p<0.001). 
Time since diagnosis was different across all groups (F[3,2378]=56.31; 
p<0.001), except between lung and prostate cancer. Benzodiazepine receptor agonist 
use was lowest in prostate (3.8%) and colorectal (4.6%) cancer, and highest in lung 
cancer (9.4%; X2[3]=542.39;p=0.007). Comparing only breast and prostate cancer, 
hormone therapy was significantly higher for prostate cancer (59.9% versus 37.5%); 
X2[1]=41.29;p<0.001). Finally, cancer-specific differences were seen among all 
symptoms that appeared in models (see Table 3.3 for pairwise relationships). Groups 
sizes were uneven, and fewer significant correlates were identified in smaller groups. 
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Table 3.2 Sample characteristics overall and stratified by severity of disturbed sleep 
 TOTAL 
SAMPLE 
Sleep not       
Disturbed 
Sleep Mildly 
Disturbed 
Sleep Moderately  
Disturbed  
Sleep Severely  
Disturbed 
  
TOTAL SAMPLE N (%) N (%) N (%) N (%) N (%)   2382 (100.0) 887 (37.2) 807 (36.5) 306 (12.6) 319 (13.4) F p 
AGE, YEARS   
Mean 60.9 62.8 60.7 60.2 57.0   
Std. Deviation (12.2) (12.3) (11.8) (12.0) (12.4) 18.55 <0.001* 
SEX Χ 2 p 
Male 693 (29.1) 271 (30.6) 251 (28.9) 92 (30.1) 79 (24.8)   
Female 1689 (70.9) 616 (69.4) 619 (71.2) 214 (69.9) 240 (75.2) 3.98 0.264 
RACE   
White 2052 (86.1) 750 (84.6) 789 (90.7) 264 (86.3) 247 (77.4)   
Black 283 (11.9) 118 (13.3) 71 (8.2) 33 (10.8) 62 (19.4)   
Other 47 (2.0) 19 (2.1) 10 (1.2) 9 (2.9) 10 (3.1) 39.47 <0.001* 
ETHNICITY   
Hispanic 187 (8.1) 89 (10.0) 50 (5.8) 17 (5.6) 37 (11.6)   
Non-Hispanic 2195 (91.9) 798 (90.0) 820 (94.3) 289 (94.4) 282 (88.4) 16.45 0.001* 
PRIMARY SITE   
Breast 1212 (50.9) 429 (48.4) 450 (51.7) 155 (50.7) 178 (55.8)   
Colorectal 570 (23.9) 237 (26.7) 204 (23.5) 71 (23.2) 58 (18.2)   
Prostate 237 (10.0) 97 (10.9) 83 (9.5) 31 (10.1) 26 (8.2)   
Lung 363 (15.2) 124 (14.0) 133 (15.3) 49 (16.0) 57 (17.9) 14.74 0.098 
CANCER STATUS   
Disappearance 908 (38.1) 375 (42.3) 327 (37.6) 96 (31.4) 110 (34.5)   
Partial response 122 (5.1) 38 (4.3) 46 (5.3) 18 (5.9) 20 (6.3)   
Stable 1029 (43.2) 371 (41.8) 372 (42.8) 141 (46.1) 145 (45.5)   
Progression 323 (13.6) 103 (11.6) 125 (14.4) 51 (16.7) 44 (13.8) 16.89 0.050 
HYPNOTIC USE    
None 1822 (76.5) 757 (85.3) 660 (75.9) 203 (66.3) 202 (63.3) 95.37 <0.001* 
BzRA 156 (6.6) 27 (3.0) 57 (6.6) 35 (11.4) 37 (11.6) 7.80 0.253† 
Short-acting BZD 229 (9.6) 62 (7.0) 89 (10.2) 37 (12.1) 41 (12.9)   
Long-/Intermediate- acting BZD 175 (7.4) 41 (4.6) 64 (7.4) 31 (10.1) 39 (12.2)   
† A secondary analysis of hypnotic use only revealed no difference in hypnotic use by class.
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Table 3.3 Sample characteristics overall and for cancer-specific subgroups, including all significant correlates 
  Total  
Sample 
Breast  
Cancer 
Colorectal 
Cancer 
Lung  
Cancer 
Prostate  
Cancer Χ
2 Test p-value 
   N (%) N (%) N (%) N (%) N (%)   
  2382 (100.0) 1212 (50.9) 570 (24.0) 363 (15.2
) 
237 (10.0)   
Sex Male 693 (29.1) 3 (0.2) 293 (51.4) 160 (44.1) 237 (100.0) 1200 <0.001 
 Female 1689 (70.9) 1209 (99.8) 277 (48.6) 203 (55.9) 0 (0.0) 4.77* 0.029* 
Race White 2052 (86.2) 1064 (87.8) 473 (83.0) 316 (87.1) 199 (84.0) 12.33 0.055 
 Black 283 (11.9) 126 (10.4) 85 (14.9) 37 (10.2) 35 (14.8)   
 Other 47 (2.0) 22 (1.8) 12 (2.1) 10 (2.8) 3 (1.3)   
Ethnicity Hispanic 187 (7.9) 83 (6.9) 65 (11.4) 13 (3.6) 26 (11.0) 23.96 <0.001 
 Non-Hispanic 2195 (92.2) 1129 (93.2) 505 (88.6) 350 (96.4) 211 (89.0)   
Cancer status Disappearance 909 (38.2) 642 (53.0) 194 (34.0) 42 (11.6) 31 (13.1) 308.43 <0.001 
 Partial response 120 (5.0) 35 (2.9) 25 (4.4) 37 (10.2) 23 (9.7)   
 Stable 1030 (43.2) 420 (34.7) 256 (44.9) 221 (60.9) 133 (56.1)   
 Progression 323 (13.6) 115 (9.5) 95 (16.7) 63 (17.4) 50 (21.1)   
BzRA use  No 2226 (92.8) 1125 (92.8) 544 (95.4) 329 (90.6) 228 (96.2) 12.10 0.007 
 Yes 156 (7.2) 87 (7.2) 26 (4.6) 34 (9.4) 9 (3.8)   
Hormone therapy No 1779 (74.7) 758 (62.5) 566 (99.3) 360 (99.2) 95 (40.1) 542.39 <0.001 
 Yes 603 (25.3) 454 (37.5) 4 (0.7) 3 (0.8) 142 (59.9) 41.29 <0.001** 
Anticonvulsants No 2237 (93.9) 1142 (94.2) 540 (94.7) 331 (94.5) 224 (91.2) 5.76 0.124 
 Yes 145 (6.1) 70 (5.8) 30 (5.3) 13 (5.5) 32 (8.8)   
         
* A secondary evaluation of sex and cancer site was performed for the colorectal and lung cancer groups only. 
** A secondary evaluation of hormone therapy and cancer site was performed for the breast and prostate cancer groups only.  
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Table 3.3 (continued) Sample characteristics overall and for cancer-specific subgroups, including all significant correlates 
  Total  
Sample 
Breast  
Cancer 
Colorectal 
Cancer 
Lung  
Cancer 
Prostate  
Cancer F-test p-value 
  Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE)   
Age (years)a   60.91 (0.25) 57.57 (0.33) 61.37 (0.53) 64.74 (0.56) 70.99 (0.62) 109.47 <0.001 
Years since 
diagnosis 
 2.88 (0.09) 3.49 (0.14) 1.83 (0.09) 1.30 (0.09) 4.67 (0.30) 56.31 <0.001 
Symptom severity Disturbed sleep 2.58 (0.06) 2.69 c (0.09) 2.26 b,l (0.12) 2.86 c (0.16) 2.38 (0.18) 4.43 0.004† 
 Cognitive difficulty 1.95 (0.05) 2.03 (0.07) 1.71 l (0.10) 2.25 c (0.13) 1.66 (0.14) 5.40 0.001 
 Constipation  1.42 (0.05) 1.33 (0.07) 1.30 (0.10) 2.03 a (0.15) 1.18 (0.14) 9.06 <0.001 
 Cough 1.18 (0.04) 0.98 (0.05) 0.91 (0.08) 2.43 a (0.14) 0.95 (0.14) 51.84 <0.001 
 Distress 1.96 (0.05) 2.02 l (0.08) 1.79  (0.11) 2.37 b,p (0.14) 1.40 l (0.15) 7.75 <0.001 
 Drowsiness 2.42 (0.05) 2.35 (0.08) 2.34 (0.11) 2.96 a (0.14) 2.19  (0.15) 6.14 0.004 
 Fatigue 3.29 (0.06) 3.16 (0.08) 3.17 (0.12) 4.07 a (0.15) 3.02 (0.19) 10.72 <0.001 
 Nausea 0.93 (0.04) 0.83 (0.06) 1.17 p (0.09) 1.20 p (0.11) 0.47 c,l (0.08) 9.98 <0.001 
 Pain 1.89 (0.06) 1.87 (0.08) 1.74 (0.11) 2.31 (0.15) 1.66 (0.17) 4.10 0.007† 
 Anorexia 1.46 (0.05) 1.19 c,l (0.07) 1.68 b (0.11) 2.20 b,p (0.15) 1.12 l (0.15) 18.29 <0.001 
 Neuropathy 2.05 (0.06) 1.79 c (0.08) 2.72 b,p (0.13) 2.10 (0.14) 1.68 c (0.16) 15.88 <0.001 
 
† Pairwise comparisons did not meet p < 0.01 level of significance. 
a-p Significantly different (p<0.001) in post-hoc Scheffe pairwise contrasts (comparison to a: all; b: breast: c: colorectal; l: lung; p: prostate). 
BzRA: benzodiazepine receptor agonist 
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Models for sleep disturbance 
Overall sample (N=2,382). The best-fitting model [Table 3.4] accounted for 
43.4% of variance in SD severity scores (F(10,2371)=180.34; p<0.001; adj R2=0.434; 
BIC’=-1288.363). Significant correlates were: age, benzodiazepine receptor agonist 
(BzRA) use, and eight cancer symptoms (cognitive difficulty, constipation, cough, 
distress, drowsiness, fatigue, nausea, pain). 
Breast cancer (N=1,212). The best-fitting model [Table 3.4a] accounted for 
46.1% of variance (F(8,1203)=152.57; p<0.001; adj R2=0.461; BIC’=-700.014). 
Significant correlates were: age, hormone therapy, and six cancer symptoms (cognitive 
difficulty, cough, distress, drowsiness, fatigue, nausea) 
Colorectal cancer (N=570). The best-fitting model [Table 3.4b] accounted for 
48.2% of variance (F(7,562)=67.09; p<0.001; adj R2=0.482; BIC’=-337.644). 
Significant correlates were: stable disease status and four symptoms (anorexia, distress, 
fatigue, pain). 
Lung cancer (N=363). The best-fitting model [Table 3.4c] accounted for 37.1% 
of variance (F(4,358)=54.78; p<0.001; adj R2=0.371; BIC’=-148.805). Only four 
symptoms were significant correlates (cognitive difficulty, constipation, distress, 
neuropathy). 
Prostate cancer (N=237). The best-fitting model [Table 3.4d] accounted for 
27.2% of variance (F(3,233)=30.03; p<0.001; adj R2=0.272; BIC’=-61.981). 
Significant correlates were: anticonvulsant use for pain, and two symptoms (distress, 
drowsiness). 
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Table 3.4 Model for correlates of sleep disturbance in a large sample of persons with breast, lung, colorectal, and prostate cancer 
 
 
Total sample (n=2382) N (%) 
Regression 
Coefficient 
Robust 
Std. Error 
Standardized 
Regr. Coeff. p-value 
Benzodiazepine receptor agonist use  
No 2226 (93.6)     
Yes 156 (6.6) 0.714 (0.195) 0.061 <0.001 
 Mean (SD)     
Age  60.91 (0.25) -0.015a (0.004) -0.061a <0.001 
Symptom severity scores       
Cognitive difficulty 1.95 (0.05) 0.108 (0.028) 0.089 <0.001 
Constipation 1.41 (0.05) 0.073 (0.027) 0.063 0.006 
Cough 1.18 (0.04) 0.100 (0.029) 0.074 0.001 
Distress 1.96 (0.05) 0.302 (0.030) 0.270 <0.001 
Drowsiness 2.42 (0.05) 0.091 (0.033) 0.083 0.006 
Fatigue 3.29 (0.06) 0.150 (0.030) 0.149 <0.001 
Nausea 0.93 (0.04) 0.087 (0.032) 0.060 0.007 
Pain 1.89 (0.06) 0.095 (0.028) 0.088 0.001 
F(10,2371)=180.34; p<0.001; adj R2=0.434; BIC’=-1288.363 
a. Coefficients for age are shown for one-year units. For a 10-year increase in age, the regression coefficient (b) goes to -0.15 and the standardized regression 
coefficient (β) goes to -0.61. 
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Table 3.4a Model for correlates of sleep disturbance for participants with breast cancer 
4a. Breast cancer (n=1212) N (%) 
Regression 
Coefficient 
Robust 
Std. Error 
Standardized 
Regr. Coeff. p-value 
Hormone therapy  
No 758 (62.5)     
Yes 454 (37.5) 0.386 (0.131) 0.063 0.003 
 Mean (SD)     
Age  57.57 (0.39)b -0.023 (0.006) -0.089b <0.001 
Symptom severity scores       
Cognitive difficulty 2.03 (0.07) 0.119 (0.038) 0.097 0.002 
Cough 0.98 (0.06) 0.114 (0.043) 0.076 0.009 
Distress 2.02 (0.08) 0.333 (0.041) 0.300 <0.001 
Drowsiness 2.35 (0.08) 0.118 (0.045) 0.107 0.010 
Fatigue 3.16 (0.08) 0.211 (0.043) 0.203 <0.001 
Nausea 0.83 (0.06) 0.136 (0.044) 0.089 0.002 
F(8,1203)=152.57; p<0.001; adj R2=0.461; BIC’=-700.014 
b. Coefficients for age are shown for one-year units. For a 10-year increase in age, the regression coefficient (b) goes to -0.23 and the standardized regression 
coefficient (β) goes to -0.89. 
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Table 3.4b Model for correlates of sleep disturbance for participants with colorectal cancer 
4b. Colorectal Cancer (N=570) N (%) 
Regression 
Coefficient 
Robust 
Std. Error 
Standardized 
Regr. Coeff. p-value 
Clinical status        
Disappearance 194 (34.04)     
Partial response 25 ( 4.39) -0.690 (0.498) -0.052 0.166 
Stable 256 (44.91) -0.532 (0.186) -0.096 0.004 
Progression 95 (16.67) -0.220 (0.240) -0.030 0.360 
 Mean (SD)     
Symptom severity scores       
Anorexia 1.68 (0.11) 0.216 (0.050) 0.210 <0.001 
Distress 1.79 (0.11) 0.286 (0.052) 0.265 <0.001 
Fatigue 3.17 (0.12) 0.183 (0.048) 0.192 <0.001 
Pain 1.74 (0.11) 0.251 (0.054) 0.247 <0.001 
F(7,562)=67.09; p<0.001; adj R2=0.482; BIC’=-337.644 
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Table 3.4c Model for correlates of sleep disturbance for participants with lung cancer 
4c. Lung Cancer (N=363) Mean (SD) 
Regression 
Coefficient 
Robust 
Std. Error 
Standardized 
Regr. Coeff. p-value 
Symptom severity scores       
Cognitive difficulty 2.26 (0.13) 0.204 (0.071) 0.174 0.004 
Constipation 2.03 (0.15) 0.178 (0.052) 0.175 0.001 
Distress 2.37 (0.14) 0.389 (0.069) 0.347 <0.001 
Neuropathy 2.10 (0.15) 0.196 (0.059) 0.182 0.001 
F(4,358)=54.78; p<0.001; adj R2=0.371; BIC’=-148.805 
 
Table 3.4d Model for correlates of sleep disturbance for participants with prostate cancer 
4d. Prostate Cancer (N=237) N (%) 
Regression 
Coefficient 
Robust 
Std. Error 
Standardized 
Regr. Coeff. p-value 
Anticonvulsant for pain       
No 224 (94.51)     
Yes 13 ( 5.49) -1.329 -0.394 -0.107 0.001 
 Mean (SD)     
Symptom severity scores       
Distress 1.40 (0.15) 0.475 -0.078 0.377 <0.001 
Drowsiness 2.19 (0.15) 0.301 -0.085 0.250 <0.001 
F(3,233)=30.03; p<0.001; adj R2=0.272; BIC’=-61.981 
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Correlates of sleep disturbance 
Table 3.5 provides an overview of sleep disturbance severity (SDS) correlates 
in each model, along with corresponding regression coefficients and standardized 
coefficients. Consistency in measurement methods permits comparison of relative 
importance for each correlate across models. 
Demographic characteristics 
In addition to age, sex, race, and ethnicity, we evaluated driving status, 
employment status, recent employment change, and personal and family history of 
depression. We found no associations with any demographic variable except age. 
In bivariate analyses, Black and Hispanic participants were more likely to report 
either no sleep disturbance or severe sleep disturbance than their white and non-
Hispanic counterparts [Table 3.2], but these findings did not persist in regression 
models and may reflect response bias, rather than actual differences. Studies have 
shown that Hispanics and blacks in the United States have a higher tendency to respond 
at the extreme ends of Likert-type response scales than non-Hispanics and whites.227-230 
Age. In the overall sample, older age correlated with decreased SDS scores (b=-
0.015; β=-0.061; p<0.001). In sub-analysis by cancer site, however, age correlated with 
SDS for breast cancer only (b=-0.023; β=-0.089; p=0.003). The overall finding likely 
reflects the breast cancer cohort, which comprised 50.9% of the total sample; without 
this group, age no longer correlated with SDS overall. The breast cancer group is 
distinct for being 99.8% female. Sex did not correlate with SDS in any model in this 
study, but females have greater risk of insomnia in general.31  
Clinical characteristics 
Site of primary cancer did not correlate with SDS, nor did cancer stage or ECOG 
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performance status.* Also evaluated were: pain duration, pain mechanism, 
psychological distress (evaluated by clinician), cognitive function, and disease status. 
No clinical characteristic correlated with SDS overall; for participants with colorectal 
cancer, stable disease status (versus disappearance) correlated with decreased SDS (b=-
0.532; β=-0.096; p=0.041). 
Treatment characteristics 
No associations were found with clinician type, support group, counseling, and 
pain treatment. Among cancer-specific therapies (chemotherapy and radiotherapy 
[current and prior], immunotherapy, hormone therapy, treatment stage, and prior 
number of regimens), only hormone therapy correlated with SDS, and only for breast 
cancer (b=0.386; β=0.063; p=0.003). (NB: frequency of hormone therapy was 
negligible (<1%) for colorectal and lung cancers.)   
Supportive medications 
Among many medications prescribed for symptom management, our analysis 
included only those with documented effects on sleep [Table1]. Of special interest are 
the sedative-hypnotic benzodiazepines [BZDs] (e.g., temazepam, clonazepam) and 
benzodiazepine receptor agonists [BzRAs] (e.g., zolpidem, zaleplon), classically used 
to treat sleep disturbances. In the overall sample, BzRA use correlated with increased 
SDS (b=0.714; β=0.061; p<0001), but no other associations (positive or negative) were 
found for sedative-hypnotics.  
A noteworthy finding was substantially decreased SDS (b=-1.329; β=-0.107; 
p=0.001) among participants with prostate cancer using anticonvulsants for pain (e.g., 
gabapentin, pregabalin, which have known hypnotic effects); among all models, this 
was the largest regression coefficient.   
                                                
* Eastern Cooperative Oncology Group (ECOG) Performance Status grading system231 starts at 0 for 
'fully active without restriction’. Increasing scores represent worsening functional status (up to 5 = 
death). Because of small sample size, grades 3 and 4 were evaluated together. 
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Table 3.5 Comparison of regression coefficients (b) and standardized regression coefficients (β) for models of sleep disturbance, overall 
and by cancer type  
 
 All  
Cancer Sites 
N = 2,382 
Breast  
Cancer 
N = 1,212 
Colorectal 
Cancer 
N = 570 
Lung 
Cancer 
N = 363 
Prostate 
Cancer 
N = 237 
  b β b β b β b β b β 
Symptom severity Distress 0.302 0.270 0.333 0.300 0.286 0.265 0.389 0.347 0.469 0.373 
 Fatigue 0.150 0.149 0.211 0.203 0.183 0.192     
 Cognitive problems 0.108 0.089 0.119 0.097   0.204 0.174   
 Pain 0.092 0.088   0.251 0.247     
 Drowsiness 0.091 0.083 0.118 0.107     0.319 0.265 
 Cough 0.100 0.074 0.114 0.076       
 Constipation 0.073 0.063     0.178 0.175   
 Nausea 0.087 0.060 0.136 0.089       
 Anorexia     0.216 0.210     
 Neuropathy       0.196 0.182   
Age  -0.015a -0.061b -0.023a -0.089b       
BzRA use  0.714 0.061         
Hormone therapy    0.386 0.063       
Clinical status Stable     -0.532 -0.096     
Anticonvulsants for pain         -1.329 -0.107 
b: Regression coefficient. 
β: Standardized regression coefficient. 
a. Coefficients for age are shown for one-year units. For a 10-year increase in age, the regression coefficient (b) goes to -0.15 and the standardized regression 
coefficient (β) goes to -0.61. 
b. Coefficients for age are shown for one-year units. For a 10-year increase in age, the regression coefficient (b) goes to -0.23 and the standardized regression 
coefficient (β) goes to -0.89.
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Cancer symptoms 
In addition to disturbed sleep, eighteen other symptoms [Table 3.1] were 
evaluated. Among cancer types, symptom severity scores were often highest in the lung 
cancer group and lowest in the prostate cancer group [Table 3.3]. Distress was the only 
symptom that correlated with SDS in all models; it also had the largest standardized 
regression coefficient in each model (overall: b=0.302; β=0.270;p<0.001). 
• Fatigue was scored most severe (on average) in all groups, and correlated with 
SDS overall and for breast and colorectal cancer (overall: b=0.150; β=0.149; 
p<0.001).  
• Pain correlated with SDS overall and in colorectal cancer (overall: b=0.095; 
β=0.88; p=0.001).  
• Drowsiness correlated with SDS overall and in breast and prostate cancer 
(overall: b=0.091; β=0.083; p=0.006).  
• Nausea correlated with SDS overall and in breast cancer (overall: b=0.087; 
β=0.060; p=0.007).  
• Cough correlated with SDS overall and in breast cancer (overall: b=0.100; 
β=0.074; p=0.001).  
• Anorexia correlated with SDS for colon cancer only (b=0.216; β=0.210; 
p<0.001).  
• Neuropathy correlated with SDS for lung cancer only (b=0.196; β=0.182; 
p=0.001).  
 
Discussion 
We aimed to identify significant correlates of sleep disturbance among a broad 
array of variables and in a clinically and demographically diverse sample of persons 
with cancer. Most previous studies have focused on narrower patient populations (e.g., 
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women with breast cancer, patients undergoing chemotherapy, patients with advanced 
disease) and/or have evaluated a more limited set of covariates. In addition, variability 
in methods and measures across studies complicates interpretation of the aggregate 
literature. In the present study, we evaluated a large sample in its entirety, as well as in 
cancer-specific partitions. Consistent measurement across these analyses permits more 
meaningful comparisons of the relative importance of each correlate. 
 
Prevalence of sleep disturbance  
In our large sample (N=2,382) of patients with breast, colorectal, lung, or 
prostate cancer, 62.8% reported some degree of disturbed sleep, and 26.2% scored their 
sleep disturbance as moderate to severe (≥5 on a scale of 0=‘not present’ to 10=’as bad 
as you can imagine’). Previous studies of large mixed cancer samples report similar 
results. Stepanski et. al. found 55% of participants (N=11,445) had trouble sleeping, 
and 26% classified their sleep troubles as moderate to severe;81 80% of chemotherapy 
(N=823) recipients evaluated by Palesh et. al. reported disturbed sleep and 43% met the 
diagnostic criteria for insomnia;80 and Romito et. al. classified 66% of chemotherapy 
recipients (N=403) as bad sleepers.93  
 
Cancer symptoms and sleep disturbance 
In modeling correlates of sleep disturbance, our most prominent finding was the 
overwhelming relationship between cancer symptoms and disturbed sleep. Initial 
regression models were saturated with numerous factors, including cancer symptoms, 
demographic and clinical characteristics, cancer treatment variables, and medication 
use. Final regression models, however, consisted primarily of cancer symptoms, and 
only five non-symptom factors correlated with SDS. In separate analyses [Appendix 
B], models tested without symptom variables accounted for only 10% to 19% of SDS 
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variance (and no model resolved for prostate cancer); with symptoms included, models 
accounted for between 27% and 48% of SDS variance. Although symptoms figure 
substantially in each model, the mixture of symptoms is inconsistent across cancer 
types, and some associations were unexpected. Cough correlated with SDS in breast 
cancer, but not lung cancer (despite significantly higher cough severity scores in the 
lung cancer group). Constipation correlated with SDS in lung cancer, but no 
gastrointestinal symptoms correlated with SDS in colorectal cancer (despite 
significantly higher diarrhea severity scores).  
It is noteworthy that severity of symptoms did not dictate models. For example, 
in the lung cancer group, average pain severity was higher than in any other group, and 
the most severe-rated symptom was fatigue; yet neither fatigue nor pain correlated with 
SDS in participants with lung cancer. Similarly, despite the prominence of cancer 
symptoms in models, the magnitude of association (indicated by regression 
coefficients) is modest for individual symptoms. Conceivably, generally low severity 
scores across symptoms may have restricted the effect size range of our models. 
Nonetheless, our findings suggest that, even when symptoms are fairly well-controlled, 
clinically important relationships between sleep and other symptoms may be present. 
Furthermore, the models highlight the potential for individual symptoms of mild 
severity to accrue into substantial symptom load. These observations may have 
important implications for patients, because mild symptoms can easily be overlooked. 
In surveys of patients with cancer and disturbed sleep, between 38% and 85% 
did not discuss the issue with clinicians; often because it seemed unimportant relative 
to the cancer itself.93,232 Mild symptoms may also go unrecognized in clinical 
assessments. For example, among 8,265 adults with cancer, 70% did not meet 
diagnostic thresholds for anxiety or depression,233 yet in the present study, at least half 
of the participants reported some level of sadness (50%) or distress (55%). In our 
sample, distress (rated by patients) stands out as the most universal and strongest 
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(indicated by standardized regression coefficients) correlate of SDS. Notably, however, 
clinician-rated psychological distress was not a correlate, nor was history of diagnosed 
depression (personal or family). Evaluating symptoms independently and in terms of 
diagnostic thresholds may fail to unmask additive effects that may manifest from mild 
symptoms occurring contemporaneously. 
Unfortunately, symptom multiplicity is a hallmark of cancer and its treatment. 
Fatigue, pain, and insomnia are often experienced concurrently in oncology, and it has 
been proposed that these symptoms (along with depression and cognitive difficulty, in 
some models)234 represent a syndrome with a common underlying mechanism.235 In the 
present study, however, these associations were not consistent across groups; fatigue 
did not correlate with SDS in lung or prostate cancer, and although pain was a correlate 
overall, in sub-group analysis it correlated with SDS only in colorectal cancer. These 
findings signal the possibility of additional clinically important interactions between 
sleep and other symptoms, some of which may have more relevance for certain patient 
populations than the fatigue-pain-insomnia relationship. Uncovering such associations 
may help in clarifying pathophysiologic mechanisms and developing more targeted 
interventions for cancer symptom management. 
 
Distress 
Among the eighteen symptoms evaluated, distress was the strongest and only 
universal correlate of sleep disturbance. There is growing evidence that distress and 
disrupted sleep are related, perhaps reciprocally.236-240 Considerable variation in the 
operationalization of distress, however, complicates interpretation. The National 
Comprehensive Cancer Network (NCCN) describes ‘distress’ as encompassing a range, 
“from common normal feelings of vulnerability, sadness, and fears to problems that can 
become disabling, such as depression, anxiety, panic, social isolation, and existential 
and spiritual crisis.”241 In other oncology literature, ‘distress’ is a more global term, 
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including physical dimensions as well (also termed ‘symptom distress’).242 Because the 
NCCN has identified ‘emotional’ as a stigmatizing term, along with ‘psychological’ 
and ‘psychiatric’,241 terms such as ‘bother’ and ‘upset’ are used in some surveys to 
distinguish emotional distress from physical distress, but participants may have 
different interpretations for these terms.242 Furthermore, with only a single measure, it 
is impossible to make distinctions between, for example, participants with financial 
worries and those with existential crises. In this study, therefore, the strong correlation 
observed between distress and sleep disturbance may represent a number of diverse 
relationships and processes. A clear understanding of sleep-distress interactions would 
allow for more focused and effective interventions, but this requires an increase in the 
number and precision of measures used to characterize both sleep disturbance and 
distress. A few recent studies have employed polysomnography to measure sleep 
objectively,236,238,239 but measures for stress are limited and simulated stressors may have 
little bearing on real-life experiences. Longitudinal studies in oncology settings would 
likely yield a wealth of insights. 
 
Non-symptom correlates of sleep disturbance  
Five non-symptom factors correlated with SDS: age (overall and breast cancer), 
clinical status (colorectal cancer), hormone therapy (breast cancer), benzodiazepine use 
(overall), and anticonvulsant use for pain (prostate cancer).  
Age. In the general population, risk of sleep disturbance increases with age,31 
yet we found the opposite trend: SDS decreased with age in breast cancer participants 
and overall (although the overall result was likely driven by the large breast cancer 
cohort). Other studies of cancer symptoms have also observed inverse relationships 
between age and sleep disturbance.80,89,243 Suggested explanations include psychosocial 
and treatment factors pertinent to younger people, who generally have better baseline 
health and functional status and may have more demanding social roles. These patients 
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may receive more aggressive treatments with greater toxicities81 and/or experience 
decrements in health and function more profoundly.244 Younger patients may also have 
greater unmet needs for psychosocial support, relative to retirees no longer caring for 
children.89,245 Similarly, in studies not specific to cancer it has been suggested that older 
adults may be more tolerant of sleep disturbance because they experience less ‘role 
impairment’ from daytime effects of sleep loss.27,246 Several psychosocial, clinical, and 
treatment variables were evaluated in this study, but symptoms – especially distress – 
were generally better correlates of SDS. After excluding symptoms, however, recent 
employment change correlated with increased SDS in every group. Notably, breast 
cancer participants were distinct from other groups by being the youngest and almost 
all female. It may be worth investigating whether younger females experience unique 
psychosocial stressors (e.g., childcare, eldercare) not measured in this study.  
Clinical status. Among participants with colorectal cancer, those in remission 
(disappearance) reported worse SDS than those with stable disease. A similar, but non-
significant, trend was seen for partial response and progression. The relative association 
is small (standardized regression coefficient = -0.096), but nonetheless counterintuitive. 
Given the physical and psychological distress associated with cancer and its treatment, 
one might expect improved sleep after remission. There is some evidence, however, 
that colorectal cancer survivors have worse health-related quality of life than survivors 
of other solid tumor cancers.247-249 In particular, patients with ileostomy/colostomy 
report disrupted sleep from leakage, ballooning, and anxiety about such events.250,251 
We were unable to control for this variable, however, as it was not measured in the 
original SOAPP study. 
Cancer treatment. The only cancer treatment correlated with SDS was hormone 
therapy for breast cancer. Hormone blockade is common for treating breast and prostate 
cancer. Although therapeutic targets differ by site (prostate: testosterone; breast: 
estrogen and/or progesterone), common side effects in both cases include hot flashes 
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and night sweats, which can disrupt sleep. In our sample, hormone therapy was more 
common in prostate cancer, but correlated with SDS only in breast cancer. Prevalence 
estimates for hot flashes are varied, but risk does not appear markedly greater for 
women (51%-81%) than men (69%-76%).252 It may be, however, that hot flashes in 
women are more severe or less well controlled (e.g., citalopram is an effective remedy, 
but contraindicated in women taking tamoxifen). Comparative evaluations of hot 
flashes in both men and women may yield new insights for prevention and treatment. 
Medications. Two medication classes correlated with SDS in our study: 
benzodiazepine receptors agonists (BzRAs, e.g. zolpidem, zaleplon), and 
anticonvulsants used for pain (e.g. pregabalin, gabapentin). In the whole cohort, BzRA 
use correlated with a 0.7-point increase in SDS severity. Since BzRAs are indicated for 
insomnia, correlation between sleep disturbance and BzRA use is unsurprising. Ideally, 
however, BzRA users would report decreased symptom severity, relative to non-users. 
It may be that BzRA users comprise the worst cases whose scores would be 
dramatically higher without treatment. Alternatively, our results may be confounded by 
unmeasured use of over-the-counter or non-pharmacological remedies. Notably, 
however, we did observe a substantial 1.3-point SDS decrease in men with prostate 
cancer using anticonvulsants for pain. This result is unlikely related to severity of sleep 
disturbance (higher in breast and lung cancer, lower in colorectal cancer) or prevalence 
of anticonvulsant use (no difference across groups), but may be related to pain control 
(lowest reported severity in prostate cancer). Although SOAPP data do not identify 
specific anticonvulsants, gabapentin and pregabalin have the best evidence for cancer-
related neuropathy.253 Furthermore, these anticonvulsants are sedating and appear to 
increase slow-wave (SWS) and rapid eye-movement (REM) sleep254 (considered vital 
to physical and mental restoration, respectively),255 whereas BzRAs may inhibit or 
fragment these sleep stages.256 Our findings of positive (for BzRAs) or null (for BZDs) 
correlations between SDS and hypnotics call into question whether these standard 
 98 
insomnia treatments are the best choice for people with cancer. The effectiveness of 
sedative-hypnotics in this setting has not been established in clinical trials, and more 
research – including evaluation of drugs that could target multiple symptoms – is 
needed.  
 
Comparisons across cancer types 
The key similarity among cancer-specific groups was the importance of 
symptoms as correlates of sleep disturbance. Distress was the only universal correlate, 
and its largest relative effect was seen in prostate and lung cancer (standardized 
regression coefficients: 0.373 and 0.347, respectively). Fatigue, pain, drowsiness, and 
cognitive problems appeared in multiple models, but other correlates were shared. It 
should be noted, however, that groups were unmatched on several sample 
characteristics [Table 3.3] and in size. Commonalities may have gone undetected due 
to loss of power in smaller groups (e.g., lung and prostate cancer). 
  
Strengths and limitations 
To our knowledge, this is the largest and most comprehensive epidemiological 
study of sleep disturbance in oncology that allows for comparisons across different 
cancer types, but several limitations must be considered. As a secondary analysis, 
selection bias cannot be ruled out and subgroups were not matched in size or 
demographic characteristics. Furthermore, generalizability may be limited to 
ambulatory patients with solid tumors treated by an oncology group in the Eastern 
United States. The single subjective sleep disturbance measure likely captured a wide 
variety of sleep disturbances (e.g., restless limbs, apnea, delayed onset, early waking, 
feeling unrestored), but did not permit distinctions among them. Selection of 
independent variables was based on a causal model, but the cross-sectional design and 
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unknown duration of sleep disturbance (and certain correlate variables) prohibit causal 
inference. Finally, use of non-prescription medications, supplements, alcohol was not 
accounted for and could confound our results.  
 
Conclusions 
We aimed to identify, from a large set of variables, the most important correlates 
of sleep disturbance in persons with cancer. Based on the 3P (predisposing, 
precipitating, perpetuating) model of insomnia, we evaluated demographics, clinical 
characteristics, cancer treatments, palliative medications, and cancer symptoms. 
Although average symptom severity scores were generally mild (mostly ≤ 3 on a 0 to 
10 scale), cancer symptoms dominated the models. Comparing across cancer-specific 
subgroups, distress was the only universal correlate, but cognitive difficulty, 
drowsiness, and fatigue were also common. Benzodiazepine receptor agonists, 
specifically indicated for insomnia, correlated with a small increase in SDS overall (no 
associations were found with other hypnotics), while use of anticonvulsants for pain 
correlated with a relatively large SDS decrease in prostate cancer. The clinical and 
research implications of these findings are: 1) Even when individual symptoms are 
mild, patients with multiple symptoms may experience substantially worsened sleep. 
Research aimed at identifying causal pathways and interactions may help clinicians to 
better manage overall symptom burden. 2) Standard pharmacotherapy for insomnia 
may not benefit persons with cancer as much as treatments that target multiple 
symptoms. Hypnotics are not well studied in this population and more research is 
needed. 
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3.2 SECTION II: MANUSCRIPT 2 
Hypnotic Use Prevalence and Correlates in Solid Tumor Cancers 
Introduction 
For well over a decade, oncology clinicians and researchers have recognized 
sleep disturbance to be an important problem for patients.80,81,93 It is one of the most 
common and severe cancer symptoms reported,82,90,110 and can reduce health-related 
quality of life,87,91,111 exacerbate other cancer symptoms81,137 and worsen prognoses.88,89 
Yet to date, there is little evidence to guide treatment in this setting.156,164 
Sleep disturbance may be treated both pharmacologically and non-
pharmacologically. The most studied non-pharmacologic option is cognitive behavioral 
therapy for insomnia (CBT-I) to correct beliefs and behaviors that interfere with sleep.3 
CBT-I is free of adverse effects, and benefits can be long-lasting, but it often takes time 
to see results.3 In persons with cancer, CBT-I has shown promise for improving 
insomnia.121-124 When acute relief is needed, however, or when sleep disturbance is not 
primarily due to beliefs and behaviors, pharmacologic insomnia treatments (hypnotics) 
may be preferred. 
Historically, hypnotic use has been common in oncology settings. Among 1,984 
Canadians with cancer surveyed in 2004, 41% received prescriptions for hypnotics, 
37% had used hypnotics at some time since diagnosis, and 23% currently used 
hypnotics.135 Similarly, in the late 1990s, 26% of 909 Israeli oncology patients reported 
hypnotic use in the previous week.136 In the United States (US), estimates of hypnotic 
use in oncology exceeded 50% in the 1970s and 1980s, with benzodiazepines and 
antihistamines being prescribed most frequently.137,138 These figures far outpace use of 
hypnotics in the general population, which is estimated at about 3-4%.145,257 
More recent patterns of hypnotic use in US oncology patients are not well 
studied. This is noteworthy because the current standard-of-care drugs for insomnia, 
benzodiazepine receptor agonists (BzRAs), were introduced in the 1990s. Zolpidem 
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(Ambien®, Sanofi) first entered the US market in 1992, followed by zaleplon 
(Sonata®, Pfizer) in 1999, and eszopiclone (Lunesta®, Sunovion Pharmaceuticals) in 
2004.143 With the hypnotic efficacy of benzodiazepines, but fewer side effects, BzRAs 
quickly became preferred for insomnia, accounting for about 40% of hypnotic use 
nationwide by 2010.145 In the US oncology setting, however, recent knowledge of 
hypnotic use is, to date, limited to a few small studies [Table 3.6]. Current data on 
which drugs are being prescribed, how often, and to whom, is a vital first step in 
assessing, and improving, the treatment of sleep disturbance in persons with cancer.  
This study aims to quantify hypnotic use in a large diverse sample of persons 
with cancer, and to identify – from a large number of demographic, clinical, treatment, 
and clinician assessment variables – the significant correlates of hypnotic use by cancer 
patients overall, as well as for specific types of cancer. 
 
Table 3.6 Summary of recent studies quantifying hypnotic us in US oncology patients 
Study Time Period Site Sample Findings 
Koopman et. al. 
(2002) 141 
Secondary 
analysis 
January 1991  
to  
December 
1996 
Multiple sites.  
San Francisco 
Bay Area, CA 
97 women with 
metastatic or 
locally recurrent 
breast cancer 
37% reported sleeping 
pill use within last 30 
days 
Guo et. al. 
(2007) 140 
Medical record 
review 
September 
2002, through      
October 2003  
Large tertiary 
care cancer 
center. 
Houston,  TX  
96 adults 
undergoing acute 
inpatient 
rehabilitation  
24% were given 
hypnotics upon 
discharge 
Moore at. al. 
(2011)258 
April 2003  
through 
May 2006  
Multiple sites. 
Midwestern 
US 
219 women 
receiving 
chemotherapy for 
breast cancer 
20% used sleep aids 
prior to chemotherapy;  
use decreased over 
time (12-18%) 
Costantini C, 
Ale-Ali A, 
Helsten T. 
(2011) 142 
Medical record 
review 
April 2008 
through       
March 2010  
 
University of 
California. 
San Diego, CA 
124 women 
receiving 
chemotherapy for 
breast cancer 
32% received hypnotic 
prescriptions during 
chemotherapy; 
benzodiazepines 
comprised 39% of 
prescriptions 
 
 102 
Methods 
This was a secondary analysis of the Symptom Outcomes and Practice Patterns 
(SOAPP) study conducted from March 3, 2006 to May 19, 2008 in about 40 clinics and 
academic centers located primarily in the Eastern United States. This study is a 
secondary analysis of the SOAPP data, and the support of the ECOG-ACRIN* Cancer 
Research Group and SOAPP Study Steering Committee in accessing these data is 
acknowledged. The results and conclusions in this paper are those of the authors and 
do not indicate concurrence by ECOG-ACRIN or the SOAPP Study Steering 
Committee.  
 
Participants 
Outpatients at least 18 years of age at any stage of care for invasive breast, lung, 
prostate, or colorectal cancer were eligible to participate; respondents with inadequate 
cognitive function (assessed by a study screener) were excluded.171 Clinicians provided 
clinical data, including medication use, and evaluated patient quality of life in multiple 
health-related domains. Patients provided demographic data. 
 
Study variables 
Hypnotic use. In the original SOAPP study, clinicians identified patient 
medications by category. The ‘hypnotics’ category comprised benzodiazepines 
(BZDs), and non-BZDs. Examples listed for non-benzodiazepine hypnotics were 
zolpidem (a BzRA) and chloral hydrate. Chloral hydrate was not widely used in 
oncology studies immediately preceding the introduction of BzRAs, and is not 
commonly used in recent studies of the general population. Therefore, this study 
assumes that ‘non-benzodiazepine hypnotics’ represent mainly BzRAs. BZDs were 
                                                
* A merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of 
Radiology Imaging Network (ACRIN) 
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further partitioned into long- or intermediate-acting (e.g, clonazepam, clorazepate, 
flurazepam, lorazepam) and short-acting (e.g., oxazepam, triazolam, alprazolam) 
because short-acting BZDs are sometimes used for anxiety, independently of sleep 
disturbance. We note, however, that clinicians may have assigned BZDs differently, as 
categorization by duration of action is not consistent in the literature. 
Correlate variables. Many demographic, clinical, treatment, and clinician 
assessment variables were measured in the original SOAPP study. For this analysis, we 
identified the following four categories of potential hypnotic use correlates: 
1. Disturbed sleep was rated by patients at its worst in the last 24 hours (scaled 
from 0=‘Not present’ to 10=‘As bad as you can imagine’) as part of a survey 
adapted from the MD Anderson Symptom Inventory (MDASI).224 To aid 
interpretation, we defined the following sleep disturbance groups: None (0), 
Mild (1-4), Moderate (5-6), and Severe (7-10). Although the literature is not 
conclusive, cut-points of 5 and 7 are often identified as clinically meaningful 
thresholds for cancer symptom assessments that use 0 to 10 scales (e.g., 
Edmonton Symptom Assessment Scale, Brief Fatigue Inventory, Brief Pain 
Inventory).179,180,182  
2. Sleep disturbance risk factors may be categorized by the ‘3P' model of insomnia 
as predisposing (e.g.,  physiological, psychological, or socioeconomic factors 
that increase vulnerability to sleep disruption), precipitating (e.g., life events 
that trigger acute insomnia), and/or perpetuating (e.g., factors that inhibit 
adaptation and return to normal sleeping patterns).183 Established predisposing 
factors for insomnia in the general population include older age, female sex, 
history of mental illness, and low socioeconomic status. In the context of cancer, 
sleep may be disrupted by clinical factors (e.g., disease stage, functional status) 
and treatments (e.g., chemotherapy, hormone therapy). Table 3.7 lists 
demographic, clinical, and treatment variables included in saturated models. 
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Table 3.7 Potential mediators of sleep disturbance included in models for hypnotic 
use 
Demographic variables Clinical variables Treatment variables 
Age  Primary site Prior radiotherapy 
Sex Breast Current radiotherapy 
Male Colorectal Prior number of regimens 
Female Prostate None 
Race Lung 1 
White Months since diagnosis 2 
Black Cancer stage 3 or more 
Other* No evidence of disease Current chemotherapy 
Ethnicity Local/regional None 
Hispanic Metastatic Systemic single 
Non-Hispanic Local/regional/metastati
c 
Systemic multi 
Employment status Cancer status Nonsystemic/Noncytotoxic 
Part-time Disappearance Current immunotherapy 
Full-time Partial response Current hormone therapy 
Not employed Stable Current treatment stage 
Employment change in last 4 
weeks 
Progression None 
Driving in last 4 weeks ECOG performance status Adjuvant 
History of depression 0 Non-metastatic 
Family history of depression 1 Metastatic 
 2 Attending support group 
 3 & 4 Attending counseling 
 Cognitive function  
 No impairment  
 Partial impairment  
 Pain history  
 None currently  
 < 48 hours  
 < 1 month  
 > 1 month  
 > 6 months  
 Pain mechanism  
 None  
 Nociceptive  
 Neuropathic   
 Psychological distress  
* Excluded due to small cell sizes 
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Table 3.8 Medications commonly used in cancer symptom management with known 
or potential effects on sleep.  
* Approved by United States Food & Drug Administration for treatment of insomnia. 
† Over-the-counter (nonprescription) medications. 
Drug class Examples Use in oncology General 
effect 
5-HT3 
antagonists 
Ondansetron, 
granisetron, 
dolasetron 
Nausea & vomiting Sedating 
Anticonvulsants Gabapentin, 
pregabalin 
Nerve pain Sedating 
Antidepressants Doxepin*, 
trazodone, 
mirtazapine 
Nerve pain Sedating 
Antihistamines  Diphenhydramine*†, 
doxylamine*†, 
chlorpheniramine†, 
promethazine, 
hydroxyzine 
Hypersensitivity 
reaction 
Sedating 
Antipsychotics Olanzapine, 
quetiapine 
Delirium – Not studied Sedating 
Cannabinoids Dronabinol Pain, nausea & 
vomiting – Not studied 
Sedating 
Corticosteroids Dexamethasone, 
prednisolone 
Nausea & vomiting, 
pain, 
immunosuppression, 
others 
Excitatory 
Miscellaneous 
anxiolytics & 
antidepressants 
Buspirone, 
hydroxyzine, 
trazodone, 
mirtazapine, 
quetiapine, 
olanzapine 
Anxiety, depression, 
insomnia, delirium 
Sedating 
Neurokinin-1 
inhibitors 
Aprepitant  Nausea & vomiting Sedating 
Opioid 
analgesics 
Morphine, fentanyl Pain Sedating 
Other 
antiemetics 
Promethazine, 
metoclopramide 
Nausea & vomiting Sedating 
Tricyclic 
antidepressants 
Amitriptyline, 
nortriptyline, 
Depression, anxiety, 
nerve pain 
Sedating 
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3. Medications used to control symptoms often have effects on sleep [Table 3.8]. 
Sedating drugs could negatively correlate with hypnotic use either by 
incidentally obviating their need or due to being deliberately prescribed for this 
indication. Alternatively, increased hypnotic use might be observed in 
participants using corticosteroids, which have detrimental effects on sleep.  
4. Clinician assessments of patient experiences. In the SOAPP study, clinicians 
assessed patients’ health-related quality of life in two ways. First, by identifying 
from a list of symptoms (e.g., pain, fatigue, cough) and lifestyle problems (e.g., 
spiritual problems, financial problems), the top three3 areas causing difficulty 
for their patients. Second, by rating (from 0=‘Not at all’ to 4=‘Extremely’) the 
degree to which their patients were bothered by difficulties related to: cancer, 
cancer treatments, comorbidities, side effects from symptom care medications, 
and weight gain/loss. We also evaluated type of clinician (attending physician, 
resident or fellow, advanced practice nurse or nurse practitioner, physician 
assistant, other) as a potential correlate of hypnotic use. 
Statistical analyses 
Software. Statistical analyses were conducted using the following software: 
Stata (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: 
StataCorp LP.), SAS (SAS Institute. 2015. The SAS system for Windows. Release 9.4. 
SAS Institute, Cary, NC.), and IVEware (University of Michigan. 2002. IVEware: 
Imputation and Variance Estimation Software). 
Missing data analysis. The percentage of missing values was low (<4%) for 
most independent variables, except ethnicity (7.18%), current hormone therapy 
(16.25%), and current immunotherapy (18.35%), none of which were included in final 
models. With a large number of variables, however, listwise deletion would reduce the 
sample by about 25%. Using SAS software and a callable routine built with IVEWare, 
                                                
3 This study evaluated only the top two-ranked areas; the third item was mostly missing. 
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values were multiply imputed (m=5) through sequential multiple regression by chained 
equations to accommodate heterogeneity of variable type and distribution.201-203 
Comparison of imputed datasets by analysis of variance (ANOVA) revealed no 
differences for any variables, except current hormone therapy (F=5.54 [1,13903], 
p=0.0186). Final regression analyses were, therefore, performed on a singly-imputed 
dataset, to facilitate additional analytic procedures, including regression diagnostics. 
Statistical analyses. Starting with a saturated model [Table 3.7], we used binary 
logistic regression to identify correlates of hypnotic use. Models were reduced based 
on significance level for each correlation coefficient, and model fit was evaluated with 
Bayesian Information Criterion values. For each factor level, we estimated hypnotic 
use probabilities standardized to the total group (covariates controlled using weighted 
averages).207,208 After modeling the total sample, cancer site-specific models were 
evaluated using the same methods. To mitigate Type I error risk from multiple analyses, 
we used a significance cutoff of p <0.01.  
 
Results 
Sample characteristics 
Of 3,106 participants in the SOAPP study, 2,382 met the inclusion criteria. The 
sample was 71% female, 86% white, and mean age was 61 years (range, 23 to 93 years). 
A total of 62.8% reported at least some degree of sleep disturbance [score >0/10]; 
26.3% rated their sleep disturbance as moderate to severe [score  >=5/10].  
Hypnotic use. Overall, 23.5% of participants used a BZD/BzRA hypnotic. 
Among those reporting any degree of sleep disturbance, 28.8% used a hypnotic. For 
moderate-to-severe sleep disturbance, 35.2% used hypnotics. Hypnotic users were, on 
average, slightly younger than non-users, and hypnotic use was more common in 
females, whites, non-Hispanics, participants with breast cancer, and those with stable 
disease [Table 3.9].  
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Table 3.9 Sample characteristics overall and dichotomized by hypnotic use 
  TOTAL 
SAMPLE 
No 
Hypnotic Use 
 
Hypnotic Use F p 
  Mean    (SD) Mean    (SD) Mean    (SD)   
 Age, years 60.9 (12.2) 61.7 (12.2) 58.3 (11.8) 34.50 < 0.001* 
TOTAL SAMPLE  
N (%) N (%) N (%)   
2382 (100.0) 1822 (76.5) 560 (23.5) Χ 2 p 
Sleep disturbance severity None [0] 887 (37.2) 757 (41.6) 130 (23.2) 87.144 <0.001* 
 Mild [1-4] 870 (36.5) 660 (36.2) 210 (37.5)   
 Moderate [5-6] 306 (12.9) 203 (11.1) 103 (18.4)   
 Severe [7-10] 319 (13.4) 202 (11.1) 117 (20.9)   
Sex Male 693 (29.1) 566 (31.1) 127 (22.7) 16.603 <0.001* 
 Female 1689 (70.9) 1256 (68.9) 433 (77.3)   
Race White 2052 (86.1) 1539 (84.5) 512 (91.4) 18.745 <0.001* 
 Black 283 (11.9) 246 (13.5) 38 (6.8)   
 Other 47 (2.0) 37 (2.0) 10 (1.8)   
Ethnicity Hispanic 187 (8.1) 154 (8.5) 24 (4.3) 10.755 0.001* 
 Non-Hispanic 2195 (91.9) 1668 (91.6) 536 (95.7)   
Primary site Breast 1212 (50.9) 914 (50.2) 298 (53.2) 25.345 <0.001* 
 Colorectal 570 (23.9) 444 (24.4) 126 (22.5)   
 Prostate 237 (10.0) 256 (14.1) 107 (19.1)   
 Lung 363 (15.2) 208 (11.4) 29 (5.2)   
Cancer status Disappearance 908 (38.1) 758 (41.6) 151 (27.0) 39.505 <0.001* 
 Partial response 122 (5.1) 89 (4.9) 32 (5.7)   
 Stable 1029 (43.2) 736 (40.4) 291 (52.0)   
 Progression 323 (13.6) 239 (13.1) 86 (15.4)   
Clinician: sleep is a top 
HRQoL problem 
No 2120 (89.0) 1629 (89.4) 491 (87.7) 1.308 0.253 
Yes 262 (11.0) 193 (10.6) 69 (12.32)   
HRQoL: health-related quality of life          
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The distribution of hypnotic use by class was fairly even: 31% long- or 
intermediate-acting BZDs, 41% short-acting BZDs, and 28% BzRAs [Figure 3.1]. We 
note that this distribution is subject to some uncertainty, because classification of BZDs 
by duration of action is not consistent in the literature. There were no differences in 
hypnotic class used on the basis of sleep disturbance severity, age, sex, race, ethnicity, 
primary site, or cancer status.  
 
Figure 3.2 Distribution of 
hypnotic use by class. 
Examples of intermediate-
/long-acting BZDs include: 
clonazepam, clorazepate, 
and flurazepam. Short-
acting BZDs include 
oxazepam, triazolam, and 
alprazolam. BzRAs include 
zolpidem and zaleplon. 
Classification by duration 
of action is inconsistent for 
some BZDs (e.g., 
lorazepam, alprazolam). 
 
Cancer site-specific groups. Primary cancer sites were: breast (51%), colorectal 
(24%), lung (15%), and prostate (10%). Table 3.10 shows subsample characteristics 
for each cancer site. On average, breast cancer patients were youngest (57.6 ± 11.4 
years), and prostate cancer patients were oldest (71.0 ± 9.5 years; F[3,2378]=109.47; 
p<0.001). No gender difference was detected between lung and colorectal cancer 
(evaluated separately from breast and prostate cancer). Groups differed by 
Hispanic/non-Hispanic ethnicity (X2[3]=23.96;p<0.001), but not race. Cancer 
disappearance was most common for breast cancer, while lung and prostate cancer had 
higher frequencies of partial response, progression, and stable disease 
(X2[9]=308.43;p<0.001). 
 110 
Models for hypnotic use 
Table 3.11 shows the best-fitting models for correlates of hypnotic use overall, 
and in each cancer-specific group. Along with regression coefficients, we report 
predicted probabilities and relative risk ratios.  
Overall sample (N=2,382). The model for the total sample accounts for 12.6% 
of variance (Χ 2(19)=388.52; p<0.001; adjusted R2=0.126; BIC’=-240.779). Correlates: 
race, history of depression, clinical status, opioids, corticosteroids, promethazine, 
neurokinin-1 inhibitors, miscellaneous anxiolytics/ antidepressants, metoclopramide, 
and clinician rating for patients’ difficulty with cancer treatment. 
Breast cancer (N=1,212). Model accounts for 15.1% of variance 
(Χ2(16)=256.75; p<0.001; adjusted R2=0.151; BIC’=-143.147). Correlates: race, 
history of depression, clinical status, promethazine, neurokinin-1 inhibitors, 5-HT3 
antagonists, metoclopramide, and clinician rating for patients’ difficulty with cancer 
treatment. 
Colorectal cancer (N=570). Model accounts for 7.2% of variance 
(Χ2(6)=65.42; p<0.001; adjusted R2=0.072; BIC’=-27.347). Correlates: psychological 
distress, opioid use, corticosteroids, and promethazine. 
Lung cancer (N=363). Model accounts for 7.8% of variance (Χ2(4)=50.34; 
p<0.001; adjusted R2=0.078; BIC’=-26.759). Correlates: race, history of depression, 
corticosteroids. 
Prostate cancer (N=237). Model accounts for 10.4% of variance (Χ2(5)=34.26; 
p<0.001; adjusted R2=0.104; BIC’=-6.924). Correlates: promethazine, and clinician 
rating for patients’ difficulty with cancer. 
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Table 3.10  Sample characteristics overall and for cancer-specific subgroups, including all significant correlates 
  Total Sample Breast Cancer Colorectal Cancer Lung Cancer Prostate Cancer   
   N (%) N (%) N (%) N (%) N (%)   
  2382 (100.0) 1212 (50.9) 570 (24.0) 363 (15.2) 237 (10.0) Χ2 Test p-value 
Sleep 
disturbance 
severity score 
None [0] 887 (37.2) 429 (35.4) 237 (41.6) 124 (34.2) 97 (40.9) 14.7 0.098 
Mild [1-4] 870 (36.5) 450 (37.1) 204 (35.8) 133 (36.6) 83 (35.0)   
Moderate [5-6] 306 (12.9) 155 (12.8) 71 (12.5) 49 (13.5) 31 (13.1)   
 Severe [7-10] 319 (13.4) 178 (14.7) 58 (10.2) 57 (15.7) 26 (11.0)   
Sex Male 693 (29.1) 3 (0.2) 293 (51.4) 160 (44.1) 237 (100.0) 1200 <0.001 
 Female 1689 (70.9) 1209 (99.8) 277 (48.6) 203 (55.9) 0 (0.0) 4.77* 0.029* 
Race White 2052 (86.2) 1064 (87.8) 473 (83.0) 316 (87.1) 199 (84.0) 12.33 0.055 
 Black 283 (11.9) 126 (10.4) 85 (14.9) 37 (10.2) 35 (14.8)   
 Other 47 (2.0) 22 (1.8) 12 (2.1) 10 (2.8) 3 (1.3)   
Ethnicity Hispanic 187 (7.9) 83 (6.9) 65 (11.4) 13 (3.6) 26 (11.0) 23.96 <0.001 
 Non-Hispanic 2195 (92.2) 1129 (93.2) 505 (88.6) 350 (96.4) 211 (89.0)   
History of 
depression 
No 187 (7.9) 83 (6.9) 65 (11.4) 13 (3.6) 26 (11.0) 23.96 <0.001 
Yes 2195 (92.2) 1129 (93.2) 505 (88.6) 350 (96.4) 211 (89.0)   
Psychological 
distress 
No 1727 (72.5) 887 (73.2) 417 (73.2) 240 (66.1) 183 (77.2) 10.47 0.015 
Yes 655 (27.5) 325 (26.8) 153 (26.8) 123 (33.9) 54 (22.8)   
Clinical status Disappearance 909 (38.2) 642 (53.0) 194 (34.0) 42 (11.6) 31 (13.1) 308.43 <0.001 
 Partial response 120 (5.0) 35 (2.9) 25 (4.4) 37 (10.2) 23 (9.7)   
 Stable 1030 (43.2) 420 (34.7) 256 (44.9) 221 (60.9) 133 (56.1)   
 Progression 323 (13.6) 115 (9.5) 95 (16.7) 63 (17.4) 50 (21.1)   
Pain treatment None 909 (38.2) 642 (53.0) 194 (34.0) 42 (11.6) 31 (13.1) 308.43 <0.001 
 Opioids 120 (5.0) 35 (2.9) 25 (4.4) 37 (10.2) 23 (9.7)   
 Non-opioids 1030 (43.2) 420 (34.7) 256 (44.9) 221 (60.9) 133 (56.1)   
 Combination 323 (13.6) 115 (9.5) 95 (16.7) 63 (17.4) 50 (21.1)   
Medication use Corticosteroids 459 (19.3) 198 (16.3) 116 (20.4) 97 (26.7) 48 (20.3) 20.24 <0.001 
 Promethazine 392 (16.5) 170 (14.0) 135 (23.7) 68 (18.7) 19 (8.0) 40.51 <0.001 
 NK-1 inhibitors  95 (3.99) 67 (5.5) 16 (2.8) 12 (3.3) 0 0 19.87 <0.001 
 Misc. Anxiolytics/ADs 26 (1.1) 14 (1.2) 10 (1.8) 2 (0.6) 0 0 5.96 0.113 
 Metoclopramide 55 (2.3) 23 (1.9) 15 (2.6) 14 (3.9) 3 (1.3) 6.17 0.104 
 5-HT3 antagonists 426 (17.9) 170 (14.0) 160 (40.3) 363 (2.7) 19 (8.0) 71.00 <0.001 
Top quality of 
life problem 
Distress 262 (11.0) 147 (12.1) 55 (9.7) 35 (9.6) 25 (10.6) 3.37 0.338 
Sleep 262 (11.0) 160 (13.2) 38 (6.7) 33 (9.1) 31 (13.1) 19.33 <0.001 
* A secondary evaluation of sex and cancer site was performed for the colorectal and lung cancer groups only.
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Table 3.11 Logistic regression model for correlates of hypnotic use in solid tumor cancers 
Total sample (n=2382) N (%) 
Regression 
Coefficient (SE) 
 
p-value 
Predicted 
Probability (SE) 
Relative 
Riska 
Sleep Disturbance Severity         
None [0] 887 (37.2) 0.37 (0.13)  0.18 (0.01)  
Mild [1-4] 870 (36.5) 0.77 (0.17) 0.567 0.23 (0.01) 1.28 
Moderate [5-6] 306 (12.9) 0.89 (0.17) 0.001* 0.30 (0.02) 1.66 
Severe [7-10] 319 (13.4)   0.058 0.32 (0.02) 1.77 
Race         
White 2051 (86.1) -0.90 (0.20)  0.25 (0.01)  
Black 284 (11.9) -0.40 (0.40) <0.001* 0.13 (0.02) 0.54 
Other 47 (2.0)   0.286 0.19 (0.05) 0.77 
History of Depression         
No 1718 (72.1) 0.74 (0.11)  0.20 (0.01)  
Yes 664 (27.9)   <0.001* 0.32 (0.02) 1.60 
Clinical status         
Disappearance 909 (38.2) 0.14 (0.25)  0.20 (0.01)  
Partial response 121 (5.1) 0.41 (0.13) 0.567 0.22 (0.03) 1.10 
Stable 1027 (43.1) 0.33 (0.17) 0.001* 0.26 (0.01) 1.31 
Progression 325 (13.6)   0.058 0.25 (0.02) 1.24 
Pain treatment         
None 1460 (61.3) 0.44 (0.15)  0.22 (0.01)  
Opioids 362 (15.2) 0.18 (0.14) 0.004* 0.28 (0.02) 1.32 
Non-opioids 437 (18.4) 0.29 (0.23) 0.167 0.24 (0.02) 1.12 
Combination 123 (5.2)   0.247 0.26 (0.03) 1.20 
Corticosteroid use         
No 1923 (80.7) 0.65 (0.13)  0.21 (0.01)  
Yes 459 (19.3)   <0.001* 0.32 (0.02) 1.50 
Promethazine use         
No 1990 (83.5) 0.62 (0.13)  0.22 (0.01)  
Yes 392 (16.5)   <0.001* 0.32 (0.02) 1.47 
Neurokinin-1 inhibitor use         
No 2287 (96.0) 0.93 (0.24)  0.23 (0.01)  
Yes 95 (4.0)   <0.001* 0.39 (0.05) 1.72 
Miscellaneous anxiolytic/antidepressant use       
No 2356 (98.9) 1.32 (0.43)  0.23 (0.01)  
Yes 26 (1.1) 0.37 (0.13) 0.003* 0.18 (0.01) 2.03 
Metoclopramide use         
No 2327 (97.7)    0.23 (0.01)  
Yes 55 (2.3) 1.03 (0.31) 0.001* 0.41 (0.06) 1.80 
Clinician rating: cancer treatment bothers patient      
Not at all 592 (24.9)    0.16 (0.02)  
A little bit 879 (36.9) 0.51 (0.17) 0.002* 0.23 (0.01) 1.43 
Moderately 631 (26.5) 0.80 (0.17) <0.001* 0.27 (0.02) 1.73 
Quite a bit 236 (9.9) 0.98 (0.21) <0.001* 0.30 (0.03) 1.92 
Extremely 44 (1.9) 0.93 (0.38) 0.014 0.29 (0.06) 1.87 
Likelihood ratio Χ2 (21)=388.52; p<0.001; adjusted pseudo (McFadden’s) R2=0.124; BIC’=-225.256 
a. For each factor level, relative risk is calculated relative to the reference level. 
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Table 3.11a Logistic regression model for correlates of hypnotic use in breast cancer 
a. Breast cancer (n=1212) N (%) 
Regression 
Coefficient (SE) 
 
p-value 
Predicted 
Probability (SE) 
Relative 
Riska 
Sleep Disturbance Severity         
None [0] 429 (35.4)    0.18 (0.02)  
Mild [1-4] 450 (37.1) 0.29 (0.19) 0.141 0.22 (0.02) 1.21 
Moderate [5-6] 155 (12.8) 0.93 (0.24) <0.001* 0.32 (0.03) 1.78 
Severe [7-10] 178 (14.7) 1.27 (0.23) <0.001* 0.38 (0.03) 2.13 
Race         
White 1064 (87.8)    0.26 (0.01)  
Black 126 (10.4) -1.09 (0.30) <0.001* 0.13 (0.03) 0.49 
Other 22 (1.8) -0.18 (0.57) 0.701 0.23 (0.08) 0.90 
History of Depression         
No 812 (67.0)    0.21 (0.01)  
Yes 400 (33.0) 0.62 (0.16) <0.001* 0.31 (0.02) 1.44 
Clinical status         
Disappearance 642 (69.8)    0.20 (0.02)  
Partial response 36 (2.97) 0.49 (0.41) 0.255 0.27 (0.06) 1.34 
Stable 418 (34.5) 0.54 (0.17) 0.001* 0.28 (0.02) 1.38 
Progression 116 (9.6) 0.65 (0.25) 0.015 0.30 (0.04) 1.48 
Promethazine use         
No 1042 (76.3)    0.23 (0.01)  
Yes 170 (23.7) 0.66 (0.21) 0.002* 0.34 (0.03) 1.48 
Neurokinin-1 inhibitor use         
No 1145 (94.5)    0.23 (0.01)  
Yes 67 (5.5) 1.21 (0.31) <0.001* 0.44 (0.06) 1.91 
5-HT3 antagonists         
No 1042 (76.3)    0.23 (0.01)  
Yes 170 (23.7) 0.71 (0.20) 0.001* 0.34 (0.03) 1.51 
Metoclopramide use         
No 1189 (98.1)    0.24 (0.01)  
Yes 23 (1.9) 1.55 (0.51) 0.002* 0.52 (0.10) 2.15 
Clinician: distress is a top HRQoL problem      
No 1065 (87.9)    0.23 (0.01)  
Yes 147 (12.1) 0.69 (0.21) 0.001* 0.34 (0.03) 1.48 
Clinician rating: cancer treatment bothers patient      
Not at all 363 (30.0)    0.17 (0.02)  
A little bit 438 (36.1) 0.60 (0.22) 0.008* 0.25 (0.02) 1.48 
Moderately 290 (23.9) 0.78 (0.23) 0.001* 0.27 (0.02) 1.65 
Quite a bit 99 (8.2) 1.22 (0.30) <0.001* 0.35 (0.04) 2.12 
Extremely 22 (1.8) 0.86 (0.56) 0.115 0.29 (0.09) 1.73 
Likelihood ratio Χ2(18)=254.23; p<0.001; adjusted pseudo (McFadden’s) R2=0.145; BIC’=-126.433 
HRQoL: Health-related quality of life 
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Table 3.11b Logistic regression model for correlates of hypnotic use in colorectal cancer 
b. Colorectal cancer (n=570) N (%) 
Regression 
Coefficient (SE) 
 
p-value 
Predicted 
Probability (SE) 
Relative 
Riska 
Psychological distress         
No 417 (73.2)    0.189 (0.02)  
Yes 153 (26.8) 0.74 (0.23) 0.001* 0.31 (0.04) 1.66 
Pain treatment         
None 378 (66.3)    0.18 (0.02)  
Opioids 79 (13.9) 0.96 (0.29) 0.001* 0.34 (0.05) 1.92 
Non-opioids 79 (13.9) 0.63 (0.30) 0.038 0.28 (0.05) 1.55 
Combination 34 (6.0) 0.55 (0.43) 0.199 0.26 (0.07) 1.48 
Corticosteroid use         
No 454 (80.0)    0.19 (0.02)  
Yes 116 (20.0) 0.96 (0.24) <0.001* 0.35 (0.04) 1.90 
Promethazine use         
No 435 (76.3)    0.19 (0.02)  
Yes 135 (21.7) 0.81 (0.23) 0.001* 0.32 (0.04) 1.74 
Likelihood ratio Χ2(6)=65.42; p<0.001; adjusted pseudo (McFadden’s) R2=0.072; BIC’=-27.347 
 
 
Table 3.11c Logistic regression model for correlates of hypnotic use in lung cancer 
c. Lung cancer (n=363) N (%) 
Regression 
Coefficient (SE) 
 
p-value 
Predicted 
Probability (SE) 
Relative 
Riska 
Race         
White 317 (87.3)    0.32 (0.03)  
Black 36 (9.9) -1.54 (0.57) 0.007* 0.11 (0.05) 0.33 
Other 10 (2.8) -0.60 (0.76) 0.435 0.22 (0.11) 0.68 
History of depression         
No 260 (73.8)    0.23 (0.03)  
Yes 95 (26.2) 1.21 (0.27) <0.001* 0.48 (0.05) 2.06 
Corticosteroid use         
No 266 (73.3)    0.23 (0.03)  
Yes 97 (26.7) 1.16 (0.26) <0.001* 0.47 (0.05) 2.00 
Likelihood ratio Χ2(6)=50.34; p<0.001; adjusted pseudo (McFadden’s) R2=0.078; BIC’=-26.795 
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Table 3.11d Logistic regression model for correlates of hypnotic use in prostate cancer 
d. Prostate cancer (n=237) N (%) 
Regression 
Coefficient (SE) 
 
p-value 
Predicted 
Probability (SE) 
Relative 
Riska 
Promethazine use         
No 218 (92.0)    0.10 (0.02)  
Yes 19 (8.0) 2.30 (0.60) <0.001* 0.45 (0.12) 4.71 
Clinician: how much is patient 
bothered by cancer 
       
Not at all 60 (25.3)    0.06 (0.03)  
A little bit 86 (36.3) 0.79 (0.72) 0.276 0.11 (0.03) 1.93 
Moderately 53 (22.4) 1.30 (0.73) 0.073 0.16 (0.05) 2.86 
Quite a bit 29 (12.2) 0.20 (0.92) 0.826 0.07 (0.04) 1.19 
Extremely 9 (3.8) 3.60 (0.97) <0.001* 0.62 (0.17) 10.84 
Likelihood ratio Χ2(5)=34.26; p<0.001; adjusted pseudo (McFadden’s) R2=0.104; BIC’=-6.924 
 
Correlates of hypnotic use 
Sleep disturbance severity 
Moderate sleep disturbance severity correlated with hypnotic use overall (p<0.001). 
This most likely represents the breast cancer group, however, which comprised half of the 
total sample and was the only subgroup in which sleep disturbance correlated with hypnotic 
use. Relative to participants with breast cancer reporting no sleep disturbance, hypnotic use 
was more likely for those with moderate (RR:1.78, p<0.001) or severe sleep disturbance 
(RR:2.13, p<0.001). 
 
Demographic characteristics 
Race correlated with hypnotic use overall and for breast and lung cancer. Overall, 
hypnotic use was 1.85 times more likely for whites than for black participants (RR for 
blacks: 0.54, p<0.001). In the breast cancer group, whites were twice as likely as blacks to 
use hypnotics (RR:0.49, p<0.001), and three times more likely in the lung cancer group 
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(RR:0.33, p<0.001). An ad hoc analysis found no association between race and whether 
clinicians identified sleep as a priority problem. 
History of depression increased the likelihood of hypnotic use overall (RR: 1.60, 
p<0.001), as well as for breast (RR:1.44, p<0.001) and lung cancer (RR:2.06, p<0.001). 
 
Clinical characteristics 
Psychological distress, assessed by clinicians, correlated with hypnotic use in 
colorectal cancer only (RR: 1.66, p=0.001). 
Clinical status was the only tested clinical variable correlated with hypnotic use 
overall. In the total sample, participants with stable disease were about 30% more likely to 
use hypnotics (RR: 1.31, p<0.001) than those in remission (disappearance). This likely 
reflects the group with breast cancer, in which stable disease similarly correlated with 
hypnotic use (RR: 1.38, p<0.001). 
 
Treatment characteristics 
No associations were found with clinician type, support group, counseling, any 
cancer-specific therapies (chemotherapy, radiotherapy, immunotherapy, hormone 
therapy), treatment stage, or prior number of regimens.   
 
Supportive medications  
Opioid analgesic use correlated with a 30% increase in hypnotic use, relative to no 
pain medication use, in the overall sample (RR: 1.32, p=0.004). For participants with 
colorectal cancer, opioid use nearly doubled the likelihood of hypnotic use (RR: 1.92, 
p=0.001).  
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Among the other evaluated symptom control medications with known effects on 
sleep, we found the following: 
• Corticosteroids, used widely in oncology for antiemesis and immunosuppression, 
among other purposes, have excitatory central nervous system effects that can 
disrupt sleep.105 Corticosteroid users were 50% more likely to use hypnotics overall 
(RR: 1.5, p<0.001), and twice as likely in the colorectal (RR: 1.9, p<0.001) and 
lung cancer (RR:2.0, p<0.001) groups. Despite increased hypnotic use by lung 
cancer participants using corticosteroids, post hoc analysis revealed this to be the 
only group in which corticosteroid use correlated with sleep disturbance 
(Χ2(3)=14.46; p=0.002). 
• Promethazine, a strongly sedating antiemetic/antihistamine, appeared in nearly 
every model. Likelihood of hypnotic use for promethazine users was 50% higher 
overall (RR: 1.47, p<0.001) and for breast cancer (RR:1.48, p=0.002). Larger 
increases were seen in colorectal (RR: 1.74, p<=.001), and prostate cancer (RR: 
4.71, p<0.001).  
• 5-HT3 antagonists are antiemetics that may have beneficial effects on rapid eye 
movement (REM) sleep.259 They correlated with hypnotic use in breast cancer only 
(RR: 1.51, p=0.001). 
• Neurokinin-1 inhibitors are antiemetics that may improve improve sleep 
maintenance and prolong REM sleep with minimal sedation.260 They correlated 
with hypnotic use overall (RR: 1.72, p<0.001), and for breast cancer (RR: 1.91, 
p<0.001), but were not evaluated in any other group due to small cell sizes. 
• Metoclopramide, an antiemetic that can cause drowsiness,261 correlated with 
hypnotic use overall (RR: 1.80, p=0.001), and for breast cancer (RR: 2.15, 
p=0.002), but was not evaluated in any other group due to small cell sizes. 
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• Miscellaneous anxiolytics / antidepressants were undefined, but those not 
otherwise explicitly listed in the SOAPP survey include hydroxyzine, buspirone, 
mirtazapine, trazodone, quietiapine, and olanzapine, all of which are sedating. 
Hypnotic use increased overall (RR: 2.03, p=0.003); cancer-specific groups were 
not evaluated due to small cell sizes. 
 
Clinician ratings 
Top health-related quality of life problems. From more than 20 symptom and 
health-related quality of life (HRQoL) items, clinicians were asked to identify the top three 
that most affected their patients’ HRQoL. We evaluated the top two items, as the third was 
missing for most patients. The five most frequently identified problems were fatigue 
(42%), pain (29%), sleep (11%), distress (11%), and neuropathy (11%).  
• Sleep. Notably, hypnotic use was not higher among participants for whom 
clinicians identified sleep as a top HRQoL issue. This raises the question of whether 
sleep disturbance is untreated due to lack of recognition. To explore this, we 
conducted a post-hoc chi-squared test and found agreement (significant 
association) between patients reporting sleep disturbance and clinicians identifying 
sleep as a priority problem (Χ2(3)=98.09; p<0.001). This finding suggests that 
clinicians successfully recognized their patients sleep concerns, but did not 
prescribe a hypnotic for other reasons. 
• Distress was the only top-ranked HRQoL problem correlated with hypnotic use, 
and only for participants with breast cancer (RR: 1.48, p=0.001). Post-hoc chi-
squared analysis found agreement between patients reporting distress and clinicians 
identifying distress as a priority problem (Χ2(10)=32.19; p<0.001), and identifying 
psychological distress in the clinical assessment (Χ2(10)=133.03; p<0.001). 
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Patient’s level of bother. Clinicians also rated the extent to which their patients 
were bothered by difficulties related to: cancer, cancer treatments, comorbidities, side 
effects from symptom care medications, and weight gain/loss. Ratings were scaled from 
0=’not at all’ to 5=’extremely’. Only two of these items correlated with hypnotic use: 
cancer and cancer treatment.  
• Cancer treatment. Overall, probability of hypnotic use was higher for those rated 
to be bothered ‘a little bit’ (RR: 1.43, p=0.002), ‘moderately’ (RR: 1.73, p<0.001), 
or ‘quite a bit’ (RR: 1.92, p<0.001). The pattern was similar for breast cancer 
participants; ‘a little bit’ (RR: 1.48, p=0.008), ‘moderately’ (RR: 1.65, p=0.001), or 
‘quite a bit’ (RR: 2.12, p<0.001). 
• Cancer. In the prostate cancer group, those rated to be ‘extremely’ bothered by 
cancer were 10 times more likely to use hypnotics (RR: 10.84, p<0.001), but this 
result must be interpreted cautiously in light of the small cell size (n=9). 
 
Discussion 
To our knowledge, this is the first large US study of hypnotic use in a diverse 
sample of ambulatory cancer patients since benzodiazepine receptor agonists (BzRAs) 
became the standard of care, about a decade ago.  
 
Prevalence of hypnotic use 
The hypnotics we studied were benzodiazepines (BZDs) and benzodiazepine 
receptor agonists (BzRAs). Although their mechanism of action is the same, BZDs have 
more widespread effects throughout the central nervous system, and therefore more uses, 
but also more side effects than BzRAs.262 In our sample of 2,382 participants, 24% used a 
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BZD or BzRA hypnotic; this is considerably higher than the general population estimate 
of 1.6%,145 but well below the prevalence of sleep disturbance (62.8%). More importantly, 
BZD use outpaced BzRA use. In national estimates, BzRAs are preferred over BZDs by 
more than two to one.145 In our sample, the ratio was inverted. Reliance on short-acting 
BZDs may be attributable, in part, to their role in treating anxiety and reducing anticipatory 
nausea and vomiting.263 Use of a longer-acting BZD is a concern, however, in persons with 
cancer, not only because of the additional side-effects, but also because next-day residual 
effects can exacerbate fatigue and cognitive difficulties.126  
 
Correlates of hypnotic use 
The proportion of variance explained by our models was small (7-15%), but we did 
find some noteworthy relationships that warrant further investigation. 
Sleep disturbance. A key finding in our study was the inconsistency with which 
sleep disturbance, as perceived by clinicians as well as by patients, correlated with hypnotic 
use. Our findings raise two issues. First, a significant correlation between sleep disturbance 
severity and hypnotic use, as seen in participants with breast cancer, may indicate treatment 
failure. Effective therapy should correlate with reduced symptom severity. A possible 
explanation is nonadherence with prescribed hypnotics, but we expect this would be less 
likely as symptom severity increases. Nonetheless, the effects of hypnotics in persons with 
cancer are not well studied. More research is needed to confirm their usefulness in this 
population and identify optimal regimens. The second issue is the high prevalence of sleep 
disturbance and relatively lower rate of hypnotic use, suggesting patients may be 
undertreated. Especially troubling was our finding that, even though clinicians often 
correctly identified when sleep was a priority problem for their patients, this was 
uncorrelated with hypnotic use. Clinicians tend to underestimate symptom severity, or 
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altogether miss symptoms that are mild or subjective in nature,264 which may explain this 
finding. Also, other drug classes (e.g., antidepressants, antipsychotics) not classified as 
hypnotics in this study may have been prescribed as sleep aids. We also note that 
prescriptions for hypnotics may more likely come from primary care physicians.265 The 
American Society of Clinical Oncology (ASCO) recommends, however, that symptom 
management be integral to all stages of oncology care.266 Little is known about prescriber 
knowledge of and attitudes toward hypnotic use in oncology, but general practitioners 
surveyed in the United Kingdom mostly endorsed negative attitudes toward BZD/BzRA 
hypnotics,267 In the US, 90% of general practitioners surveyed in Ohio (n=580) rated their 
knowledge of sleep disorders as fair to poor,268 and a 2005 survey found that sleep medicine 
comprised less than 2% of the content of medical textbooks. If practitioner beliefs and 
knowledge are barriers to treatment of sleep disturbance in oncology, then efforts should 
be made to improve awareness, but more research is needed to make this determination. 
Racial disparity. Another important finding was racial disparity in hypnotic use. 
Sleep disturbance severity did not differ on the basis of race, nor did clinician ranking of 
sleep as a priority, yet white participants were about twice as likely to use hypnotics as 
blacks, overall and in the breast cancer group, and three times more likely in the lung cancer 
group. This finding is consistent with some limited research on hypnotic use,269,270 and 
parallels well-documented disparities in pain treatment.271-273 Troublingly, a review of pain 
management in emergency departments found that disparity was most frequent for pain 
that could not be objectively confirmed  (e.g., headache, back pain, abdominal pain).274 
Given the subjective nature of sleep disturbance,  a similar discounting of patient reports 
by clinicians may contribute to hypnotic use disparity. Conversely, prescribing of 
hypnotics may be influenced by patient requests, as observed among practitioners in 
German nursing homes.275 Several studies have found that blacks are less likely than whites 
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to believe that psychotropic medications (e.g., antidepressants, anxiolytics) are beneficial, 
more likely to have concerns about risks (e.g. addiction, impairment), and less likely to 
request or adhere to prescriptions.276-279 Notably, however, in a sample of patients already 
experienced with psychotropic treatments, no such difference in beliefs was found.280 There 
is evidence that lack of healthcare knowledge contributes to delayed help-seeking for 
cancer alarm symptoms (e.g., pain, palpable masses), leading to delays in cancer diagnosis 
for black patients.281,282 If the same applies to help-seeking for symptom management, then 
interventions that build patients’ awareness of the availability and efficacy of treatments 
may help to improve treatment equality. Racial disparity in hypnotic use is doubtless as 
multifaceted an issue as disparity in pain management, but is less well-studied. Much more 
research is needed to identify contributing factors and develop successful interventions for 
eliminating inequalities in the treatment of sleep disturbance.   
Corticosteroid use. Sleep disruption is a common side effect of corticosteroids, so 
concurrent use of hypnotics is expected. Findings in lung cancer participants, however, 
may point to greater unmet needs. Only for lung cancer participants was corticosteroid use 
associated with sleep disturbance, even though corticosteroid users in that group were twice 
as likely to use hypnotics. Due to inappropriate hormone production by tumors, a small 
proportion (<5%) of lung cancer patients develop hypercortisolism (Cushing’s) syndrome, 
and as many as 50% may experience subclinical cortisol elevation.283 Sleep disruptions are 
known to occur in Cushing’s disease,284,285 and likely occur, albeit to a lesser extent, even 
with smaller cortisol elevations. This might help to explain our findings and would suggest 
that extra measures may be needed to address sleep disturbance in patients with lung 
cancer. 
Polypharmacy. Excluding corticosteroids, all other medications we evaluated are 
sedating to various degrees. These drugs are primarily indicated for pain, anxiety, 
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depression, and nausea/vomiting, all of which can disrupt sleep, so it is unsurprising that 
their use also correlates with hypnotic use. There is concern, however, that polypharmacy 
with sedating drugs could increase fall risk, already heightened in this population.286  
Notably, promethazine – so sedating it can be used alone as a sleep aid287 – correlated with 
BZD/BzRA hypnotic use in every model except lung cancer. Polypharmacy also increases 
the risk of drug interactions. Because of substantial medication burden, the risk of drug 
interactions is high in oncology.288,289 Even among patients receiving supportive care only, 
one study found potential interactions in nearly one-third (31%) of cases.290 Of particular 
concern are opioids, which correlated with a nearly two-fold increase in hypnotic use for 
participants with colorectal cancer. Although opioid analgesics can improve sleep 
maintenance for patients awakened by overnight pain,291,292 they may disrupt sleep 
architecture.293,294 More importantly, BZD use in conjunction with opioids can exacerbate 
opioid-induced respiratory depression, increasing the risk of fatal overdose.295 Management 
of complex symptom burdens along with complex antineoplastic regimens can be 
improved by engaging oncology pharmacists to assess and optimize regimens.289,296,297 A 
better base of evidence is also needed, however, including prospective trials to identify the 
safest, most cost-effective therapies.   
Clinicians. Although there was no relationship between clinician-identified sleep 
disturbance and participant hypnotic use, clinician-identified distress was correlated. 
Participants with breast cancer were more likely to use hypnotics if their clinicians 
identified distress as a priority problem or indicated that their patient was bothered by 
difficulties related to cancer treatment. A remarkable 10-fold increase was correlated with 
for participants with prostate cancer deemed ‘extremely’ bothered by cancer itself, but this 
result may be spurious, given the small, uneven sample size. Post hoc analyses indicated 
agreement between clinicians’ assessments and patient-reported distress, but this was also 
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true of sleep disturbance (yet clinician-identified sleep disturbance was uncorrelated with 
hypnotic use). The past decade has seen increased awareness of and emphasis on the 
psychosocial needs of persons with cancer.298-301 The International Psycho-Oncology 
Society (IPOS) recently identified distress as the 6th Vital Sign,302 and efforts have been 
made to identify optimal screening tools.300 Clinicians have expressed reservations about 
incorporating such screening into practice, however, because of limited ability to provide 
(or refer patients to) treatment.303 Distress management guidelines developed by the 
National Comprehensive Cancer Network (NCCN) may help to address those concerns,241 
and, consistent with growing evidence relating distress and disrupted sleep,236-240 the 
guidelines include sleep disturbance as both a symptom and risk factor.241 Notwithstanding 
the relationship with distress, sleep disturbance can have many other causes and 
manifestations, the NCCN offers no guidelines for managing sleep disturbance beyond a 
few recommendations in the distress management guidelines. This may explain why 
clinicians were more likely to prescribe sleep aids to recognizably distressed patients; in 
absence of sleep-specific guidance, clinicians may be inclined to address sleep disturbance 
under the rubric of distress, if at all. As more evidence becomes available, efforts should 
be made to develop oncology-specific guidelines for managing sleep disturbance and to 
educate oncology clinicians. 
  
Strengths and limitations 
This study benefitted from a large sample and many measured variables, which 
permitted assessment not only across the entire sample, but also between cancer-specific 
groups, using consistent measurement and analytic methods. Cancer-specific groups were 
not well matched in size and for some characteristics, however, and generalizability of our 
results may be limited to ambulatory cancer patients treated by an oncology group in the 
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Eastern United States. A major limitation was the imprecise identification and 
classification of drugs, thus our analyses were limited to BZD/BzRA hypnotics and we 
were unable to evaluate or control for use of other classes of drugs as sleep aids. We were 
also unable to determine whether medications prescribed were actually taken. As a 
secondary analysis of survey data, this study is subject to selection and recall bias. With 
these limitations, and the fact that models accounted for only small proportions of variance 
(≤ 15%), it is difficult to draw firm conclusions, but our findings raise important questions 
and can serve as a starting point to building a much needed base of evidence. 
 
Conclusions 
We aimed to identify, from a large set of variables, correlates of BZD/BzRA 
hypnotic use in persons with solid tumors. While the prevalence of hypnotic use, especially 
BZDs, was high relative to the general population, it was low relative to the prevalence of 
sleep disturbance in the sample. There is little evidence documenting the effects of these 
drugs in persons with cancer, and, therefore, little guidance for their use. Prospective trials 
are needed to assess the safety and efficacy of hypnotics in this population. Several sedating 
medications correlated with concomitant hypnotic use, putting this population at increased 
risk of drug interactions, including fatal respiratory depression with opioid analgesia. 
Pharmacists can make important contributions to the palliative care team by optimizing 
medication regimens. Prescribing patterns for hypnotics raised several concerns that should 
be further investigated, including undertreatment, racial bias, patient help-seeking 
behavior, polypharmacy, prescribers’ attitudes, and disagreement between patient reports 
and clinician assessments. We suggest that studies evaluating prescribing behaviors along 
with clinician assessments of the patient experience may prove enlightening. 
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3.3 SECTION III: MANUSCRIPT 3 
Change in cancer-symptom burden and health-related quality of life associated with 
sleep disturbance and hypnotic use in solid tumor cancers. 
Introduction 
At least half of all people with cancer experience sleep disturbance, and about 25% 
report the problem as moderate to severe.80,81,93 The frequently observed clustering of sleep 
disturbance with other cancer symptoms such as pain, depression, and fatigue,118,120,304 
suggests underlying pathophysiology that is shared, to some extent.235 Correspondingly, 
there is evidence of bidirectional relationships; that is, while sleep disturbance can 
exacerbate other cancer symptoms, such as pain and fatigue, these symptoms can also 
disrupt sleep. Improved understanding of relationships among cancer symptoms can help 
clinicians to streamline therapies; targeting a common etiology would require fewer 
interventions to manage symptom burden than would treating each symptom individually. 
Relationships of pain, depression, and fatigue with sleep disturbance are well 
documented in the literature, but these are also symptoms that are commonly evaluated.169 
With mounting evidence for the role of sleep in homeostatic systems (e.g., metabolism,59,60 
immune function44-47), it is reasonable to expect that relationships exist between sleep and 
other cancer symptoms that are less frequently measured (e.g., cognitive function, appetite 
loss).169 If this is the case, then therapies that improve sleep may prove to be integral in 
managing the total symptom burden of cancer. 
Unsurprisingly, hypnotic use is common in the oncology setting, with estimates 
ranging from 20% to 37%.140-142,258 Hypnotics are not well studied in persons with cancer,159 
however, and guidelines for treatment of cancer-related insomnia are substantially limited 
by lack of evidence.156,157 It should not be assumed that accepted treatments for insomnia 
in the general population are appropriate for people with cancer. The oncology setting 
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presents additional sources of sleep disruption as well as increased potential for drug-drug 
and drug-disease interactions, which can result in overall worsened outcomes. For 
example, benzodiazepine receptor agonists (BzRAs), which are considered first-line 
therapy for insomnia, could worsen cancer-related fatigue by producing next-morning 
drowsiness, motor incoordination, and cognitive difficulties.9,10 
This study seeks to address research gaps pertaining to sleep disturbance and its 
treatment in people with cancer, with two primary aims: 1. To evaluate differences in 
symptom burden and health-related quality of life between hypnotic users and non-users. 
2. To evaluate how changes in sleep disturbance severity relate to changes in other cancer 
symptoms and to health-related quality of life.  
  
Methods 
Data collection 
From March 3, 2006 to May 19, 2008 the Eastern Cooperative Oncology Group 
(ECOG) conducted the Symptom Outcomes and Practice Patterns (SOAPP, also known as 
E2Z02) study in about 40 clinics and academic centers located primarily in the Eastern 
United States. Participants rated the severity of nineteen symptoms at the first visit, and at 
a second visit approximately 28 days later.171 This study is a secondary analysis of the 
SOAPP data, and the support of the ECOG-ACRIN* Cancer Research Group and SOAPP 
Study Steering Committee in accessing these data is acknowledged. The results and 
conclusions in this paper are those of the authors and do not indicate concurrence by 
ECOG-ACRIN or the SOAPP Study Steering Committee.  
 
                                                
* A merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology 
Imaging Network (ACRIN) 
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Participants 
Outpatients at least 18 years of age at any stage of care for invasive breast, lung, 
prostate, or colorectal cancer were eligible to participate; respondents with inadequate 
cognitive function (assessed by a study screener) were excluded.171 Our analyses included 
participants whose hypnotic use was the same at both visits (i.e., ‘yes’ at both visits for the 
same hypnotic, or ‘no’ at both visits).  
 
Study variables 
At intake and approximately four weeks later, participants were asked to score their 
symptom severity at its worst in the past 24 hours on a scale from 0=’not present’ to 10=’as 
bad as you can imagine’. Nineteen symptoms were evaluated: hair loss, appetite loss, 
memory loss, constipation, cough, feeling depressed, diarrhea, feeling distressed (upset), 
drowsiness, dyspnea, fatigue, nausea, nerve pain, pain, itching, disturbed sleep, sore mouth, 
vomiting, and dry mouth.224 The survey was an expansion of the 13-item MD Anderson 
Symptom Inventory (MDASI), which also included six health-related quality of life 
(HRQoL) measures: general activity, mood, work relations with other people, walking, and 
enjoyment of life. Participants were asked to indicate the extent to which symptoms 
interfered with each HRQoL item on a scale from 0=’Did not interfere’ to 10=’interfered 
completely’. A systematic review of HRQoL studies found that the detection threshold for 
meaningful change was, in many cases, one-half standard deviation.176 In MDASI 
validation studies, standard deviations for symptoms ranged from 1.95 to 2.31; the authors 
therefore suggest a 1-point change may be minimally important (i.e., clinically 
significant).175 Recognizing that an ideal method for determining clinical significance has 
yet to be established, and that results may vary across subpopulations even when methods 
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are consistent,177,225 the present study nonetheless assumes a 1-point change in symptom 
severity to be clinically meaningful. 
Demographic information was collected from participants at intake, and clinicians 
provided clinical data and medication lists at intake and follow-up. 
 
Statistical methods 
Software 
Statistical analyses were conducted using the following software: Stata (StataCorp. 
2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP.) and the 
Stata module PSMATCH2 (version 4.0.11, 2014).184, SAS (SAS Institute. 2015. The SAS 
system for Windows. Release 9.4. SAS Institute, Cary, NC.), and IVEware (University of 
Michigan. 2002. IVEware: Imputation and Variance Estimation Software). 
 
Missing data imputation  
The percentage of missing values was low (<4%) for most independent variables, 
except ethnicity (7.18%). With a large number of variables, however, listwise deletion 
would reduce the sample by about 25%. Using SAS software and a callable routine built 
with IVEWare, values were multiply imputed (m=5) through sequential multiple 
regression by chained equations to accommodate heterogeneity of variable type and 
distribution.201-203 Comparison of imputed datasets by analysis of variance (ANOVA) 
revealed no differences for any variables of interest. Analyses were, therefore, performed 
on a singly-imputed dataset, to facilitate use of advanced analytic procedures. 
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Matching cases and comparators 
Participants not using hypnotics were matched to hypnotic users on the basis of 
Mahalanobis distance within calipers of 0.2 standard deviations of a propensity score.209 
Propensity scores, representing the probability of being in the treatment group were 
estimated with a probit model of baseline characteristics thought to predict treatment.210 
The variables used for matching were: age, sex, race, ethnicity, primary cancer site, history 
of depression, and sleep disturbance severity score at intake. The Mahalanobis metric is a 
multidimensional measure of distance between two observations.211 Each estimate can be 
used alone to select matches, but use of both, first identifying candidates whose propensity 
scores are within calipers, then selecting from those based on minimal Mahalanobis 
distance, appears to provide more balanced samples than either method alone.209 Average 
outcomes in the hypnotics group were estimated based on the average of differences across 
matched cases, and conditional variance was estimated using fifty neighbors (~12.5% of 
the group size) to produce heteroscedasticity-consistent standard errors.212 Comparator 
cases were weighted based on the frequency with which they were used as controls. 
Matching was conducted to reduce the effects of selection bias (where covariates can have 
confounding effects on outcomes),210 and to reduce Type-I error risk from 
heteroscedasticity (exacerbated by unequal group sizes).213 
 
Statistical tests 
The main hypotheses of interest were 1.) to compare changes in symptom severity 
and HRQoL between hypnotic users and non-users, and 2.) to assess the relationship 
between changes in sleep disturbance and changes in other symptoms and HRQoL. 
Hotelling’s T2 test (an omnibus version of the paired t-test214), with degrees of freedom 
corrected for heteroscedasticity,215 was used to compare changes in symptom severity and 
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HRQoL between hypnotic users and non-users. Following a statistically significant 
multivariate result, post-hoc two-sided t-tests (with Welch’s approximation of degrees of 
freedom for unequal variance) were performed to evaluate individual symptoms. 
Multivariate regressions were conducted to evaluate how sleep disturbance severity change 
related to changes in other cancer symptoms and HRQoL, controlling for hypnotic use. 
Significance level was set to p < 0.01 for all analyses. 
 
Results 
Sample characteristics 
A total of 2,217 participants met the inclusion criteria; of these, 456 used hypnotics 
and 1,761 were non-users. The matching procedure identified 411 cases of hypnotic use 
that were matched to 1,241 weighted comparators, for a total weighted sample size of 822. 
The distribution of propensity scores across the two groups was similar, and two additional 
metrics for covariate balance are presented in Table 3.12: a.) standardized difference in 
percent of bias, and b.) two-sided t-tests for equality of means in the two samples. 
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Table 3.12 Covariate balance, before and after matching, between the treatment 
(Hypnotic Use) and weighted comparator (No Hypnotic Use) groups 
  Mean  % 
Reduction 
|bias| 
t-testb 
Variable Unmatched(U) Matched (M) Treated Control 
% 
Biasa t p>|t| 
Age Group        
 U 1.90 2.21 -26.4   -4.99 0.000 
 M 1.93 1.93 0.0 100.0 0.00 1.000 
Ethnicity        
 U 0.96 0.92 16.5  2.89 0.004 
 M 0.98 0.98 0.0 100.0 0.00 1.000 
Race        
 U 0.10 0.18 -20.0  -3.58 0.000 
 M 0.07 0.07 0.0 100.0 0.00 1.000 
Sex        
 U 0.77 0.69 18.8  3.48 0.001 
 M 0.79 0.79 0.0 100.0 0.00 1.000 
History of depression       
 U 0.43 0.23 42.6  8.52 0.000 
 M 0.40 0.40 0.0 100.0 0.00 1.000 
Primary cancer site       
 U 0.91 0.89 1.4  0.27 0.790 
 M 0.82 0.82 0.0 100.0 0.00 1.000 
Sleep disturbance severity at intake      
 U 1.35 0.90 43.6  8.53 0.000 
 M 1.30 1.30 0.0 100.0 0.00 1.000 
a. Standardized difference in percent bias is the percent difference in group means divided by the square 
root of the average variance.  
b. Two sided t-test for equality of means in treatment versus comparator group. 
 
 
Initial symptom severity scores are shown in Table 3.13. Disturbed sleep was the 
second most severely scored symptom with a mean (± standard deviation) score of 3.39 
(±3.08).  It should be noted that this measure was used for statistical matching, thus both 
groups share the same mean. Severity of four symptoms (hair loss, pain, diarrhea, and 
mouth sores) differed between groups, with the more severe scores always occurring in the 
hypnotic-user group. 
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Table 3.13 Initial symptom severity scores for the total sample, treatment group 
(Hypnotic Use), and weighted comparator group (No Hypnotic Use), 
ordered by decreasing severity for total sample. 
 Total Sample No Hypnotic Use Hypnotic Use   
Symptom  Mean (SD) Mean (SD) Mean (SD) t-test p 
Fatigue 4.07 (2.88) 3.84 (2.82) 4.29 (2.93) 2.23 0.026 
Disturbed sleep 3.39 (3.08) 3.39 (3.02) 3.39 (3.15) -0.01 0.992 
Drowsiness 3.09 (2.79) 3.05 (2.74) 3.12 (2.84) 0.40 0.689 
Hair loss 2.53 (3.59) 2.13 (3.38) 2.93 (3.79) 3.21 0.001* 
Feeling distressed 2.50 (2.71) 2.33 (2.52) 2.67 (2.89) 1.79 0.074 
Memory loss 2.49 (2.58) 2.47 (2.54) 2.50 (2.62) 0.12 0.903 
Dry mouth 2.48 (3.04) 2.36 (3.15) 2.60 (2.92) 1.14 0.256 
Feeling depressed 2.27 (2.66) 2.04 (2.42) 2.51 (2.89) 2.50 0.013 
Numbness/tingling 2.27 (2.83) 2.17 (2.68) 2.37 (2.98) 1.02 0.307 
Pain 2.09 (2.67) 1.81 (2.46) 2.38 (2.87) 3.10 0.002* 
Shortness of breath 1.86 (2.55) 1.77 (2.51) 1.96 (2.60) 1.07 0.287 
Constipation 1.77 (2.73) 1.58 (2.56) 1.97 (2.89) 2.02 0.044 
Appetite loss 1.75 (2.63) 1.58 (2.44) 1.91 (2.80) 1.85 0.065 
Cough 1.42 (2.30) 1.45 (2.29) 1.39 (2.31) -0.38 0.704 
Diarrhea 1.30 (2.43) 0.94 (2.19) 1.67 (2.66) 4.29 <0.001* 
Nausea 1.06 (2.14) 0.94 (1.95) 1.18 (2.32) 1.60 0.111 
Itching 0.89 (2.15) 0.85 (2.18) 0.94 (2.13) 0.57 0.571 
Mouth sores 0.75 (1.80) 0.55 (1.48) 0.94 (2.07) 3.10 0.002* 
Vomiting 0.39 (1.46) 0.34 (1.27) 0.45 (1.62) 1.15 0.251 
SD: standard deviation 
 
 
Initial scores for symptom burden interference with HRQoL are shown in Table 
3.14. Severity of three HRQoL measures (work, activity, and mood) differed between 
groups, with the more severe scores always occurring in the hypnotic-user group. 
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Table 3.14 Initial scores for symptom burden interference with health-related quality of 
life (HRQoL) for the total sample, treatment group (Hypnotic Use), and 
weighted comparator group (No Hypnotic Use), ordered by decreasing 
severity for total sample. 
 Total Sample No Hypnotic Use Hypnotic Use   
HRQoL Measure  Mean (SD) Mean (SD) Mean (SD) t-test p 
Work 3.08 (3.04) 2.73 (2.81) 3.42 (3.25) 3.26 0.001* 
Activity 2.92 (2.88) 2.60 (2.66) 3.24 (3.09) 3.18 0.002* 
Walking 2.71 (3.05) 2.46 (2.82) 2.95 (3.26) 2.30 0.021 
Enjoyment of life 2.61 (2.94) 2.39 (2.82) 2.82 (3.06) 2.09 0.036 
Mood 2.45 (2.71) 2.16 (2.57) 2.73 (2.84) 3.02 0.003* 
Relationships 1.70 (2.54) 1.62 (2.52) 1.78 (2.56) 0.90 0.367 
SD: standard deviation 
 
 
MANOVA: Hypnotic use and changes in symptom severity and HRQoL  
The test for differences across mean changes in symptom severity between hypnotic 
users and non-users was significant (F(19,720.8) =16.51, p<0.001). Results of post hoc 
individual t-tests are shown in Table 3.15. Changes in severity were different for all 
symptoms except: cough, hair loss, mouth sores, and vomiting. Hypnotic users reported 
decreased severity for all remaining symptoms except one: diarrhea. The symptom with 
the largest between-group mean [standard error] difference was numbness/tingling (1.29 
[0.13]), followed by sleep (1.02 [0.16]). No differences in HRQoL measures were found 
on the basis of hypnotic use (F(6,590.5) =0.68, p=0.6682).
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Table 3.15 Individual Welch’s two-sided t-tests to detect differences in symptom severity change on the basis of hypnotic 
(benzodiazepine/benzodiazepine receptor agonist) use. 
 Overall 
N=1652 
No Hypnotic Use 
N=411 
Hypnotic Use 
N=411 Mean    
 
Symptom Mean (SD) Mean (SD) Mean (SD) Difference (SE) t df p 
Numbness/tingling 0.91 (2.82) 1.24 (2.96) -0.06 (2.08) 1.29 (0.13) 9.76 999 <0.001* 
Disturbed sleep 0.07 (2.51) 0.32 (2.30) -0.70 (2.95) 1.02 (0.16) 6.42 585 <0.001* 
Feeling distressed 0.25 (2.30) 0.48 (2.23) -0.45 (2.37) 0.92 (0.13) 6.96 668 <0.001* 
Fatigue  0.06 (2.34) 0.27 (2.29) -0.57 (2.40) 0.84 (0.13) 6.21 676 <0.001* 
Appetite loss 0.57 (2.20) 0.75 (2.22) 0.04 (2.05) 0.70 (0.12) 5.92 755 <0.001* 
Nausea 0.20 (1.97) 0.37 (1.94) -0.30 (1.97) 0.67 (0.11) 5.97 693 <0.001* 
Constipation 0.35 (2.52) 0.51 (2.63) -0.13 (2.10) 0.64 (0.13) 5.05 872 <0.001* 
Itching 0.20 (1.82) 0.35 (1.68) -0.26 (2.13) 0.61 (0.12) 5.33 590 <0.001* 
Drowsiness 0.02 (2.33) 0.16 (2.31) -0.38 (2.35) 0.54 (0.13) 4.02 692 <0.001* 
Shortness of breath 0.21 (1.71) 0.32 (1.67) -0.15 (1.76) 0.48 (0.10) 4.81 674 <0.001* 
Feeling depressed 0.11 (2.09) 0.22 (2.07) -0.21 (2.10) 0.43 (0.12) 3.58 693 <0.001* 
Memory loss 0.01 (2.19) 0.11 (2.19) -0.30 (2.16) 0.41 (0.12) 3.35 711 <0.001* 
Dry mouth 0.21 (2.15) 0.30 (2.06) -0.06 (2.37) 0.35 (0.13) 2.70 629 0.007* 
Pain 0.24 (2.04) 0.31 (2.05) 0.00 (2.00) 0.30 (0.11) 2.69 720 0.007* 
Diarrhea -0.24 (2.09) -0.37 (2.19) 0.14 (1.68) -0.51 (0.10) -4.93 911 <0.001* 
Hair loss -0.29 (3.27) -0.35 (3.39) -0.11 (2.86) -0.24 (0.17) -1.41 823 0.158 
Mouth sores 0.09 (1.57) 0.07 (1.51) 0.17 (1.74) -0.10 (0.10) -1.03 627 0.305 
Cough -0.24 (1.60) -0.25 (1.60) -0.21 (1.60) -0.03 (0.09) -0.37 699 0.709 
Vomiting 0.02 (1.24) 0.03 (1.24) 0.00 (1.23) 0.02 (0.07) 0.33 711 0.739 
SD: standard deviation; SE: standard error 
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Multivariate regression: symptom burden onto hypnotic use and sleep disturbance 
severity change 
Table 3.16 provides results for the multivariate regression of changes in cancer 
symptom severity onto both hypnotic use and change in sleep disturbance severity (SDS). 
Symptoms are listed in decreasing order of R2 for the overall model (i.e., both hypnotic use 
and SDS as independent variables). 
 
Sleep disturbance. For all symptoms, increased SDS was associated with increased 
severity. The strongest associations were with: feeling distressed, dry mouth, and 
fatigue. For those symptoms, hypnotic use and SDS change together accounted for 
25%, 20%, and 17%, respectively, of variance in symptom severity change. For 
these symptoms, the increases in severity corresponding with a 1-point increase in 
SDS were: (reported with regression coefficient [b] ± standard error): 
• 0.46-point increase in feeling distressed (b: 0.46 ±0.02, p<0.001) 
• 0.38-point increase in dry mouth (b: 0.38 ±0.02, p<0.001), and  
• 0.37-point increase in fatigue (b: 0.37 ±0.02, p<0.001).  
The weakest associations (model R2 = 0.05) were observed with numbness/tingling 
(b: 0.26 ±0.03, p<0.001) and pain (b: 0.18 ±0.02, p<0.001). Regardless of statistical 
significance, low R2 values (<0.05) for the following symptoms suggest little meaningful 
relationship with SDS: itching, hair loss, constipation, diarrhea, and mouth sores. 
 
Hypnotic use. Hypnotic use was associated with changes in only one symptom. Holding 
changes in SDS constant, use of hypnotics was associated with a 0.31 decrease in 
fatigue (b: -0.31 ±0.11, p=0.004). Together, hypnotic use and SDS change 
accounted for 17% of the change in fatigue severity. 
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Table 3.16 Multivariate regression evaluating changes in cancer symptom severity 
associated with change in sleep disturbance severity, controlling for 
benzodiazepine/benzodiazepine receptor agonist hypnotic use. 
 Symptom   Coefficient (SE) Model R2 t p 
Feeling distressed SDS increase 0.46 (0.02) 0.25 23.15 <0.001* 
 Hypnotic use -0.13 (0.10)  -1.26 0.207 
Dry mouth SDS increase 0.38 (0.02) 0.20 19.99 <0.001* 
 Hypnotic use 0.21 (0.10)  2.19 0.029 
Fatigue SDS increase 0.37 (0.02) 0.17 17.28 <0.001* 
 Hypnotic use -0.31 (0.11)  -2.92 0.004* 
Shortness of breath SDS increase 0.26 (0.02) 0.14 16.28 <0.001* 
 Hypnotic use 0.03 (0.08)  0.36 0.722 
Feeling depressed SDS increase 0.30 (0.02) 0.13 15.84 <0.001* 
 Hypnotic use 0.00 (0.10)  0.03 0.974 
Drowsiness SDS increase 0.30 (0.02) 0.11 13.84 <0.001* 
 Hypnotic use -0.17 (0.11)  -1.55 0.122 
Nausea SDS increase 0.24 (0.02) 0.10 12.99 <0.001* 
 Hypnotic use -0.13 (0.09)  -1.37 0.170 
Cough SDS increase 0.19 (0.02) 0.09 12.33 <0.001* 
 Hypnotic use -0.08 (0.08)  -1.05 0.296 
Memory loss SDS increase 0.22 (0.02) 0.07 10.75 <0.001* 
 Hypnotic use -0.15 (0.11)  -1.40 0.163 
Vomiting SDS increase 0.13 (0.01) 0.07 11.34 <0.001* 
 Hypnotic use 0.10 (0.06)  1.61 0.107 
Appetite loss SDS increase 0.23 (0.02) 0.06 10.61 <0.001* 
 Hypnotic use 0.20 (0.11)  1.85 0.065 
Numbness/tingling SDS increase 0.26 (0.03) 0.05 8.92 <0.001* 
 Hypnotic use 0.12 (0.14)  0.83 0.406 
Pain SDS increase 0.18 (0.02) 0.05 9.34 <0.001* 
 Hypnotic use 0.13 (0.10)  1.34 0.180 
Itching SDS increase 0.10 (0.02) 0.02 5.65 <0.001* 
 Hypnotic use -0.19 (0.09)  -2.13 0.033 
Constipation SDS increase 0.13 (0.02) 0.02 5.36 <0.001* 
 Hypnotic use -0.04 (0.13)  -0.30 0.762 
Diarrhea SDS increase 0.06 (0.02) 0.01 3.05 0.002* 
 Hypnotic use 0.19 (0.10)  1.80 0.072 
Mouth sores SDS increase 0.03 (0.02) 0.01 1.97 0.049 
 Hypnotic use 0.19 (0.08)  2.42 0.016 
Hair loss SDS increase -0.02 (0.03) 0.00 -0.67 0.503 
 Hypnotic use -0.12 (0.16)  -0.76 0.445 
SDS: sleep disturbance severity; SE: standard error 
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Multivariate regression: HRQoL onto hypnotic use and sleep disturbance severity change 
Table 3.17 provides results for the multivariate regression of HRQoL measures 
onto both hypnotic use and change in sleep disturbance severity (SDS). HRQoL items are 
listed in decreasing order of R2 for the overall model (i.e., hypnotic use and change in SDS 
as independent variables). 
 
Sleep disturbance. Increased SDS was associated with increased interference for all 
HRQoL measures, except work. None of the associations, however, were strong. 
The largest proportion of variance explained by SDS change and hypnotic use was 
6%, for mood (R2 = 0.06); a 1-point increase in SDS was associated with a 0.23-
point increase in overall symptom burden interference with mood (b: 0.23 ±0.02, 
p<0.001).  
 
Hypnotic use. Holding changes in SDS constant, hypnotic use was associated with a 0.4-
point increase in symptom burden interference with work:(b: 0.41 ±0.14, p=0.003). 
 
A second multivariate analysis was performed to control for changes in all other 
symptoms. The model R2 values shown in Table 3.18 reflects the entire set of independent 
variables (i.e., hypnotic use, change in SDS, and all other symptom changes as independent 
variables). Notably, inclusion of all symptoms in models increased the proportion of 
variance in HRQoL explained by about ten-fold for all items, except work. 
 
Sleep disturbance. After controlling for changes in other symptoms, only two HRQoL 
items (mood, enjoyment) were associated with SDS. Regression coefficients were 
vanishingly small, however, and negative, suggesting slightly improved HRQoL 
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with increased SDS. The largest proportion of variance explained by SDS change 
and hypnotic use was 6%, for mood (R2 = 0.06); a 1-point increase in SDS was 
associated with a 0.23-point increase in overall symptom burden interference with 
mood (b: 0.23 ±0.02, p<0.001).  
 
Hypnotic use. Virtually identical with the previous model, holding changes in all symptoms 
constant, hypnotic use was associated with a 0.4-point increase in overall symptom 
burden interference with work:(b: 0.41 ±0.14, p=0.003). 
 
 
Table 3.17 Multivariate regression evaluating changes in health-related quality of life 
associated with change in sleep disturbance severity, controlling for 
BZD/BzRA hypnotic use. 
 Symptom   Coefficient (SE) Model R2 t p 
Mood SDS increase 0.23 (0.02) 0.06 10.2 <0.001* 
  Hypnotic use -0.02 (0.11)  -0.2 0.845 
Activity SDS increase 0.24 (0.03) 0.04 7.98 <0.001* 
  Hypnotic use -0.08 (0.15)  -0.52 0.602 
Enjoyment SDS increase 0.20 (0.02) 0.04 7.98 <0.001* 
  Hypnotic use -0.20 (0.12)  -1.61 0.109 
Relationships SDS increase 0.18 (0.02) 0.04 7.93 <0.001* 
  Hypnotic use -0.04 (0.11)  -0.37 0.711 
Walking SDS increase 0.20 (0.03) 0.03 7.47 <0.001* 
  Hypnotic use 0.11 (0.13)  0.82 0.414 
Work SDS increase 0.06 (0.03) 0.01 2.29 0.022 
  Hypnotic use 0.41 (0.14)  2.99 0.003* 
BZD: benzodiazepine; BzRA: BZD receptor agonist; SDS: sleep disturbance severity; SE: standard error 
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Table 3.18 Multivariate regression evaluating changes in health-related quality of life 
associated with change in sleep disturbance severity, controlling for 
BZD/BzRA hypnotic use and for changes in all other symptoms. 
 Symptom   Coefficient (SE) Model R2 t p 
Mood SDS increase -0.07 0.03 0.46 -3.19 0.001* 
  Hypnotic use 0.06 0.09  0.71 0.480 
Activity SDS increase -0.07 0.03 0.54 -2.54 0.011 
  Hypnotic use -0.03 0.11  -0.26 0.798 
Enjoyment SDS increase -0.09 0.02 0.47 -3.65 <0.001* 
  Hypnotic use -0.19 0.10  -1.95 0.052 
Relationships SDS increase 0.04 0.03 0.35 1.60 0.110 
  Hypnotic use -0.12 0.10  -1.27 0.205 
Walking SDS increase -0.02 0.03 0.36 -0.68 0.495 
  Hypnotic use 0.18 0.11  1.63 0.103 
Work SDS increase 0.03 0.04 0.01 0.81 0.420 
  Hypnotic use 0.41 0.14  2.95 0.003* 
BZD: benzodiazepine; BzRA: BZD receptor agonist; SDS: sleep disturbance severity; SE: standard error 
 
 
Discussion 
Sleep disturbance is a well-recognized problem for persons with cancer, and 
hypnotic use is common in this population. Relationships between disturbed sleep and 
cancer-related pain, fatigue, and depression are well documented, but interactions with 
other cancer symptoms have not been well studied. Little is known, also, about the effects 
of hypnotics in persons with cancer, whose response may be mediated by the complexities 
of disease status and medication regimens. We conducted this study to contribute to those 
knowledge gaps.   
 
Symptom burden  
Hypnotic use. Comparing BZD/BzRA hypnotic users against non-users, we found 
that hypnotic users reported decreased severity for most, but not all, symptoms. Assuming 
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a 1-point change to be the minimum threshold for clinical significance, three symptoms 
stood out: numbness/tingling, disturbed sleep, and feeling distressed (1.3-point, 1.0-point, 
and 0.9-point reductions, respectively). With hypnotic use, decreased sleep disturbance 
severity (SDS) was an expected finding. Decreased distress is also unsurprising; BZDs, 
which are anxiolytic as well as sedating, comprised 74% of the hypnotics used. We did 
find it noteworthy, however, that the largest change was seen in numbness/tingling. BZDs 
are not recommended for treatment of neuropathic pain, but their mechanism of action is 
similar to other agents used for this indication.305,306 Gabapentin and pregabalin are 
considered first-line agents for chemotherapy-induced neuropathy.307 These 
anticonvulsants act to increase levels of γ-aminobutyric acid (GABA), the most abundant 
inhibitory neurotransmitter in the central nervous system.133  BZDs bind near type A 
receptor sites for GABA, and act to enhance its inhibitory effects.308 Because GABA-A 
receptors are widespread throughout the nervous system, drugs – such as BZDs – that are 
non-selective for receptor subtypes can have a broad range of activity, including sedative, 
hypnotic, anxiolytic, myorelaxant, amnestic, and anasthetic effects. BZD receptor agonists 
(BzRAs) such as zolpidem and zaleplon, on the other hand, have primarily hypnotic effects 
because they are selective for a1 subtypes (which primarliy mediate sleep).125 Thus, while 
there is some evidence that BZDs can attenuate neuropathic pain,309 concerns over side 
effects limit their appeal. In persons with cancer, in particular, BZD use has been associated 
with daytime drowsiness, dry mouth, morning delerium, and respiratory depression.146,147 
Nonetheless, our findings lend support for the hypothesis that drugs specifically targeting 
the subtype(s) of GABA-A receptors involved in transmission of pain signals (most likely, 
a2, a3, and a5) may be effective for controlling neuropathic pain.310 Retrospective 
evaluations of GABA-ergic drug use in persons with cancer may provide insights to 
supplement the current body of preclinical findings. 
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Change in sleep disturbance severity. Sleep disturbance has often been observed to 
occur concurrently with cancer-related fatigue, depression, and pain,118,120,304 and this was 
borne out in our study, as well. Our results stand out from prior studies, however, in finding 
significant relationships with thirteen additional symptoms: feeling distressed, dry mouth, 
shortness of breath, drowsiness, nausea, cough, memory loss, vomiting, appetite loss, 
numbness/tingling, pain, itching, constipation, and diarrhea. We also note the relatively 
small association between sleep and pain, despite the frequency with which those two 
symptoms are identified together in symptom clusters. Attempts to identify symptom 
clusters are motivated, in part, by the possibility of discovering a single underlying cause 
to target therapeutically.235 Characterization of clusters may be subject to information bias, 
however, because pain and fatigue are among the most commonly measured symptoms.169 
In this study, the symptoms most strongly associated with sleep disturbance were: feeling 
distressed, fatigue, dry mouth, and shortness of breath. While we cannot determine 
underlying causal pathways and directions from this study, our findings suggest that sleep 
is integrally related not just to a few symptoms, but to overall symptom burden. Prospective 
studies measuring sleep and symptom burden both subjectively and objectively would be 
needed to confirm this. 
We were unable to evaluate the extent to which initiation of hypnotic use changed 
severity of sleep disturbance in this study because patients were evaluated during the course 
of treatment, rather than at initiation. We did control for hypnotic use, however, when 
evaluating associations between SDS change and changes in other symptoms. Only one 
symptom, fatigue, changed with hypnotic use (0.31-point decrease in severity), suggesting 
that much of the difference in symptom burden between BZD/BzRA hypnotic users and 
non-users may be mediated by changes in sleep disturbance.  
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Health-related quality of life  
Hypnotic use. For items measuring symptom burden interference with health-
related quality of life (HRQoL), MANOVA revealed no differences in severity change 
between hypnotic users and non-users. Although some improvements to HRQoL have been 
observed in clinical trials of BzRA hypnotics,311,312 our null findings are consistent with 
prior studies in general populations. In a survey of almost 3,000 subjects in Japan (where 
BZDs comprised about 40% of hypnotics used),144 insomniacs using hypnotics had lower 
mental and physical HRQoL scores than non-using insomniacs.64 The investigators 
suggested that gains in sleep may have been overshadowed by next-day residual adverse 
effects of BZDs (e.g., sedation, amnesia, myorelaxation).64 More recently, in a nationally-
representative United States sample (N=104,274), participants with insomnia reported the 
same reductions in physical and mental HRQoL regardless of whether or not they used 
BZD/BzRA hypnotics (17% of hypnotics used were BZDs).313 Comparisons across studies 
may not be valid, however, as each used different measures for HRQoL. Furthermore, the 
HRQoL portion of the MDASI survey has not been evaluated for sensitivity to detect 
changes related to sleep disturbance or its treatment.  
Change in sleep disturbance severity. Controlling for hypnotic use, increased SDS 
was associated with increased symptom burden interference for all HRQoL measures, 
except work. A note of caution is due here, since only 18% of participants worked full-
time (27% worked part-time, 56% were unemployed). Although the item was worded as 
“work (including work around the house)”, it is possible that participants experiencing 
difficulties with symptom burden scored interference with work low simply because they 
were not working. We also note that relationships with other HRQoL measures were not 
strong. Models explained ≤ 6% of variance in HRQoL and regression coefficients were 
≤0.24. When we performed a second analysis including all symptom changes as covariates, 
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the models accounted for substantially more variance. Relationships between SDS and 
HRQoL virtually disappeared, however, suggesting that relationships between sleep 
disturbance and HRQoL, as detected by this instrument, were mediated by other symptoms.  
Interestingly, we noted a 0.4-point increase in interference with work associated 
with hypnotic use. This result is difficult to interpret, however, as the model accounted for 
only 1% of variance, and results of the MANOVA indicated no such relationship. 
Furthermore, while it is a known problem that both BZD and BzRAs can produce next-day 
sedation that may affect daytime performance,9,314 in this sample they were associated with 
a slight (0.31-point) improvement to fatigue. These contradictions may reflect differing 
needs and symptom burdens between patients who are working and those who have 
reduced their workload or stopped working altogether.  
 
Strengths & Limitations 
This study benefitted from a longitudinal, rather than cross-sectional design, which 
allowed evaluation of change. A major limitation, however, was that it evaluated patients 
during the course of treatment, rather than at initiation. Thus, we were unable to evaluate 
the extent to which initiation of hypnotic use changed severity of sleep disturbance. Having 
a large initial sample permitted statistical matching of comparators to cases, which can 
reduce selection bias in a retrospective study and more closely approximate a randomized 
controlled design. We could not control for unmeasured confounders, however, and cannot 
be certain that all important covariates were included in the matching models. Residual 
confounding may remain. Results may also be confounded by undocumented use of other 
sleep aids, including over-the-counter medications, off-label drugs, and alcohol, or by non-
adherence to prescribed hypnotics. Surveys are subject to recall bias, and the sensitivity of 
the MDASI survey instrument to assess changes in HRQoL related to sleep has not been 
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evaluated. Finally, our results may not be generalizable beyond ambulatory solid-tumor 
cancer patients treated by an oncology group in the Eastern United States. These limitations 
notwithstanding, our findings have revealed relationships that should be further explored 
in prospective trials. 
 
Conclusions 
Sleep disturbance (SD) is recognized as one of the most common and most severe 
cancer symptoms,82,90,110 and benzodiazepines (BZDs) and benzodiazepine receptor 
agonists (BzRAs) are frequently used in this setting,140-142,258 even though there is little 
evidence to guide their use. To address this gap, we evaluated symptom burden and health-
related quality of life outcomes associated with sleep disturbance and hypnotic use in a 
large sample of participants with solid tumors. Cancer-related pain, fatigue, and depression 
have commonly been associated with sleep disturbance, but we found that relationships 
may exist for many other symptoms. Sleep disturbance also appears to correlate with 
reduced health-related quality of life, but this may depend on interactions between 
disturbed sleep and other cancer symptoms. Given the multifarious somatic effects of sleep, 
however, it is reasonable to hypothesize that effective management of sleep disturbance is 
essential to minimizing burden from a wide spectrum of symptoms. Studies testing this 
hypothesis may help to better define relationships between symptoms and uncover causal 
pathways.  
Use of BZD/BzRA hypnotics in this study correlated with lower overall symptom 
burden, but the extent to which this was mediated by effects on sleep – versus other effects 
of the drugs – was unclear. Two new drug classes have been developed for treatment of 
insomnia (melatonin receptor agonists, dual-acting orexin antagonists), and a few others 
(including antidepressants, anticonvulsants, and antipsychotics) are now recognized to 
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have sleep-promoting effects. With different mechanisms of action, each drug class also 
has unique effects on sleep, as well as a particular set of other therapeutic actions. Future 
studies designed to distinguish between sleep-related changes in symptom burden and non-
sleep-related therapeutic effects of the drugs would allow clinicians to make more strategic 
prescribing decisions for patients with differing symptom burdens. 
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3.4 SECTION IV: TARGET JOURNALS 
 
Table 3.19 is a listing of journals whose aims and scope are consistent with the 
manuscripts presented in this chapter. Because the studies in these manuscripts were 
specific to this country, all but one journal is based in the United States. Most journals 
listed a cost of $3,000 to $5,000 for the option of open access publishing, but no other 
publication charges were listed. The Source Normalized Impact per Paper (SNIP), a metric 
that takes into account the subject field of a publication,d is listed for each journal, along 
with sample papers on topics related to this project. 
                                                
d Moed HF. Measuring contextual citation impact of scientific journals. Journal of Informetrics. 
2010;4(3):265-277. doi:10.1016/j.joi.2010.01.002. 
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Table 3.19 Listing of target journals for manuscripts presented in this dissertation 
Journal Publisher / Organization Aims & Scope 
Supportive Care in Cancer 
SNIP: 1.291 
Springer / Multinational Association of 
Supportive Care in Cancer  
Scientific & social information on all aspects of supportive care in cancer.  
Primarily covers medical, technical and surgical supportive therapies. 
Nursing, rehabilitative, psychosocial and spiritual issues are also included. 
Comparison of subgroups of breast cancer patients on pain and co-occurring symptoms following chemotherapy. Langford DJ, et.al. 2016 
Identification of distinct subgroups of breast cancer patients based on self-reported changes in sleep disturbance. Van Onselen C, et.al. 2012 
Journal of Pain & Symptom 
Management 
SNIP: 1.483 
Elsevier / American Academy of Hospice 
& Palliative Medicine, National Hospice 
& Palliative Care Organization 
Interdisciplinary. Clinical research & best practices for relief of illness burden. 
Clinical trials, epidemiology, instrument development, health services studies, 
systematic and narrative reviews, case series and case reports 
Trajectories of sleep disturbance and daytime sleepiness in women before and after surgery for breast cancer. Van Onselen C, et.al. 2013 
Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. Kwekkeboom KL, et.al. 2010 
Sleep-wake disturbances in patients with advanced cancer and their family carers. Gibbins J, et. al. 2009 
American Journal of 
Hospice and Palliative Care 
SNIP: 0.798 
Prime National Publishing 
 
 
Articles on multidisciplinary care, end of life issues, pain & symptom 
management psychosocial aspects, quality of care. Emphasis on information 
directly applicable to care of the patient/family at the bedside. 
Insomnia in Patients With Advanced Cancer. Mellar P, et.al. 2013 
An Observational Study of Insomnia and Nightmare Treated With Trazodone in Patients With Advanced Cancer. Hitoshi T, et.al. 2012 
Journal of Pain & Palliative 
Care Pharmacotherapy 
SNIP: 0.386 
Taylor & Francis 
 
 
Acute, chronic, and end-of-life symptom management.  
Sedative-Hypnotics and the Treatment of Insomnia. Jill E. Allen & Christopher R. Jones. 2010 
Quetiapine for Sleep. Scott Yost & Jacob White. 2010 
Journal of Psychosocial 
Oncology 
SNIP: 0.670 
Taylor & Francis / Association of 
Oncology Social Work 
Interdisciplinary: education, epidemiology, medical oncology, nursing, nutrition, 
physical therapy, psychiatry, psychology, public health, social work, surgical 
oncology. Exploratory, hypothesis testing, & program evaluation research. 
Psychosocial resources and sleep disturbance before chemotherapy for gynecologic cancer. Bryan J, et.al. 2016 
Exploring the Relationship Between Fear of Cancer Recurrence and Sleep Quality in Cancer Survivors. Berrett-Abebe J, et.al. 2015 
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Chapter 4:  Conclusions 
 
The purpose of this project was to address substantial knowledge gaps in the 
literature pertaining to the management of sleep disturbance in persons with cancer. Even 
though sleep disturbance is recognized as one of the most common and most severe 
symptoms of cancer,82,90,110 there is scant evidence to guide its treatment.156,164 Data on 
oncology-specific contributing and mediating factors are needed for the development of 
preventative measures and recognition of at-risk patients. Research that documents the 
response of this unique population to hypnotic medications is vital to ensuring patients 
receive the safest and most effective treatments. As this knowledge base builds, evidence-
based guidelines for management of cancer-related sleep disturbance can take shape. To 
that end, this project contributes the following findings: 
1) Prevalence and correlates of sleep disturbance severity in a large sample of solid 
tumor cancer patients, and compared across cancer-specific subgroups; 
2) Prevalence and correlates of benzodiazepine (BZD) and benzodiazepine receptor 
agonist (BzRA) hypnotic use in a large sample of solid tumor cancer patients, and 
compared across cancer-specific subgroups; 
3) Changes in severity of cancer symptoms and in health-related quality of life 
associated with BZD/BzRA hypnotic use and with change in severity of sleep 
disturbance. 
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4.1 SECTION I:  SUMMARY OF FINDINGS 
4.1.1 Prevalence and correlates of sleep disturbance severity 
The prevalence and correlates of sleep disturbance in oncology have been evaluated 
in several studies, but findings are difficult to synthesize due to heterogeneity in study 
populations, designs, and methods. An advantage for this study was the use of data from 
the Symptom Outcomes and Practice Patterns (SOAPP) survey, which provided not only a 
large and diverse sample of participants, but also substantially more variables than previous 
studies of cancer-related sleep disturbance. This, along with consistency in measurement 
of all symptom severity variables, allowed for meaningful comparisons of the relative 
importance of correlates within, and between, cancer-specific subsamples. 
In this study, the most important correlates of sleep disturbance were other cancer 
symptoms. Notably, however, most symptoms were mild, on average, and severity seemed 
uncorrelated with sleep disturbance. Comparing across cancer-specific subgroups, distress 
was the only universal correlate, but cognitive difficulty, drowsiness, and fatigue were also 
common. Benzodiazepine receptor agonists, specifically indicated for insomnia, correlated 
with a small increase in sleep disturbance severity overall (no associations were found with 
benzodiazepines), while use of anticonvulsants for pain correlated with a relatively large 
decrease in severity of sleep disturbance for prostate cancer. These findings suggest that 
even when individual symptoms are mild, patients with multiple symptoms may experience 
substantially worsened sleep. For the symptom of distress, in particular, the consistency of 
its correlation with sleep disturbance may mark an important therapeutic target. In addition, 
identifying alternate therapies may be essential, as it appears from this study that standard 
pharmacotherapy for insomnia may not benefit persons with cancer as much as treatments 
that target multiple symptoms.  
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4.1.2 Prevalence and correlates of benzodiazepine (BZD) and benzodiazepine 
receptor agonist (BzRA) hypnotic use 
Despite the prevalence of cancer-related sleep disturbance,90 and a history of 
reliance on hypnotic medications,137-139 little is known about current patterns of hypnotic 
use among oncology patients in the United States (US). Following the introduction of 
benzodiazepine receptor antagonists (BzRAs) in the late 20th century in the US, prescribing 
practices in the general population changed dramatically.145 Benzodiazepines (BZDs) have 
fallen out of favor and the relatively safer BzRAs are now the drug of choice. It is unclear 
whether these changes extend to the oncology setting, but obtaining current data on which 
drugs are being prescribed, and how commonly, is an important first step in evaluating the 
management of sleep disturbance in persons with cancer.   
Prevalence of hypnotic use, especially BZDs, in this sample was high relative to 
the general population, but low relative to the prevalence of sleep disturbance. Racial 
disparity was observed in this sample, with rates of hypnotic use two to three times higher 
among whites, as compared to blacks. Several sedating medications correlated with 
hypnotic use, including opioid analgesics and the strongly sedating anti-emetic 
promethazine. An association with clinician-identified distress was also noted, yet no 
association was found between clinician-identified sleep disturbance and hypnotic use. 
These findings raise concerns about under-treatment of sleep disturbance, which may be a 
function of patient help-seeking behavior, but may also reflect prescribers’ attitudes toward 
medications, disagreement between patient reports and clinician assessments, and social 
determinants such as racial bias or access to care. Polypharmacy with sedatives and a heavy 
reliance on benzodiazepines are also concerning due to increased risk of drug interactions, 
including fatal respiratory depression with opioid analgesia. 
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4.1.3 Changes to cancer symptom burden and health-related quality of life 
associated with BZD/BzRA hypnotic use and with change in severity of sleep 
disturbance  
Few studies have evaluated the outcomes associated with hypnotic use in people 
with cancer. As a result, current recommendations for management of cancer-related sleep-
disturbance are guided primarily by studies in general populations.156,157 It cannot be 
assumed, however, that standard therapies are appropriate; patients with cancer have 
additional sleep disturbance risk factors and markedly higher risks of adverse medication 
events and interactions. Conversely, some side-effects that are usually unwanted (e.g., 
weight gain) may be welcome in this setting. Observed clustering of certain symptoms 
(e.g., pain, fatigue, and sleep disturbance) may bespeak a common underlying biological 
pathway to target therapeutically, but identifying those relationships and characterizing the 
interactions are key to optimizing symptom management.  
In this sample, reduced sleep disturbance severity (SDS), over approximately four 
weeks, correlated with improvement in nearly all symptoms measured, but most notably: 
distress, dry mouth, and fatigue. Reduced SDS also correlated with improved health-related 
quality of life (HRQoL), but this likely reflects interactions between sleep and other cancer 
symptoms. Use of hypnotics in this study appeared to have little correlation with HRQoL, 
but did correlate with lower overall symptom burden. The extent to which this was 
mediated by effects on sleep – versus other effects of the drugs – was unclear. These pan-
symptom findings are consistent with the growing documentation of sleep-related activity 
in virtually all somatic systems, and indicate that future studies of cancer-related sleep 
disturbance, and treatments, should incorporate measures for a broad range of cancer 
symptoms. Distinguishing sleep-related changes in symptom burden from non-sleep-
related effects of drugs would allow for more strategic management of patients with 
differing symptom burdens, and may shed light on underlying mechanisms.  
 153 
4.2 SECTION II: RELEVANCE TO TRANSLATIONAL SCIENCE 
 
This project can be classified as health outcomes research, which, on the spectrum 
of translational science, would be subsumed under clinical implementation and public 
health (sometimes referred to as T3 and T4, respectively). Inspiration for this study, 
however, spans the spectrum. The pervasiveness of cancer-related sleep disturbance, and 
its intractableness, were first observed during clinical practice. Merging knowledge of 
hypnotic pharmacology (molecular mechanisms of action for drugs) with sleep-related and 
cancer-related physiology (function and response of biological systems), resulted in the 
recognition that hypnotic use may yield different results in persons with cancer. The final 
impetus was the realization that no guidelines, and little evidence, existed for management 
of sleep disturbance specifically in persons with cancer. 
 
   
4.2.1 Public health 
Findings from this study on the prevalence and correlates of hypnotic use are 
applicable to health services research. First and foremost is the concern that sleep 
disturbance may be undertreated in persons with cancer, even when clinicians correctly 
identify sleep disturbance as a priority for their patients. To correct this, it will first be 
necessary to identify whether the barriers to treatment originate with prescribers (e.g., 
attitudes toward medication, perceptions of patients’ needs), patients (e.g., help-seeking 
behavior), or elsewhere (e.g., coordination of care, health insurance restrictions). Notably, 
the racial disparity in hypnotic use found in this study may point to public health concerns 
such as access to care or provider bias.  
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The observation that BZDs, which have more side effects than BzRAs, are still in 
frequent use in the oncology setting should be further investigated. Unless there is evidence 
that the benefits of BZD use in this sensitive population outweigh the risks, interventions 
such as patient education and updated clinical guidelines may be warranted. Polypharmacy 
with sedative drugs should also be further evaluated. Retrospective analyses of large 
datasets may be useful for detecting the incidence of adverse events related to sedative 
polypharmacy in persons with cancer, and identifying those patients most at risk. 
 
4.2.2 Clinical research 
The primary opportunity for clinical research related to this study is the systematic 
evaluation of hypnotics (and other sleep-promoting drugs) in persons with cancer. Most 
importantly, the high rate of BZD and BzRA use found in this study warrants evaluation 
of their safety and efficacy of in cancer patients. In addition, the finding of less severe sleep 
disturbance in men with prostate cancer taking anticonvulsants could be followed up with 
a prospective study.  
Among all possible correlates evaluated in this study, it was other cancer symptoms 
that most strongly correlated with sleep disturbance severity. Moreover, change in sleep 
disturbance severity was accompanied by change in nearly every symptom evaluated. 
Clinical research to evaluate these relationships (and their responses to therapies) can 
further our understanding of the complex interplay of cancer symptoms and their 
underlying causes. As this understanding improves, clinicians and researchers will be better 
able to strategically customize preventative and therapeutic approaches for their individual 
patients. Such findings would also help to focus drug development (or repurposing) efforts 
toward particular symptoms or symptom clusters. 
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The close relationship found in this study between distress and sleep disturbance 
represents a specific opportunity for clinical science. Both symptoms manifest in the 
physical as well as mental domains of health, and both can be treated non-
pharmacologically as well as pharmacologically. As such, it is likely that multimodal and 
interprofessional approaches will produce the best results, but clinical trials will be 
necessary to determine the ideal configuration of therapeutic elements. 
 
4.2.3 Pre-clinical and basic research 
Relationships between sleep disturbance and other cancer symptoms can be studied 
pre-clinically by way of genome-wide association studies, which may help to uncover key 
biological processes and novel drug targets. Basic research and preclinical pharmacology 
studies can also aid in the interpretation of results from this study, and can help in 
determining the suitability of alternative therapies. For example, regulation of appetite and 
sleep tend to be in opposition, as evidenced by the neuropeptide orexin, which increases 
appetite and suppresses sleep. This study, however, found that appetite loss increased as 
sleep disturbance severity increased. If this finding is confirmed in other studies, it might 
suggest regulatory activity not yet characterized by basic scientists.  
 
4.3 SECTION III: FUTURE WORK 
This project was undertaken as a preliminary contribution to the evaluation and 
improvement of current standards of care. If afforded the opportunity, future work would 
include additional “real-world” evaluations of hypnotic use with the goal of identifying 
and testing drugs already in use that can be repurposed or used more effectively for 
management of sleep disturbance and other symptoms of cancer. 
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Appendix A: Patient Survey 
Patients participating in the Symptom Outcomes and Practice Patterns (SOAPP) 
study were asked to provide demographic information (Patient On-Study Form) and to 
complete a symptom severity and interference survey (MDASI-ECOG Form) at the initial 
visit. At the follow-up visit, approximately four weeks later, participants were asked to 
repeat the symptom severity and interference survey (MDASI-ECOG Form).  
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Appendix B: Clinician Survey 
Clinicians participating in the Symptom Outcomes and Practice Patterns (SOAPP) 
study were asked to provide baseline clinical data (Baseline Data Form, Clinician On-Study 
Form) and to evaluate their patients’ health-related quality of life (Clinician On-Study 
Form, Section 4) at the initial visit.  
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Appendix C: Kernel Density Plot for Specific Aim 1 
Specific Aim 1 used linear regression to evaluate the correlates of sleep disturbance 
severity. (See Section 2.6.2.1 Specific Aim 1: Correlates of Sleep Disturbance Severity.) 
The following kernel density plot, showing the distribution of residuals in comparison to a 
normal distribution, is one of several regression diagnostic tests conducted.  
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